NZ789486A - Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof - Google Patents
Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereofInfo
- Publication number
- NZ789486A NZ789486A NZ789486A NZ78948617A NZ789486A NZ 789486 A NZ789486 A NZ 789486A NZ 789486 A NZ789486 A NZ 789486A NZ 78948617 A NZ78948617 A NZ 78948617A NZ 789486 A NZ789486 A NZ 789486A
- Authority
- NZ
- New Zealand
- Prior art keywords
- xaa
- cysteine
- derivative
- misc
- feature
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title claims abstract description 252
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 230000001225 therapeutic Effects 0.000 title claims abstract description 23
- 230000002218 hypoglycaemic Effects 0.000 claims abstract description 57
- 206010020993 Hypoglycaemia Diseases 0.000 claims abstract description 55
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 45
- 201000008980 hyperinsulinism Diseases 0.000 claims abstract description 12
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 236
- 229960002433 Cysteine Drugs 0.000 claims description 229
- 235000018417 cysteine Nutrition 0.000 claims description 229
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 124
- 239000004472 Lysine Substances 0.000 claims description 122
- 150000001413 amino acids Chemical group 0.000 claims description 122
- 229960003646 lysine Drugs 0.000 claims description 122
- 235000018977 lysine Nutrition 0.000 claims description 122
- 108060003199 Glucagon Proteins 0.000 claims description 114
- 229960004666 Glucagon Drugs 0.000 claims description 114
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 107
- 235000001014 amino acid Nutrition 0.000 claims description 106
- 239000008194 pharmaceutical composition Substances 0.000 claims description 106
- 229960004295 valine Drugs 0.000 claims description 106
- 235000014393 valine Nutrition 0.000 claims description 106
- 239000004474 valine Substances 0.000 claims description 106
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 96
- 239000004220 glutamic acid Substances 0.000 claims description 94
- 229960002989 Glutamic Acid Drugs 0.000 claims description 93
- 235000013922 glutamic acid Nutrition 0.000 claims description 93
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 90
- 239000004475 Arginine Substances 0.000 claims description 89
- 229960003121 arginine Drugs 0.000 claims description 89
- 235000009697 arginine Nutrition 0.000 claims description 89
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 88
- 229960005261 Aspartic Acid Drugs 0.000 claims description 87
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 87
- 235000003704 aspartic acid Nutrition 0.000 claims description 87
- 102000018358 Immunoglobulins Human genes 0.000 claims description 74
- 108060003951 Immunoglobulins Proteins 0.000 claims description 74
- 229960002743 Glutamine Drugs 0.000 claims description 73
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 73
- 235000004554 glutamine Nutrition 0.000 claims description 73
- 239000000560 biocompatible material Substances 0.000 claims description 69
- 229920000642 polymer Polymers 0.000 claims description 66
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 61
- 229960001153 serine Drugs 0.000 claims description 58
- 235000004400 serine Nutrition 0.000 claims description 58
- FUOOLUPWFVMBKG-UHFFFAOYSA-N α-aminoisobutanoic acid Chemical group CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 58
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 53
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 46
- 239000004473 Threonine Substances 0.000 claims description 45
- 239000000463 material Substances 0.000 claims description 45
- 229960002898 threonine Drugs 0.000 claims description 45
- 235000008521 threonine Nutrition 0.000 claims description 45
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 40
- 229960003767 Alanine Drugs 0.000 claims description 37
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 37
- 235000004279 alanine Nutrition 0.000 claims description 37
- 230000027455 binding Effects 0.000 claims description 34
- 230000002473 insulinotropic Effects 0.000 claims description 34
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 32
- 235000005772 leucine Nutrition 0.000 claims description 32
- 229960003136 leucine Drugs 0.000 claims description 32
- 101700024131 EXE4 Proteins 0.000 claims description 31
- 229960001519 exenatide Drugs 0.000 claims description 31
- 208000008589 Obesity Diseases 0.000 claims description 30
- 208000000454 Congenital Hyperinsulinism Diseases 0.000 claims description 29
- 235000020824 obesity Nutrition 0.000 claims description 29
- 229920001223 polyethylene glycol Polymers 0.000 claims description 28
- 239000002202 Polyethylene glycol Substances 0.000 claims description 25
- 229960002885 Histidine Drugs 0.000 claims description 24
- 125000003277 amino group Chemical group 0.000 claims description 24
- 235000014304 histidine Nutrition 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 22
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 21
- 101710042131 GCG Proteins 0.000 claims description 21
- 102100003818 GCG Human genes 0.000 claims description 21
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 21
- 229960004452 Methionine Drugs 0.000 claims description 20
- 235000006109 methionine Nutrition 0.000 claims description 20
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 20
- 229960001230 Asparagine Drugs 0.000 claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 19
- 235000009582 asparagine Nutrition 0.000 claims description 19
- 239000008103 glucose Substances 0.000 claims description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 19
- 102000004965 antibodies Human genes 0.000 claims description 18
- 108090001123 antibodies Proteins 0.000 claims description 18
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 18
- 229920002307 Dextran Polymers 0.000 claims description 17
- 102100014838 FCGRT Human genes 0.000 claims description 17
- 101710003435 FCGRT Proteins 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 17
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 17
- 239000000194 fatty acid Substances 0.000 claims description 17
- 150000004665 fatty acids Chemical class 0.000 claims description 17
- 150000004676 glycans Polymers 0.000 claims description 17
- 150000002632 lipids Chemical class 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 17
- 229920001282 polysaccharide Polymers 0.000 claims description 17
- 239000005017 polysaccharide Substances 0.000 claims description 17
- 150000004804 polysaccharides Polymers 0.000 claims description 17
- 229920002101 Chitin Polymers 0.000 claims description 16
- 229960000310 ISOLEUCINE Drugs 0.000 claims description 16
- 229920001577 copolymer Polymers 0.000 claims description 16
- 229920002674 hyaluronan Polymers 0.000 claims description 16
- 229960003160 hyaluronic acid Drugs 0.000 claims description 16
- 235000014705 isoleucine Nutrition 0.000 claims description 16
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims description 16
- 229920002554 vinyl polymer Polymers 0.000 claims description 16
- QHSCIWIRXWFIGH-UHFFFAOYSA-N 2-amino-2-methylpentanedioic acid Chemical group OC(=O)C(N)(C)CCC(O)=O QHSCIWIRXWFIGH-UHFFFAOYSA-N 0.000 claims description 15
- 210000004369 Blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 150000001720 carbohydrates Chemical class 0.000 claims description 15
- 230000000875 corresponding Effects 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims description 15
- 239000000018 receptor agonist Substances 0.000 claims description 15
- 102100001249 ALB Human genes 0.000 claims description 14
- 101710027066 ALB Proteins 0.000 claims description 14
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 claims description 14
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 claims description 14
- 229920001451 Polypropylene glycol Polymers 0.000 claims description 14
- 229940050528 albumin Drugs 0.000 claims description 14
- 239000004621 biodegradable polymer Substances 0.000 claims description 14
- 229920002988 biodegradable polymer Polymers 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 13
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 13
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 13
- 229920000272 Oligonucleotide Polymers 0.000 claims description 13
- 241000700159 Rattus Species 0.000 claims description 13
- 229940035295 Ting Drugs 0.000 claims description 13
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 12
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 229940107161 Cholesterol Drugs 0.000 claims description 11
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 11
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- -1 polyoxyethylated Polymers 0.000 claims description 11
- 206010058108 Dyslipidaemia Diseases 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 10
- 108090001061 Insulin Proteins 0.000 claims description 10
- 206010061227 Lipid metabolism disease Diseases 0.000 claims description 10
- 150000003951 lactams Chemical group 0.000 claims description 10
- 102000025873 GPCR, family 2, glucagon receptor Human genes 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- 239000000539 dimer Substances 0.000 claims description 9
- 239000002464 receptor antagonist Substances 0.000 claims description 9
- 108010063919 GPCR, family 2, glucagon receptor Proteins 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 8
- 241000282412 Homo Species 0.000 claims description 8
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methyl-L-cysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 claims description 8
- 210000002808 Connective Tissue Anatomy 0.000 claims description 7
- 102000016942 Elastin Human genes 0.000 claims description 7
- 108010014258 Elastin Proteins 0.000 claims description 7
- 102000016359 Fibronectins Human genes 0.000 claims description 7
- 108010067306 Fibronectins Proteins 0.000 claims description 7
- 229960002897 Heparin Drugs 0.000 claims description 7
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 7
- 230000001419 dependent Effects 0.000 claims description 7
- 229920002549 elastin Polymers 0.000 claims description 7
- 230000037320 fibronectin Effects 0.000 claims description 7
- 229920000669 heparin Polymers 0.000 claims description 7
- 150000003384 small molecules Chemical class 0.000 claims description 7
- 102100013472 CCK Human genes 0.000 claims description 6
- 108010048926 Cholecystokinin Proteins 0.000 claims description 6
- 229940107137 Cholecystokinin Drugs 0.000 claims description 6
- 101700062901 DPP Proteins 0.000 claims description 6
- 102100003313 GHRL Human genes 0.000 claims description 6
- 101700010630 GHRL Proteins 0.000 claims description 6
- ORRDHOMWDPJSNL-UHFFFAOYSA-N Melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 claims description 6
- 108060004714 Melanin-concentrating hormone Proteins 0.000 claims description 6
- 102000004338 Transferrin Human genes 0.000 claims description 6
- 108090000901 Transferrin Proteins 0.000 claims description 6
- 230000003213 activating Effects 0.000 claims description 6
- 201000001320 atherosclerosis Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 102400001132 melanin-concentrating hormone Human genes 0.000 claims description 6
- 239000012581 transferrin Substances 0.000 claims description 6
- 208000004981 Coronary Disease Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 230000001684 chronic Effects 0.000 claims description 5
- 230000000295 complement Effects 0.000 claims description 5
- 201000008739 coronary artery disease Diseases 0.000 claims description 5
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 5
- 230000002503 metabolic Effects 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 claims description 4
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 claims description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- 102100002609 HTR2C Human genes 0.000 claims description 4
- 101710045397 HTR2C Proteins 0.000 claims description 4
- 208000009576 Hypercholesterolemia Diseases 0.000 claims description 4
- 108010028924 PPAR alpha Proteins 0.000 claims description 4
- 108010015181 PPAR delta Proteins 0.000 claims description 4
- 108010077895 Sarcosine Proteins 0.000 claims description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 4
- 239000000546 pharmaceutic aid Substances 0.000 claims description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine zwitterion Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- ARSWQPLPYROOBG-UHFFFAOYSA-N 2-azaniumyl-2,4-dimethylpentanoate Chemical compound CC(C)CC(C)(N)C(O)=O ARSWQPLPYROOBG-UHFFFAOYSA-N 0.000 claims description 3
- 102100008845 COPA Human genes 0.000 claims description 3
- 102000000393 Ghrelin Receptors Human genes 0.000 claims description 3
- 108010016122 Ghrelin Receptors Proteins 0.000 claims description 3
- 108010072447 Glicentin Proteins 0.000 claims description 3
- 102400000320 Glicentin Human genes 0.000 claims description 3
- 102100017662 LEPR Human genes 0.000 claims description 3
- 102100018756 LIPF Human genes 0.000 claims description 3
- 101700033034 LIPF Proteins 0.000 claims description 3
- 102100015117 NPY5R Human genes 0.000 claims description 3
- 101700005832 NPY6R Proteins 0.000 claims description 3
- 102100002332 PYY Human genes 0.000 claims description 3
- 229940116369 Pancreatic lipase Drugs 0.000 claims description 3
- 102000019280 Pancreatic lipase Human genes 0.000 claims description 3
- 108050006759 Pancreatic lipase Proteins 0.000 claims description 3
- 108010088847 Peptide YY Proteins 0.000 claims description 3
- SSJGXNSABQPEKM-SBUIBGKBSA-N Pyy peptide Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 SSJGXNSABQPEKM-SBUIBGKBSA-N 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 108091005508 amylin receptors Proteins 0.000 claims description 3
- 230000003042 antagnostic Effects 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 229940121360 farnesoid X receptor (FXR) agonists Drugs 0.000 claims description 3
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 claims description 3
- 108010019813 leptin receptors Proteins 0.000 claims description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 3
- IDHVLSACPFUBDY-QCDLPZBNSA-N xenin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CN=CN1 IDHVLSACPFUBDY-QCDLPZBNSA-N 0.000 claims description 3
- 108010006643 xenin 25 Proteins 0.000 claims description 3
- 108091006011 G proteins Proteins 0.000 claims description 2
- 102000030007 GTP-Binding Proteins Human genes 0.000 claims description 2
- 108091000058 GTP-Binding Proteins Proteins 0.000 claims description 2
- OWMZNFCDEHGFEP-NFBCVYDUSA-N L-Histidyl-L-seryl-L-a-aspartylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-a-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-a-glutamylglycyl -L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leu Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- 108010019598 Liraglutide Proteins 0.000 claims description 2
- 102100001186 SCT Human genes 0.000 claims description 2
- 229960002101 Secretin Drugs 0.000 claims description 2
- 108010086019 Secretin Proteins 0.000 claims description 2
- 229940121373 acetyl-CoA carboxylase inhibitors Drugs 0.000 claims description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 2
- 229960002701 liraglutide Drugs 0.000 claims description 2
- 229950002350 secretin human Drugs 0.000 claims description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 claims 48
- JEFZIKRIDLHOIF-BYPYZUCNSA-N Gln-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(O)=O JEFZIKRIDLHOIF-BYPYZUCNSA-N 0.000 claims 47
- IQHUITKNHOKGFC-MIMYLULJSA-N Thr-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IQHUITKNHOKGFC-MIMYLULJSA-N 0.000 claims 47
- 108010080629 tryptophan-leucine Proteins 0.000 claims 45
- SBMNPABNWKXNBJ-UHFFFAOYSA-N Serinyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CO SBMNPABNWKXNBJ-UHFFFAOYSA-N 0.000 claims 43
- 108010068265 aspartyltyrosine Proteins 0.000 claims 43
- NALWOULWGHTVDA-UWVGGRQHSA-N Asp-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NALWOULWGHTVDA-UWVGGRQHSA-N 0.000 claims 42
- JMEWFDUAFKVAAT-UHFFFAOYSA-N Methionyl-Asparagine Chemical compound CSCCC(N)C(=O)NC(C(O)=O)CC(N)=O JMEWFDUAFKVAAT-UHFFFAOYSA-N 0.000 claims 42
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 claims 38
- AUEJLPRZGVVDNU-STQMWFEESA-N Tyr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-STQMWFEESA-N 0.000 claims 36
- 108010078580 tyrosylleucine Proteins 0.000 claims 35
- LYMVXFSTACVOLP-ZFWWWQNUSA-N Trp-Leu Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C([O-])=O)=CNC2=C1 LYMVXFSTACVOLP-ZFWWWQNUSA-N 0.000 claims 32
- XXDVDTMEVBYRPK-XPUUQOCRSA-N Val-Gln Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O XXDVDTMEVBYRPK-XPUUQOCRSA-N 0.000 claims 27
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 claims 24
- QXRNAOYBCYVZCD-BQBZGAKWSA-N (2S)-6-amino-2-[[(2S)-2-aminopropanoyl]amino]hexanoic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN QXRNAOYBCYVZCD-BQBZGAKWSA-N 0.000 claims 23
- CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 claims 23
- 108010038633 aspartylglutamate Proteins 0.000 claims 23
- 108010069205 aspartyl-phenylalanine Proteins 0.000 claims 22
- 108010009298 lysylglutamic acid Proteins 0.000 claims 17
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims 16
- KXTAGESXNQEZKB-DZKIICNBSA-N (4S)-4-amino-5-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 KXTAGESXNQEZKB-DZKIICNBSA-N 0.000 claims 15
- 108010044940 alanylglutamine Proteins 0.000 claims 15
- ZQFAGNFSIZZYBA-UHFFFAOYSA-N γ-glutamyl-Tryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C(CCC(N)=O)N)C(O)=O)=CNC2=C1 ZQFAGNFSIZZYBA-UHFFFAOYSA-N 0.000 claims 15
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 claims 11
- FKBFDTRILNZGAI-UHFFFAOYSA-N Aspartyl-Cysteine Chemical compound OC(=O)CC(N)C(=O)NC(CS)C(O)=O FKBFDTRILNZGAI-UHFFFAOYSA-N 0.000 claims 9
- KRBMQYPTDYSENE-BQBZGAKWSA-N His-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 KRBMQYPTDYSENE-BQBZGAKWSA-N 0.000 claims 6
- 108010018006 histidylserine Proteins 0.000 claims 6
- RGTVXXNMOGHRAY-UHFFFAOYSA-N Cysteinyl-Arginine Chemical compound SCC(N)C(=O)NC(C(O)=O)CCCNC(N)=N RGTVXXNMOGHRAY-UHFFFAOYSA-N 0.000 claims 4
- 125000002707 L-tryptophyl group Chemical compound [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims 4
- CUTPSEKWUPZFLV-UHFFFAOYSA-N Threoninyl-Cysteine Chemical compound CC(O)C(N)C(=O)NC(CS)C(O)=O CUTPSEKWUPZFLV-UHFFFAOYSA-N 0.000 claims 4
- STTYIMSDIYISRG-WDSKDSINSA-N Val-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(O)=O STTYIMSDIYISRG-WDSKDSINSA-N 0.000 claims 4
- LOEKZJRUVGORIY-CAMMJAKZSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=CC=C1 LOEKZJRUVGORIY-CAMMJAKZSA-N 0.000 claims 3
- BUXAPSQPMALTOY-UHFFFAOYSA-N 2-[(2-amino-3-sulfanylpropanoyl)amino]pentanedioic acid Chemical compound SCC(N)C(=O)NC(C(O)=O)CCC(O)=O BUXAPSQPMALTOY-UHFFFAOYSA-N 0.000 claims 3
- XAEWTDMGFGHWFK-IMJSIDKUSA-N Ala-Asp Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O XAEWTDMGFGHWFK-IMJSIDKUSA-N 0.000 claims 3
- YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 claims 3
- NXTYATMDWQYLGJ-UHFFFAOYSA-N Cysteinyl-Leucine Chemical compound CC(C)CC(C(O)=O)NC(=O)C(N)CS NXTYATMDWQYLGJ-UHFFFAOYSA-N 0.000 claims 3
- HZYHBDVRCBDJJV-HAFWLYHUSA-N Ile-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O HZYHBDVRCBDJJV-HAFWLYHUSA-N 0.000 claims 3
- HIZYETOZLYFUFF-BQBZGAKWSA-N Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O HIZYETOZLYFUFF-BQBZGAKWSA-N 0.000 claims 3
- 108010066427 N-valyltryptophan Proteins 0.000 claims 3
- VBKBDLMWICBSCY-IMJSIDKUSA-N Ser-Asp Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O VBKBDLMWICBSCY-IMJSIDKUSA-N 0.000 claims 3
- 108010049041 glutamylalanine Proteins 0.000 claims 3
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 3
- HAYVTMHUNMMXCV-UHFFFAOYSA-N Cysteinyl-Alanine Chemical compound OC(=O)C(C)NC(=O)C(N)CS HAYVTMHUNMMXCV-UHFFFAOYSA-N 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- UGTZHPSKYRIGRJ-YUMQZZPRSA-N Lys-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UGTZHPSKYRIGRJ-YUMQZZPRSA-N 0.000 claims 2
- UASDAHIAHBRZQV-YUMQZZPRSA-N Met-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N UASDAHIAHBRZQV-YUMQZZPRSA-N 0.000 claims 2
- FFOKMZOAVHEWET-UHFFFAOYSA-N Serinyl-Cysteine Chemical compound OCC(N)C(=O)NC(CS)C(O)=O FFOKMZOAVHEWET-UHFFFAOYSA-N 0.000 claims 2
- ZSXJENBJGRHKIG-UHFFFAOYSA-N Tyrosyl-Serine Chemical compound OCC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UHFFFAOYSA-N 0.000 claims 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 claims 2
- 108010069495 cysteinyltyrosine Proteins 0.000 claims 2
- 150000002332 glycine derivatives Chemical compound 0.000 claims 2
- MPZWMIIOPAPAKE-UHFFFAOYSA-N 4-amino-5-[[1-carboxy-4-(diaminomethylideneamino)butyl]amino]-5-oxopentanoic acid Chemical compound OC(=O)CCC(N)C(=O)NC(C(O)=O)CCCN=C(N)N MPZWMIIOPAPAKE-UHFFFAOYSA-N 0.000 claims 1
- 230000035533 AUC Effects 0.000 claims 1
- JQDFGZKKXBEANU-UHFFFAOYSA-N Alanyl-Cysteine Chemical compound CC(N)C(=O)NC(CS)C(O)=O JQDFGZKKXBEANU-UHFFFAOYSA-N 0.000 claims 1
- PSZNHSNIGMJYOZ-WDSKDSINSA-N Asp-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PSZNHSNIGMJYOZ-WDSKDSINSA-N 0.000 claims 1
- WXOFKRKAHJQKLT-UHFFFAOYSA-N Cysteinyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CS WXOFKRKAHJQKLT-UHFFFAOYSA-N 0.000 claims 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N Cysteinyl-Phenylalanine Chemical compound SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 claims 1
- OLIFSFOFKGKIRH-WUJLRWPWSA-N Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CN OLIFSFOFKGKIRH-WUJLRWPWSA-N 0.000 claims 1
- BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 claims 1
- MYTOTTSMVMWVJN-STQMWFEESA-N Lys-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MYTOTTSMVMWVJN-STQMWFEESA-N 0.000 claims 1
- 102100003647 PPARA Human genes 0.000 claims 1
- NYQBYASWHVRESG-MIMYLULJSA-N Phe-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 NYQBYASWHVRESG-MIMYLULJSA-N 0.000 claims 1
- 239000004698 Polyethylene (PE) Substances 0.000 claims 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Quinoform Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 claims 1
- UJTZHGHXJKIAOS-WHFBIAKZSA-N Ser-Gln Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O UJTZHGHXJKIAOS-WHFBIAKZSA-N 0.000 claims 1
- GJNDXQBALKCYSZ-RYUDHWBXSA-N Val-Phe Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 GJNDXQBALKCYSZ-RYUDHWBXSA-N 0.000 claims 1
- 108010041407 alanylaspartic acid Proteins 0.000 claims 1
- 230000004579 body weight change Effects 0.000 claims 1
- 230000001771 impaired Effects 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract description 2
- 230000003451 hyperinsulinaemic Effects 0.000 abstract description 2
- 239000000562 conjugate Substances 0.000 description 108
- 125000003275 alpha amino acid group Chemical group 0.000 description 97
- 230000035492 administration Effects 0.000 description 39
- 230000000694 effects Effects 0.000 description 30
- 210000004027 cells Anatomy 0.000 description 29
- 239000003814 drug Substances 0.000 description 28
- 201000010099 disease Diseases 0.000 description 20
- 229920000023 polynucleotide Polymers 0.000 description 20
- 239000002157 polynucleotide Substances 0.000 description 20
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 230000001976 improved Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 230000037396 body weight Effects 0.000 description 13
- 230000001965 increased Effects 0.000 description 13
- 230000035772 mutation Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 230000001264 neutralization Effects 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000006011 modification reaction Methods 0.000 description 9
- 102000019622 EC 2.7.1.2 Human genes 0.000 description 8
- 108010021582 EC 2.7.1.2 Proteins 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000036499 Half live Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000000349 Chromosomes Anatomy 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 125000003172 aldehyde group Chemical group 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 239000000863 peptide conjugate Substances 0.000 description 6
- 125000003607 serino group Chemical group [H]OC(=O)C([H])(N([H])*)C([H])([H])O[H] 0.000 description 6
- 108060006634 CAMP Proteins 0.000 description 5
- 102000016901 Glutamate dehydrogenases Human genes 0.000 description 5
- 108091000037 Glutamate dehydrogenases Proteins 0.000 description 5
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 5
- 210000004185 Liver Anatomy 0.000 description 5
- 108091005771 Peptidases Proteins 0.000 description 5
- 239000011149 active material Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- 230000002085 persistent Effects 0.000 description 5
- 239000004626 polylactic acid Substances 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 201000010874 syndrome Diseases 0.000 description 5
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102100012353 DPP4 Human genes 0.000 description 4
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 4
- 208000002705 Glucose Intolerance Diseases 0.000 description 4
- 108010016076 Octreotide Proteins 0.000 description 4
- 229960002700 Octreotide Drugs 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 108010015174 exendin 3 Proteins 0.000 description 4
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002068 genetic Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- GDLBFKVLRPITMI-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound ClC1=CC=C2NC(C)=NS(=O)(=O)C2=C1 GDLBFKVLRPITMI-UHFFFAOYSA-N 0.000 description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 1-butanal Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 102000033147 ERVK-25 Human genes 0.000 description 3
- 229940096919 Glycogen Drugs 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 3
- 229940088597 Hormone Drugs 0.000 description 3
- 206010062060 Hyperlipidaemia Diseases 0.000 description 3
- 229940090044 Injection Drugs 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- 210000000496 Pancreas Anatomy 0.000 description 3
- 102000012141 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000002354 daily Effects 0.000 description 3
- 229960004042 diazoxide Drugs 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 230000004634 feeding behavior Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 102000037240 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- NBBJYMSMWIIQGU-UHFFFAOYSA-N propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 2
- KVNBDVQGENTICK-ITLPAZOVSA-N (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 KVNBDVQGENTICK-ITLPAZOVSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3-Isobutyl-1-methyl-2,6(1H,3H)-purinedione Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- 206010003246 Arthritis Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 2
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 2
- 210000004958 Brain cells Anatomy 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 229940012193 Contrave Drugs 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100008093 GCGR Human genes 0.000 description 2
- 101710023980 GCGR Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000282619 Hylobates lar Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100002644 KCNJ11 Human genes 0.000 description 2
- 108060004074 KCNJ11 Proteins 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000008466 Metabolic Disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXZWGQLGAKCNKD-DPNMSELWSA-N MolPort-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N Orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 101800001388 Oxyntomodulin Proteins 0.000 description 2
- 102400000319 Oxyntomodulin Human genes 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 210000002824 Peroxisome Anatomy 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N Rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 2
- 229960003015 Rimonabant Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 206010039911 Seizure Diseases 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229940032147 Starch Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 230000001154 acute Effects 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000021407 appetite control Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004748 cultured cells Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000021271 drinking Nutrition 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 201000010238 heart disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 239000002865 melanocortin Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 235000020825 overweight Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- FCTRVTQZOUKUIV-MCDZGGTQSA-M potassium;[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound [K+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O FCTRVTQZOUKUIV-MCDZGGTQSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- DKXIKPOYTWCGIE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-methylbutanoate Chemical compound CCC(C)C(=O)ON1C(=O)CCC1=O DKXIKPOYTWCGIE-UHFFFAOYSA-N 0.000 description 1
- DYMYLBQTHCJHOQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) butanoate Chemical compound CCCC(=O)ON1C(=O)CCC1=O DYMYLBQTHCJHOQ-UHFFFAOYSA-N 0.000 description 1
- DRLIANXPAARUMI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) pentanoate Chemical compound CCCCC(=O)ON1C(=O)CCC1=O DRLIANXPAARUMI-UHFFFAOYSA-N 0.000 description 1
- UILJLCFPJOIGLP-BYPYZUCNSA-N (2S)-2-(prop-2-enoylamino)butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)C=C UILJLCFPJOIGLP-BYPYZUCNSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- WHJKCPTVEYZNOG-UHFFFAOYSA-N 6-(hydroxymethyl)-5-methoxy-2-[4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane-3,4-diol Chemical group COCC1OC(OC)C(OC)C(OC)C1OC1C(O)C(O)C(OC)C(CO)O1 WHJKCPTVEYZNOG-UHFFFAOYSA-N 0.000 description 1
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001088417 Ammodytes americanus Species 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 229940075615 Bacillus subtilis Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 208000001183 Brain Injury Diseases 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N Bromate Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000012619 Butyl Sepharose® Substances 0.000 description 1
- 206010007541 Cardiac disease Diseases 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008129 Cerebral palsy Diseases 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 210000001728 Clone Cells Anatomy 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N Cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 208000002173 Dizziness Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010013369 EC 3.4.21.9 Proteins 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940009714 Erythritol Drugs 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 230000036081 Excretion rate Effects 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016855 Foetal distress syndrome Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940048956 Glucagon Injection Drugs 0.000 description 1
- 229940093181 Glucose Injection Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 210000004153 Islets of Langerhans Anatomy 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 206010024094 Learning disease Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000001022 Morbid Obesity Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009025 Nervous System Disease Diseases 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N Norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 102100003648 PPARD Human genes 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 101700062671 SIAE Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N Sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 208000000927 Sleep Apnea Syndrome Diseases 0.000 description 1
- 206010040979 Sleep apnoea syndrome Diseases 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 206010042772 Syncope Diseases 0.000 description 1
- 102100009508 TMPRSS15 Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 231100000611 Venom Toxicity 0.000 description 1
- 210000001048 Venoms Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001780 adrenocortical Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000009181 carbohydrate metabolism disease Diseases 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000000378 dietary Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010870 diseases of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 201000003010 gallbladder disease Diseases 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 101500013968 human Glucagon Proteins 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000002366 lipolytic Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 201000010830 physical disease Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001603 reducing Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000247 serious adverse effect Toxicity 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 201000001880 sexual dysfunction Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N silicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Abstract
The present invention relates to a glucagon derivative, a conjugate thereof, a composition comprising the same and a use thereof and, more particularly, to a therapeutic use for the metabolic syndrome, hypoglycemia and concomitant hyperinsulinemia.
Description
[DESCRIPTION]
[Invention Title]
GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION
COMPRISING SAME, AND THERAPEUTIC USE THEREOF
[Related ations]
This is a divisional application of New d Patent Application No. , which is
the National Phase Application of , which claims priority from Korean
Patent Application Numbers 10008199 filed 29 June 2016, 100182982 filed 29
December 2016, and 100069217 filed 2 June 2017, the entire contents are herein
incorporated by reference.
[Technical Field]
The present invention s to a glucagon derivative, a ate thereof, and a
composition containing the same, and a use f, in particular, a therapeutic use for metabolic
syndrome, hypoglycemia, and congenital hyperinsulinism thereof.
round Art]
Due to recent economic growth and changes in dietary habits, etc., the incidence of
metabolic syndrome-associated diseases including various diseases such as obesity,
hyperlipidemia, hypertension, arteriosclerosis, hyperinsulinemia, diabetes, and liver diseases is
rapidly increasing. These diseases may occur independently but in general they mostly occur in
a close relationship with each other, being accompanied by various symptoms.
Overweight and obesity are sible for increasing blood pressure and cholesterol
levels and causing or worsening various diseases, such as cardiac diseases, diabetes, arthritis, etc.
In addition, the problem of obesity is also becoming a major cause in the increased incidence of
arteriosclerosis, ension, hyperlipidemia, or heart diseases in children or teenagers as well
as in adults.
However, obesity is not easy to treat, e it is a complex disease associated with the
mechanisms of appetite control and energy metabolism. Accordingly, the treatment of obesity
es not only the efforts of obese patients, but also a method e of treating abnormal
mechanisms associated with appetite control and energy metabolism. Thus, efforts have been
made to p drugs for treating the abnormal mechanisms.
As a result of these efforts, drugs such as Rimonabant® (Sanofi-Aventis), Sibutramin®
(Abbott), Contrave® (Takeda), Orlistat® (Roche), etc. have been developed, but they have the
disadvantages of serious adverse effects or very weak anti-obesity effects. For e,
according to a report, Rimonabant® shows a ffect of central nervous system disorder,
Sibutramine® and Contrave® show cardiovascular side-effects, and Orlistat® shows only about 4
kg of weight loss when taken for one year.
Meanwhile, glucagon is produced by the pancreas when blood e levels drop as a
result of other medications or diseases, or e or enzyme deficiencies. Glucagon sends a
signal for glycogen breakdown in the liver and a subsequent glucose release and plays a role in
increasing blood glucose levels to a normal range. onally, glucagon has been shown to
be effective in treating hypoglycemia. The hypoglycemic therapeutic effect of glucagon is the
result of stimulating the degradation of glycogen to glucose (glycogen breakdown) or increasing
glucose production (glucose biosynthesis) d from amino acid precursors resulting in
increased glucose outflow from the liver.
In addition to the effect of increasing the blood glucose levels, glucagon suppresses
appetite and activates hormone-sensitive lipase of adipocytes to facilitate sis, y
showing an anti-obesity effect. However, the use of glucagon as a therapeutic agent has been
d because it has a low solubility and it is precipitated at a neutral pH.
Accordingly, the glucagon with improved properties alone can be effectively used for
the treatment of severe hypoglycemia, nonalcoholic steatohepatitis (NASH), dyslipidemia, etc.
due to its activities of fat decomposition and β-oxidation in the liver.
One of the glucagon derivatives, glucagon-like peptide-1 (GLP-1), is under development
as a therapeutic agent for treating lycemia in patients with diabetes. GLP-1 has the
functions of ating insulin synthesis and secretion, inhibiting glucagon secretion, slowing
gastric emptying, increasing glucose utilization, and inhibiting food intake.
Exendin-4, prepared from lizard venom and having an amino acid homology of about
50% with GLP-1, was also reported to activate the GLP-1 or, thereby improving
hyperglycemia in patients with diabetes (J Biol Chem. 1992 Apr 15; 267 (11): 7402 - 5).
However, anti-obesity drugs containing GLP-1 are reported to show side-effects such as
vomiting and nausea.
As an alternative to GLP-1, therefore, much attention has been focused on
modulin, which can bind to both receptors of the two peptides, GLP-1 and glucagon.
Oxyntomodulin is a peptide prepared from a glucagon precursor, pre-glucagon, and has the
functions of inhibiting food intake and enhancing satiety of GLP-1, and has lipolytic activity like
on, thus sing its potency in anti-obesity therapy.
However, oxyntomodulin or derivatives f have a serious drawback in that an excess
amount of the drug should be administered daily because they have low efficacy and a short in
vivo half-life. Additionally, when both activities of GLP-1 and glucagon are present in a single
peptide, the activity ratio thereof becomes fixed, and thus it is difficult to use a dual t with
various ratios. Accordingly, a ed therapy capable of using various activity ratios by
adjusting the contents of GLP-1 and glucagon may be more effective. However, for the
combined therapy, it is required to improve the physical characteristics of glucagon, which
aggregates at a neutral pH and precipitates with time, thus showing poor solubility.
Meanwhile, congenital hyperinsulinism is one of the most common causes of severe and
persistent hypoglycemia in newborns and children. Insulin is a hormone that tes blood
glucose in the human body. It plays a role in lowering blood glucose levels when blood
glucose level rises due to food , etc. However, in congenital hyperinsulinism, insulin
does not play such a role and the pancreas secretes insulin regardless of blood glucose levels.
As a , the patients become hypoglycemic.
When hypoglycemia occurs, the levels of e, ketone, e, etc., which the brain
cells mostly utilize, cannot be maintained and the energy supply from proteins and fats in the
body is blocked, resulting in damage to brain cells and thereby causing seizures, learning
disorders, cerebral palsy, ess, and even death in severe cases.
Hypoglycemia may occur temporarily due to excessive insulin secretion. Additionally,
ycemia also occurs in infants who have undergone fetal distress. Although the cause of
insulin ion is unclear, in this case, hypoglycemia can be improved within days to months.
Infants born to mothers with diabetes mellitus may have transient ycemia if the sugar
level is not well-controlled, but it does not recur if the g ds well and hypoglycemia
disappears. Another cause is persistent hyperinsulinism due to several genetic defects.
Reportedly, the causes of hyperinsulinism due to genetic defects include a mutation of SUR gene
or Kir6.2 gene on the 1 chromosome or mutation of the glucokinase (GK) gene on the
7p15-p13 chromosome, increase of GK activity, which increases GK ty, and a mutation of
the glutamate dehydrogenase (GDH) gene, which tes GDH and thereby increases the ATP
in beta-islet cells, etc.
Accordingly, immediate treatment of hypoglycemia is important for preventing brain
damage. Hypoglycemia may be treated by drinking a carbohydrate-containing beverage, but in
a severe case, glucose or glucagon injection into the vein is essential. The goal of the treatment
is to allow children to manage a normal dietary cycle with a safety device. For example, in the
case of one-year-old infants, they may be d to stay fasted for at least 14 hours to 15 hours
with medication because they sleep without eating for 10 hours to 12 hours at night.
Examples of the drugs to be used may include diazoxide, octreotide, glucagon, etc.
Diazoxide is administered orally two or three times a day. Diazoxide inhibits insulin secretion
by acting on ATP dependent K+ (KATP) l and thus it may be effective for the ent
of GK hyperinsulinism or GDH hyperinsulinism, but it is often unresponsive in autosomal
recessive nsulinism caused by a defect in the KATP pathway. Octreotide is administered
by subcutaneous injection. When octreotide is administered, the effect of octreotide is initially
exhibited, but sometimes its effect decreases after a period of time. Glucagon promotes glucose
release from the liver and is administered by subcutaneous or intravenous injection, which is
known to be used when an oral administration is not available in an emergency situation.
Among these, glucagon is currently used as a lyophilized formulation due to its low
solubility and precipitation at neutral pH, which is inconvenient because it is to be dissolved in a
solvent before use. Furthermore, when glucagon is used as a therapeutic agent for the treatment
of ital hyperinsulinism, which requires long-term treatment due to its short half-life, the
use of glucagon has been limited due to nt administration.
[Disclosure]
[Technical Problem]
An object of the present invention is to e a composition containing a glucagon
derivative or a conjugate containing the same, and specifically, a pharmaceutical composition for
preventing or treating congenital hyperinsulinism, hypoglycemia, or metabolic syndrome
containing a glucagon tive or a conjugate containing the same.
Another object of the present invention is to provide a glucagon derivative.
Still another object of the present invention is to provide an isolated polynucleotide
encoding a glucagon derivative, a vector including the polynucleotide, and an ed cell
ing the polynucleotide or the vector.
Still another object of the present invention is to e an isolated conjugate which
includes a peptide moiety and a biocompatible material moietywhich is covalently linked to the
peptide moiety. Still another object of the present invention is to provide a kit contatining a
glucagon tive or a ate containing the same, and specifically, a kit for ting or
treating congenital hyperinsulinism, hypoglycemia, or metabolic me contatining a
glucagon derivative or a conjugate ning the same.
Still another object of the present ion is to provide a method for preventing or
treating congenital hyperinsulinism including administering the glucagon derivative or an
isolated conjugate containing the same or a composition containing the same to a subject in need
thereof.
Still another object of the present invention is to e use of the glucagon derivative
or an isolated conjugate containing the same or a composition ning the same in the
preparation of a medicament for preventing or treating congenital hyperinsulinism.
Still another object of the present invention is to e a method for preventing or
treating hypoglycemia including administering the glucagon derivative or an isolated conjugate
containing the same or a composition containing the same to a subject in need thereof.
Still another object of the present invention is to provide use of the glucagon tive
or an isolated conjugate containing the same or a composition containing the same in the
preparation of a medicament for preventing or treating hypoglycemia.
Still another object of the present invention is to provide a method for preventing or
treating metabolic syndrome including administering a glucagon derivative or an isolated
conjugate or a composition containing the same to a subject in need thereof.
Still another object of the present invention is to provide use of the glucagon derivative
or an isolated ate containing the same or the ition containing the same in the
preparation of a medicament (or a ceutical composition) for preventing or treating
metabolic syndrome.
[Technical Solution]
An aspect of the present invention provides a composition containing a glucagon
tive or a conjugate containing the same, and specifically, a ceutical composition for
preventing or treating congenital hyperinsulinism, hypoglycemia, or metabolic syndrome
containing a glucagon derivative or a conjugate containing the same.
In a specific embodiment, the present invention relates to a composition containing a
glucagon derivative peptide including the amino acid sequence of the following General Formula
1, and specifically, a pharmaceutical composition for preventing or ng congenital
hyperinsulinism, hypoglycemia, or metabolic me ning a glucagon tive peptide
including the amino acid sequence of the following General Formula 1:
X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F-X23-
X24-W-L-X27-X28-X29-X30 (General Formula 1, SEQ ID NO: 45)
wherein, in General Formula 1,
X1 is histidine (H), desamino-histidyl, N-dimethyl-histidyl, β-hydroxy imidazopropionyl,
4-imidazoacetyl, β-carboxy imidazopropionyl, tryptophan (W), or tyrosine (Y), or is absent;
X2 is yl-glutamic acid, aminoisobutyric acid (Aib), D-alanine, glycine (G), Sar
hylglycine), serine (S), or D-serine;
X7 is threonine (T), valine (V), or ne (C);
X10 is tyrosine (Y) or cysteine (C);
X12 is lysine (K) or cysteine (C);
X13 is tyrosine (Y) or cysteine (C);
X14 is leucine (L) or cysteine (C);
X15 is aspartic acid (D), glutamic acid (E), or cysteine (C);
X16 is glutamic acid (E), aspartic acid (D), serine (S), α-methyl-glutamic acid, or
cysteine (C), or is absent;
X17 is aspartic acid (D), glutamine (Q), ic acid (E), lysine (K), arginine (R),
serine (S), cysteine (C), or valine (V), or is ;
X18 is alanine (A), aspartic acid (D), glutamic acid (E), arginine (R), valine (V), or
cysteine (C), or is absent;
X19 is alanine (A), ne (R), serine (S), valine (V), or cysteine (C), or is absent;
X20 is lysine (K), histidine (H), glutamine (Q), aspartic acid (D), arginine (R),
α-methyl-glutamic acid, or cysteine (C), or is ;
X21 is aspartic acid (D), glutamic acid (E), leucine (L), valine (V), or cysteine (C), or is
absent;
X23 is isoleucine (I), valine (V), or arginine (R), or is absent;
X24 is valine (V), arginine (R), alanine (A), cysteine (C), glutamic acid (E), lysine (K),
glutamine (Q), α-methyl-glutamic acid, or leucine (L), or is ;
X27 is isoleucine (I), valine (V), alanine (A), lysine (K), nine (M), glutamine (Q),
or ne (R), or is absent;
X28 is glutamine (Q), lysine (K), asparagine (N), or arginine (R), or is absent;
X29 is lysine (K), alanine (A), glycine (G), or threonine (T), or is absent; and
X30 is ne (C), or is absent;
with the proviso that when the amino acid sequence of General Formula 1 is identical to
SEQ ID NO: 1, it is excluded.
The following are additional specific embodiments of the present invention.
Specifically, as a pharmaceutical composition according to the previous specific
embodiment:
in General Formula 1,
X1 is histidine (H), tryptophan (W), or tyrosine (Y), or is absent;
X2 is serine (S) or aminoisobutyric acid (Aib);
X7 is threonine (T), valine (V), or cysteine (C);
X10 is tyrosine (Y) or cysteine (C);
X12 is lysine (K) or cysteine (C);
X13 is tyrosine (Y) or cysteine (C);
X14 is leucine (L) or ne (C);
X15 is aspartic acid (D) or cysteine (C);
X16 is glutamic acid (E), serine (S), or cysteine (C);
X17 is ic acid (D), glutamic acid (E), lysine (K), arginine (R), serine (S), cysteine
(C), or valine (V);
X18 is aspartic acid (D), glutamic acid (E), arginine (R), or cysteine (C);
X19 is alanine (A) or ne (C);
X20 is glutamine (Q), aspartic acid (D), lysine (K), or cysteine (C);
X21 is aspartic acid (D), glutamic acid (E), leucine (L), valine (V), or cysteine (C);
X23 is isoleucine (I), valine (V), or arginine (R);
X24 is valine (V), arginine (R), alanine (A), glutamic acid (E), lysine (K), ine (Q),
or leucine (L);
X27 is isoleucine (I), valine (V), alanine (A), methionine (M), ine (Q), or arginine
X28 is glutamine (Q), lysine (K), asparagine (N), or arginine (R);
X29 is threonine (T); and
X30 is ne (C) or is absent.
As the pharmaceutical composition according to any one of the previous specific
embodiments:
in General Formula 1,
X1 is histidine (H), tryptophan (W), or tyrosine (Y);
X2 is serine (S) or aminoisobutyric acid (Aib);
X7 is cysteine (C), threonine (T), or valine (V);
X10 is tyrosine (Y) or cysteine (C);
X12 is lysine (K) or cysteine (C);
X13 is tyrosine (Y) or cysteine (C);
X14 is leucine (L) or cysteine (C);
X15 is aspartic acid (D) or ne (C);
X16 is glutamic acid (E), serine (S), or cysteine (C);
X17 is glutamic acid (E), lysine (K), arginine (R), cysteine (C), or valine (V);
X18 is arginine (R) or cysteine (C);
X19 is alanine (A) or cysteine (C);
X20 is glutamine (Q) or lysine (K);
X21 is aspartic acid (D), glutamic acid (E), valine (V), or cysteine (C);
X23 is valine (V);
X24 is valine (V) or glutamine (Q);
X27 is methionine (M);
X28 is asparagine (N) or arginine (R);
X29 is threonine (T); and
X30 is cysteine (C) or is absent.
As the pharmaceutical composition ing to any one of the previous specific
embodiments:
in General Formula 1,
X1 is tyrosine (Y);
X2 is aminoisobutyric acid (Aib);
X7 is cysteine (C), threonine (T), or valine (V);
X10 is ne (Y) or ne (C);
X12 is lysine (K);
X13 is tyrosine (Y) or cysteine (C);
X14 is leucine (L) or cysteine (C);
X15 is aspartic acid (D) or cysteine (C);
X16 is glutamic acid (E), serine (S), or cysteine (C);
X17 is lysine (K), arginine (R), cysteine (C), or valine (V);
X18 is arginine (R) or cysteine (C);
X19 is alanine (A) or cysteine (C);
X20 is glutamine (Q) or lysine (K);
X21 is aspartic acid (D), glutamic acid (E), or cysteine (C);
X23 is valine (V);
X24 is glutamine (Q);
X27 is methionine (M);
X28 is asparagine (N) or arginine (R);
X29 is threonine (T); and
X30 is cysteine (C) or is absent.
As the pharmaceutical composition according to any one of the previous specific
embodiments:
in General Formula 1,
X1 is histidine (H), tryptophan (W), or tyrosine (Y), or is absent;
X2 is serine (S) or aminoisobutyric acid (Aib);
X7 is threonine (T), valine (V), or cysteine (C);
X10 is tyrosine (Y) or cysteine (C);
X12 is lysine (K) or cysteine (C);
X13 is tyrosine (Y) or ne (C);
X14 is leucine (L) or cysteine (C);
X15 is ic acid (D) or cysteine (C);
X16 is glutamic acid (E), serine (S), or cysteine (C);
X17 is aspartic acid (D), glutamic acid (E), lysine (K), ne (R), serine (S), cysteine
(C), or valine (V);
X18 is ic acid (D), glutamic acid (E), arginine (R), or cysteine (C);
X19 is alanine (A) or ne (C);
X20 is glutamine (Q), aspartic acid (D), or lysine (K);
X21 is aspartic acid (D) or glutamic acid (E);
X23 is valine (V);
X24 is valine (V) or glutamine (Q);
X27 is isoleucine (I) or methionine (M);
X28 is gine (N) or ne (R);
X29 is threonine (T); and
X30 is cysteine (C) or is absent.
As the pharmaceutical composition according to any one of the previous specific
embodiments:
in General Formula 1,
X1 is tyrosine (Y);
X2 is aminoisobutyric acid (Aib);
X7 is threonine (T);
X10 is tyrosine (Y);
X12 is lysine (K);
X13 is tyrosine (Y);
X14 is leucine (L);
X15 is aspartic acid (D) or cysteine (C);
X16 is glutamic acid (E), serine (S), or cysteine (C);
X17 is lysine (K) or arginine (R);
X18 is arginine (R);
X19 is alanine (A);
X20 is glutamine (Q), cysteine (C), or lysine (K);
X21 is aspartic acid (D), cysteine (C), valine (V), or glutamic acid (E);
X23 is valine (V) or arginine (R);
X24 is glutamine (Q) or leucine (L);
X27 is methionine (M);
X28 is asparagine (N) or ne (R);
X29 is threonine (T); and
X30 is absent.
As the pharmaceutical ition according to any one of the previous specific
embodiments, the peptide contains the amino acid ce of the following General Formula 2:
Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-W-L-MN-T-X30
(General Formula 2, SEQ ID NO: 46)
wherein, in General Formula 2,
X7 is threonine (T), valine (V), or cysteine (C);
X10 is tyrosine (Y) or cysteine (C);
X12 is lysine (K) or cysteine (C);
X15 is aspartic acid (D) or ne (C);
X16 is glutamic acid (E) or serine (S);
X17 is lysine (K) or arginine (R);
X20 is glutamine (Q) or lysine (K);
X21 is aspartic acid (D) or glutamic acid (E);
X24 is valine (V) or glutamine (Q); and
X30 is cysteine (C) or is absent.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the peptide has an isoelectric point (pI) value different from that of native
glucagon (6.8), e.g., a pI of 6.5 or less, or a pI of 7.0 or higher.
As the ceutical composition according to any one of the previous specific
embodiments, in a specific embodiment of the present invention, each amino acid in at least one
amino acid pair among the amino acid pairs of X10 and X14, X12 and X16, X16 and X20, X17
and X21, X20 and X24, and X24 and X28 in General Formula 1 or 2 is substituted with glutamic
acid or , which is capable of forming a ring, respectively.
As the pharmaceutical composition ing to any one of the previous specific
embodiments, in a ic embodiment of the present invention, each amino acid in the amino
acid pair of X12 and X16 or each amino acid in the amino acid pair of X16 and X20 or each
amino acid in the amino acid pair of X17 and X21 in General Formula 1 or 2 is respectively
substituted with glutamic acid or lysine, which is capable of forming a ring.
As the pharmaceutical composition ing to any one of the previous specific
embodiments, in a specific embodiment of the present invention, in General a 1 or 2, a
ring (e.g., a lactam ring) is formed between each amino acid in at least one amino acid pair
among the amino acid pairs of X10 and X14, X12 and X16, X16 and X20, X17 and X21, X20
and X24, and X24 and X28.
As the pharmaceutical composition according to any one of the us specific
embodiments, in a specific ment of the present ion, in General a 1 or 2, X16
is glutamic acid, X20 is lysine, and the side chains of X16 and X20 form a lactam ring.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the C-terminus of the peptide is amidated or unmodified.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the peptide is a native glucagon derivative capable of activating a glucagon
receptor.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the e includes an amino acid sequence ed from the group consisting of
SEQ ID NOS: 2 to 44.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the peptide includes an amino acid sequence selected from the group consisting of
SEQ ID NOS: 12, 13, 15, and 36 to 44.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the peptide includes the amino acid ce of SEQ ID NO: 37.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the peptide is in the form of a long-acting conjugate, in which a biocompatible
material moiety is linked to the peptide moiety, and specifically to the peptide moiety including
the amino acid sequence of l Formula 1 or 2.
As the pharmaceutical composition ing to any one of the previous specific
embodiments, the biocompatible material moiety is selected from the group consisting of a
r, fatty acid, cholesterol, n and a fragment thereof, an albumin-binding material, a
r of repeating units of a particular amino acid sequence, an antibody, an dy
fragment, an FcRn-binding material, in vivo connective tissue or a derivative thereof, a
nucleotide, fibronectin, transferrin, a saccharide, heparin, and elastin.
As the ceutical composition according to any one of the previous ic
embodiments, the polymer is selected from the group consisting of a polyethylene glycol, a
polypropylene glycol, an ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol,
polyvinyl alcohol, a polysaccharide, dextran, polyvinyl ethyl ether, a radable polymer, a
lipid polymer, chitin, hyaluronic acid, an oligonucleotide, and a combination thereof.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the FcRn-binding material is a polypeptide containing an immunoglobulin Fc
region.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the peptide moiety and the biocompatible material moiety are linked through a
linker.
As the pharmaceutical composition ing to any one of the us specific
embodiments, the linker is selected from the group consisting of a peptide, fatty acid, a
saccharide, a polymer, a low molecular weight compound, a nucleotide, and a combination
As the pharmaceutical composition according to any one of the previous specific
embodiments, the polymer is selected from the group consisting of a polyethylene glycol, a
polypropylene glycol, an ethylene -propylene glycol mer, polyoxyethylated polyol,
polyvinyl alcohol, a polysaccharide, dextran, polyvinyl ethyl ether, a biodegradable polymer, a
lipid polymer, chitin, hyaluronic acid, an oligonucleotide, and a combination thereof.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the linker is a polyethylene glycol.
As the pharmaceutical composition according to any one of the us specific
embodiments, the immunoglobulin Fc region is sylated.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the immunoglobulin Fc region is selected from the group consisting of:
(a) a CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domain;
(b) a CH1 domain and a CH2 domain;
(c) a CH1 domain and a CH3 domain;
(d) a CH2 domain and a CH3 ;
(e) a combination between one or at least two domains among a CH1 domain, a CH2
domain, a CH3 domain, and a CH4 domain, and an globulin hinge region or a part of the
hinge region; and
(f) a dimer between each domain of the heavy chain constant region and the light chain
nt region.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the polypeptide containing an immunoglobulin Fc region is in the form of a dimer.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the immunoglobulin Fc region is a native Fc derivative in which the region
capable of forming a disulfide bond is deleted, a native Fc derivative in which a part of the
amino acid(s) in the N-terminus is removed, a native Fc derivative in which a methionine residue
is added to the N-terminus, a native Fc derivative in which a complement-binding site is deleted,
or a native Fc tive in which an antibody ent cell mediated cytotoxicity (ADCC) site
is deleted.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the globulin Fc region is derived from an immunoglobulin selected from
the group consisting of IgG, IgA, IgD, IgE, and IgM.
As the pharmaceutical composition ing to any one of the previous specific
embodiments, the globulin Fc region is an IgG4 Fc region.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the immunoglobulin Fc region is an sylated Fc region derived from human
IgG4.
As the pharmaceutical composition according to any one of the previous specific
embodiments, the linker is linked to a ne residue of a peptide including the amino acid
sequence of General Formula 1 or 2.
As the pharmaceutical composition according to any one of the previous specific
embodiments, in a specific embodiment of the present invention, the linker of the conjugate is
respectively linked to the peptide moiety and the biocompatible material moiety through
nt bonds, which were respectively formed when one end of the linker reacted with an
amine group or thiol group of the biocompatible material moiety while the other end of the linker
reacted with an amine group or thiol group of the peptide moiety including the amino acid
sequence of General Formula 1 or 2, respectively.
Another aspect of the present invention provides a glucagon derivative.
In a specific embodiment, the present invention relates to an ed peptide including
the amino acid sequence of General Formula 1 represented by SEQ ID NO: 45.
In another specific embodiment, the present invention relates to an isolated e
including the amino acid sequence of the following General Formula 2:
Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-W-L-MN-T-X30
(General Formula 2, SEQ ID NO: 46)
wherein, in General Formula 2,
X7 is ine (T), valine (V), or cysteine (C);
X10 is tyrosine (Y) or cysteine (C);
X12 is lysine (K) or cysteine (C);
X15 is aspartic acid (D) or cysteine (C);
X16 is ic acid (E) or serine (S);
X17 is lysine (K) or arginine (R);
X20 is ine (Q) or lysine (K);
X21 is aspartic acid (D) or glutamic acid (E);
X24 is valine (V) or glutamine (Q); and
X30 is cysteine (C) or is absent.
In the isolated peptide according to the previous specific ment, the peptides
corresponding to SEQ ID NOS: 19, 33, 49, and 50 may be excluded from the isolated peptides
including the amino acid sequence of General Formula 2.
In the isolated peptide according to any one of the us specific embodiments, in
General Formula 2, X16 is glutamic acid, X20 is lysine, and the side chains of X16 and X20
form a lactam ring.
In the isolated peptide according to any one of the previous specific embodiments, the
C-terminus of the peptide comprising the amino acid sequence of General Formula 2 is amidated
or unmodified.
In the isolated peptide according to any one of the previous ic embodiments, the
peptide is a glucagon derivative capable of activating a glucagon receptor.
In the isolated peptide according to any one of the previous specific embodiments, the
peptide includes an amino acid sequence selected from the group ting of SEQ ID NOS: 12,
13, 15, and 36 to 44.
Still r aspect of the present invention es an ed polynucleotide
encoding the isolated peptide (specifically, the isolated peptide which includes the amino acid
sequence of General Formula 1 or 2), a vector including the isolated polynucleotide, and an
isolated cell including the polynucleotide or vector.
Still another aspect of the t invention provides an isolated conjugate including a
peptide moiety and a biocompatible material moiety covalently linked to the peptide moiety, in
which the peptide moiety has the same amino acid sequence of General a 1 or 2 or
includes the same.
In a specific embodiment, the present invention relates to an isolated conjugate including
a peptide moiety and a biocompatible material moiety covalently linked to the peptide moiety, in
which the peptide moiety has the same amino acid sequence of General Formula 1 or includes
the same.
In a specific embodiment, the present invention s to an isolated ate including
a peptide moiety and a biocompatible material moiety ntly linked to the peptide moiety, in
which the peptide moiety has the same amino acid sequence of General Formula 2 or includes
the same.
In the conjugate according to the previous specific embodiment, the biocompatible
material moiety is selected from the group consisting of a polymer, fatty acid, cholesterol,
albumin and a fragment thereof, an albumin-binding al, a polymer of repeating units of a
particular amino acid sequence, an antibody, an antibody fragment, an FcRn-binding material, in
vivo connective tissue or a derivative f, a nucleotide, fibronectin, transferrin, a saccharide,
heparin, and elastin.
In the conjugate according to any one of the previous specific ments, the polymer
is selected from the group consisting of a polyethylene glycol, a polypropylene glycol, an
ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, a
polysaccharide, dextran, nyl ethyl ether, a biodegradable polymer, a lipid r, chitin,
hyaluronic acid, an oligonucleotide, and a combination thereof.
In the conjugate according to any one of the previous specific embodiments, the
FcRn-binding material is a ptide comprising an immunoglobulin Fc region.
In the conjugate according to any one of the us specific embodiments, the peptide
region and the biocompatible material moiety are linked through a linker.
As the conjugate according to any one of the previous specific ments, the linker
is selected from the group consisting of a peptide, fatty acid, a ride, a polymer, a low
molecular weight compound, a nucleotide, and a combination f.
In the conjugate according to any one of the previous specific embodiments, the linker is
a polymer selected from the group consisting of a polyethylene glycol, a polypropylene glycol,
an ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, a
polysaccharide, dextran, polyvinyl ethyl ether, a biodegradable polymer, a lipid r, chitin,
onic acid, an oligonucleotide, and a combination thereof.
In the conjugate according to any one of the previous specific embodiments, the
biocompatible material moiety is an inding material, and the biocompatible material
moiety is linked to the peptide moiety through a linker selected from the group consisting of a
peptide, fatty acid, a saccharide, a polymer, a low molecular weight compound, a nucleotide, and
a combination thereof.
In the conjugate according to any one of the previous specific embodiments, the linker is
a polyethylene glycol.
In the conjugate ing to any one of the previous specific embodiments, the
immunoglobulin Fc region is sylated.
In the ate according to any one of the previous specific ments, the
immunoglobulin Fc region is selected from the group consisting of: (a) a CH1 domain, a CH2
domain, a CH3 domain, and a CH4 domain; (b) a CH1 domain and a CH2 domain; (c) a CH1
domain and a CH3 domain; (d) a CH2 domain and a CH3 domain; (e) a combination between
one or at least two domains among a CH1 domain, a CH2 domain, a CH3 domain, and a CH4
domain, and an immunoglobulin hinge region or a part of the hinge region; and (f) a dimer
between each domain of the heavy chain nt region and the light chain constant region.
In the conjugate according to any one of the previous specific embodiments, the
polypeptide including an immunoglobulin Fc region is in the form of a dimer.
In the conjugate according to any one of the previous ic embodiments, the
immunoglobulin Fc region is a native Fc derivative in which the region capable of forming a
disulfide bond is d, a native Fc tive in which a part of the amino acid(s) in the
N-terminus is removed, a native Fc derivative in which a methionine e is added to the
N-terminus, a native Fc derivative in which a complement-binding site is deleted, or a native Fc
derivative in which an antibody dependent cell mediated cytotoxicity (ADCC) site is deleted.
In the conjugate according to any one of the previous specific embodiments, the
immunoglobulin Fc region is derived from an immunoglobulin selected from the group
consisting of IgG, IgA, IgD, IgE, and IgM.
In the conjugate ing to any one of the previous specific embodiments, the
immunoglobulin Fc region is an IgG4 Fc .
In the conjugate according to any one of the previous specific ments, the
immunoglobulin Fc region is an aglycosylated Fc region derived from human IgG4.
In the conjugate according to any one of the previous specific ments, the linker is
linked to a cysteine residue of the peptide.
In the conjugate according to any one of the previous specific ments, in a specific
embodiment of the present invention, the linker of the conjugate is respectively linked to the
peptide moiety and the biocompatible material moiety through covalent bonds, which were
respectively formed when one end of the linker reacted with an amine group or thiol group of the
biocompatible material moiety while the other end of the linker reacted with an amine group or
thiol group of the peptide moiety including the amino acid sequence of General Formula 1 or 2,
respectively.
Still another aspect of the present invention es a pharmaceutical composition for
preventing or ng hypoglycemia containing a glucagon tive or a conjugate containing
the same and a pharmaceutically acceptable excipient.
In a specific embodiment, the t invention relates to a pharmaceutical composition
for preventing or treating hypoglycemia, which contains the isolated peptide or the isolated
conjugate, which includes a peptide moiety, that has the same sequence as that of the isolated
peptide or includes a sequence including the same, and a patible material moiety
covalently linked to the peptide moiety.
Still another aspect of the present invention provides a pharmaceutical composition for
preventing or treating metabolic me containing a glucagon derivative or a conjugate
containing the same and a pharmaceutically acceptable excipient.
In a specific embodiment, the present invention s to a pharmaceutical composition
for preventing or treating metabolic syndrome, which contains the ed e; or the
isolated conjugate, which includes a peptide moiety, that has the same sequence as that of the
isolated peptide or includes a sequence including the same, and a biocompatible material moiety
ntly linked to the peptide moiety.
In the pharmaceutical composition according to any one of the previous ic
embodiments, the pharmaceutical composition further contains at least one compound or
al having the therapeutic activity for metabolic syndrome.
In the pharmaceutical composition according to any one of the previous specific
embodiments, the compound or material having the therapeutic activity for metabolic syndrome
is selected from the group consisting of an notropic e, a glucagon like peptide-1
(GLP-1) receptor agonist, a leptin receptor agonist, a dipeptidyl peptidase-IV (DPP-IV) inhibitor,
a Y5 receptor antagonist, a melanin-concentrating hormone (MCH) receptor antagonist, a Y2/4
receptor agonist, a melanocortin 3/4 (MC 3/4) receptor agonist, a gastric/pancreatic lipase
tor, an agonist of 5-hydroxytryptamine or 2C (5HT2C, G-protein coupled), a β3A
receptor agonist, an amylin receptor agonist, a ghrelin antagonist, a ghrelin receptor antagonist, a
peroxisome erator-activated receptor alpha (PPARα) agonist, a peroxisome
erator-activated receptor delta (PPARδ) t, a Farnesoid X receptor (FXR) agonist, an
acetyl-CoA carboxylase inhibitor, a peptide YY, cholecystokinin (CCK), xenin, glicentin,
obestatin, secretin, nesfatin, insulin, and a glucose-dependent insulinotropic peptide (GIP).
In the pharmaceutical composition according to any one of the previous specific
embodiments, the insulinotropic peptide is selected from the group consisting of GLP-1,
exendin-3, exendin-4, an agonist thereof, a derivative thereof, a fragment thereof, a t
thereof, and a combination thereof.
In the pharmaceutical composition according to any one of the previous specific
embodiments, the insulinotropic peptide is an insulinotropic peptide derivative in which the
N-terminal histidine of the insulinotropic peptide is tuted with one selected from the group
consisting of desamino-histidyl, N-dimethyl-histidyl, β-hydroxy imidazopropionyl,
4-imidazoacetyl, and β-carboxy imidazopropionyl.
In the pharmaceutical composition according to any one of the previous specific
embodiments, the insulinotropic peptide is selected from the group consisting of a native
exendin-4; an exendin-4 derivative in which the N-terminal amine group of exendin-4 is deleted;
an n-4 tive in which the N-terminal amine group of exendin-4 is substituted with a
hydroxyl group; an exendin-4 derivative in which the N-terminal amine group of exendin-4 is
modified with a dimethyl group; an exendin-4 tive in which the α-carbon of the 1st amino
acid of exendin-4, histidine, is deleted; an exendin-4 derivative in which the 12th amino acid of
exendin-4, lysine, is substituted with serine, and an exendin-4 derivative in which the 12th amino
acid of exendin-4, lysine, is substituted with ne.
In the pharmaceutical ition according to any one of the previous ic
embodiments, the notropic peptide is in the form of a long-acting conjugate, which includes
a peptide moiety, that includes the same amino acid sequence as that of the insulinotropic
peptide, and a biocompatible al moiety ntly linked to the peptide moiety.
In the pharmaceutical composition according to any one of the us specific
embodiments, the biocompatible material moiety is selected from the group consisting of a
polymer, fatty acid, cholesterol, albumin and a fragment thereof, an albumin-binding material, a
polymer of repeating units of a particular amino acid sequence, an antibody, an antibody
fragment, an FcRn-binding material, in vivo connective tissue or a derivative thereof, a
tide, fibronectin, errin, a saccharide, heparin, and elastin.
In the pharmaceutical composition according to any one of the previous specific
embodiments, the polymer is selected from the group consisting of a polyethylene glycol, a
polypropylene glycol, an ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol,
polyvinyl alcohol, a polysaccharide, dextran, polyvinyl ethyl ether, a biodegradable polymer, a
lipid polymer, chitin, hyaluronic acid, an oligonucleotide, and a combination thereof.
In the pharmaceutical ition according to any one of the previous ic
ments, the FcRn-binding material is a polypeptide including an immunoglobulin Fc
region.
In the pharmaceutical composition according to any one of the previous ic
embodiments, the peptide moiety including the amino acid sequence of the insulinotropic peptide
is linked to the biocompatible material moiety through a linker.
In the pharmaceutical composition according to any one of the previous specific
embodiments, the linker is ed from the group consisting of a e, fatty acid, a
saccharide, a polymer, a low molecular weight compound, a nucleotide, and a ation
thereof.
In the pharmaceutical composition according to any one of the us specific
ments, the linker is a polymer selected from the group consisting of a polyethylene glycol,
a polypropylene , an ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol,
polyvinyl alcohol, a polysaccharide, dextran, polyvinyl ethyl ether, a biodegradable polymer, a
lipid polymer, chitin, hyaluronic acid, an oligonucleotide, and a combination f.
In the pharmaceutical composition according to any one of the previous specific
ments, the metabolic syndrome is selected from the group consisting of impaired glucose
tolerance, hypercholesterolemia, dyslipidemia, obesity, es, hypertension, nonalcoholic
steatohepatitis (NASH), atherosclerosis caused by dyslipidemia, atherosclerosis, arteriosclerosis,
coronary heart disease, stroke, etc.
In the pharmaceutical composition according to any one of the previous specific
embodiments, the insulinotropic peptide is linked to a biocompatible material moiety through a
linker selected from the group consisting of a polyethylene glycol, a polypropylene glycol, an
ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl l, a
polysaccharide, dextran, nyl ethyl ether, a biodegradable polymer such as polylactic acid
(PLA) and polylactic-glycolic acid (PLGA), a lipid polymer, chitins, hyaluronic acid, fatty acid,
a polymer, a low molecular weight compound, a nucleotide, and a combination thereof.
In the ceutical composition according to any one of the us specific
embodiments, the biocompatible material moiety is an FcRn-binding material, and the peptide
moiety including the amino acid sequence of the insulinotropic peptide is linked to a
biocompatible material moiety through a peptide linker; or a non-peptide linker selected from the
group consisting of a polyethylene glycol, a polypropylene glycol, an ne glycol-propylene
glycol copolymer, polyoxyethylated polyol, nyl alcohol, a polysaccharide, dextran,
polyvinyl ethyl ether, a radable polymer such as polylactic acid (PLA) and
polylactic-glycolic acid (PLGA), a lipid polymer, chitins, hyaluronic acid, and a combination
In the pharmaceutical composition according to any one of the previous specific
embodiments, the composition may include both (i) a conjugate, which includes the peptide
moiety including the amino acid sequence of SEQ ID NO: 37, and a biocompatible material
moiety covalently linked to the peptide moiety; and (ii) a conjugate, which es an
o-acetyl n-4 moiety where the α-carbon of the 1st amino acid of exendin-4 (i.e.,
histidine) is deleted and a biocompatible material moiety covalently linked to the imidazo-acetyl
exendin-4 moiety.
In the ceutical composition according to any one of the previous specific
embodiments, the peptide moiety including the amino acid sequence of SEQ ID NO: 37 and the
imidazo-acetyl exendin-4 moiety are linked to their respective patible material moietys
through a linker.
In the pharmaceutical composition according to any one of the previous ic
embodiments, the FcRn-binding material is a polypeptide including an immunoglobulin Fc
region.
Still another aspect of the present invention provides a method for preventing or treating
ital hyperinsulinism including administering the glucagon derivative or a conjugate
ning the same or a composition containing the same to a subject in need thereof.
Still another aspect of the t invention provides use of the glucagon derivative or
the conjugate containing the same or the composition containing the same in the preparation of a
medicament for preventing or treating congenital hyperinsulinism.
Still another aspect of the present invention provides a method for preventing or treating
hypoglycemia including administering the glucagon tive or a conjugate containing the
same or a composition ning the same to a subject in need f.
Still another aspect of the present invention provides use of the glucagon derivative or
the conjugate containing the same or the composition containing the same in the preparation of a
medicament for preventing or ng hypoglycemia.
Still another aspect of the present invention provides a method for preventing or treating
metabolic syndrome including administering the glucagon derivative or a conjugate containing
the same or a composition containing the same to a subject in need thereof.
In a specific embodiment, the method further includes administering at least one
compound or material having a therapeutic activity for metabolic syndrome.
In the method according to any one of the previous specific embodiments, the glucagon
derivative or a conjugate containing the same and the compound or material having a therapeutic
activity for metabolic syndrome is administered simultaneously, individually, or sequentially.
Still another aspect of the present ion provides use of the glucagon derivative or
the conjugate containing the same or the composition containing the same in the preparation of a
medicament (or pharmaceutical compositon) for preventing or treating metabolic syndrome.
tageous Effects of the ion]
The glucagon derivatives of the present invention have improved al properties
ed to those of native glucagon, and can be effectively used for the prevention and
treatment of metabolic syndrome, such as obesity, es, and nonalcoholic steatohepatitis
(NASH), and congenital hyperinsulinism.
[Brief Description of the gs]
shows a graph illustrating the changes in body weight of obesity animal models
(rats), which were prepared by at diet, during a single or combined administration of a
cting notropic peptide conjugate (named as a long-acting exendin-4 derivative) and a
long-acting glucagon derivative conjugate (named as a long-acting derivative of SEQ ID NO:
12) with an adjusted dose to the rats, at 3-day intervals for 15 days.
shows a result illustrating the amount of mesenteric fat of obesity animal models
(rats), which were prepared by high-fat diet, measured after a single or combined administration
of a cting insulinotropic peptide conjugate (named as a long-acting exendin-4 derivative)
and a long-acting glucagon derivative ate (named as a long-acting derivative of SEQ ID
NO: 12) with an adjusted dose to the rats for 15 days (*p < 0.05 compared to vehicle, **p < 0.01
vs. one-way ANOVA analysis).
shows a result illustrating the difference in liver weight of obesity animal models
(rats), which were prepared by high-fat diet, measured after a single or combined administration
of a long-acting insulinotropic peptide conjugate (named as a long-acting exendin-4 tive)
and a long-acting glucagon derivative conjugate (named as a long-acting derivative of SEQ ID
NO: 12) with an adjusted dose to the rats for 15 days (***p < 0.01, ***p < 0.001 compared to
vehicle vs. one-way ANOVA analysis).
shows a graph illustrating the changes in body weight (BW) of y animal
models (mice), which were prepared by high-fat diet, after a single or combined administration
of a long-acting insulinotropic peptide conjugate (named as a long-acting exendin-4 derivative)
and a long-acting glucagon derivative conjugate (named as a long-acting derivative of SEQ ID
NO: 20) with an adjusted dose to the mice for 22 days.
shows a result rating the changes in cholesterol content in blood of obesity
animal models (mice), which were prepared by high-fat diet, after a single or combined
administration of a long-acting insulinotropic e ate (named as a long-acting
exendin-4 derivative) and a long-acting glucagon derivative conjugate (named as a long-acting
tive of SEQ ID NO: 20) with an adjusted dose to the mice for 22 days.
shows a result illustrating the changes in body weight, blood cholesterol levels,
fat weight, and impaired glucose tolerance of obesity animal models , which were
prepared by high-fat diet, after a single administration of liraglutide (Novo Nordisk) and a
cting insulinotropic peptide conjugate (named as a long-acting exendin-4 derivative), or
combined administration of a long-acting insulinotropic peptide conjugate (named as a
long-acting exendin-4 derivative) and a long-acting glucagon derivative conjugate (named as a
long-acting derivative of SEQ ID NO: 37) with an adjusted dose to the mice for 28 days. The
effects compared to vehicle (administered with an excipient) are shown.
shows a result rating the effect of ameliorating hypoglycemia ing to
the administration of a long-acting conjugate of glucagon tive of SEQ ID NO: 37 in acute
hypoglycemia animal models (rats).
shows a result illustrating the effect of ameliorating hypoglycemia according to
the stration of a long-acting conjugate of glucagon derivative of SEQ ID NO: 37 in
chronic hypoglycemia animal models .
[BEST MODE]
[Detailed Description of Preferred Embodiments]
The ic s of the present invention may be explained as follows. In particular,
the explanations and embodiments disclosed in the present invention may be applied to other
explanations and embodiments, respectively. That is, all combinations of various elements
disclosed in the present invention belong to the scope of the present invention. Additionally,
the scope of the present invention should not be limited by the specific descriptions described
herein below.
Additionally, those of ordinary skill in the art may be able to recognize or confirm, using
only conventional experimentation, many equivalents to the particular aspects of the invention
described in this application. Furthermore, it is also intended that these equivalents be included
in the present invention.
Throughout the sure of the present invention, not only the conventional 1-letter
codes and 3-letter codes for amino acids present in nature but also the 3-letter codes, such as Aib
(α-aminoisobutyric acid), Sar(N-methylglycine) generally used for other amino acids, are used.
onally, the amino acids mentioned in abbreviation in the present disclosure are described
according to the IUPAC-IUB Nomenclature.
alanine A arginine R
asparagine N aspartic acid D
cysteine C glutamic acid E
glutamine Q glycine G
histidine H cine I
leucine L lysine K
methionine M phenylalanine F
e P serine S
threonine T tryptophan W
tyrosine Y valine V
An aspect of the present invention es a composition containing a glucagon
tive or a conjugate ning the same, and specifically, a pharmaceutical composition for
ting or treating congenital hyperinsulinism, hypoglycemia, or metabolic syndrome
containing a glucagon tive or a conjugate containing the same.
The glucagon derivative according to the present invention includes a e having at
least one difference in the amino acid sequence compared to native glucagon, a peptide in which
the ce of native glucagon is modified by modifying native glucagon, and a native
glucagon mimetic that can activate glucagon receptors like native glucagon.
Such a glucagon tive may be one having improved physical properties by having
an altered pI relative to native on. Additionally, the glucagon derivative may be one with
improved solubility while having the activity of activating glucagon receptors, but is not limited
thereto.
Additionally, the glucagon derivative may be a non-naturally occurring glucagon.
In particular, native glucagon may have the following amino acid ce:
His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln
-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr (SEQ ID NO: 1)
As used herein, the term “isoelectric point” or “pI” refers to the pH value at which a
molecule such as a polypeptide or e has no net charge (0). In the case of a polypeptide
with various charged functional groups, the net charge of the total polypeptide is “0” at a point
where the pH value is the same as that of the pI. The net charge of the polypeptide at a pH
higher than the pI will be negative while the net charge of the polypeptide at a pH lower than the
pI will be positive.
The pI values may be determined on an immobilized pH gradient gel consisting of
polyacrylamide, starch, or agarose by isoelectric electrophoresis, or may be ted, for
example, from an amino acid sequence using a pI/MW tool (http://expasy.org/tools/pi_tool.html;
Gasteiger et al., 2003) in an ExPASy server.
As used , the term “altered pI” refers to a pI which is different from that of native
glucagon due to the substitution of a part of the amino acid sequence of native glucagon with an
amino acid residue having a negative charge or a positive charge, i.e., a reduced or increased pI
value. The peptide with such an altered pI can exhibit improved solubility and/or high stability
at a neutral pH as a on derivative, but is not particularly limited thereto.
More specifically, the on derivative may have an altered pI value, not the pI value
(6.8) of native glucagon, and even more specifically, a pI value of less than 6.8, more
specifically, 6.7 or less, more specifically 6.5 or less, and additionally, a pI value exceeding 6.8,
7 or higher, more specifically, 7.5 or higher, but is not d thereto, and any pI value different
from that of native glucagon will belong to the scope of the present invention. In particular,
when the pI value is different from that of native glucagon and thus exhibits an ed
solubility at a neutral pH ed to that of native glucagon thus showing a low level of
aggregation, it will particularly belong to the scope of the present invention.
More specifically, the glucagon derivative may have a pI value of from 4 to 6.5 and/or
from 7 to 9.5, specifically from 7.5 to 9.5, and more specifically, from 8.0 to 9.3, but the pI value
is not d thereto. In this case, due to the lower or higher pI value compared to that of
native glucagon, an improved solubility and high stability at a neutral pH compared to that of
native glucagon can be exhibited, but is not particularly limited thereto.
Specifically, a derivative of native glucagon may be modified by any one method of
substitution, addition, deletion, and modification, or a combination f in part of the amino
acid of native glucagon.
Examples of the glucagon derivatives prepared by a combination of the above s
include a peptide which differs in at least one amino acid residue of the amino acid sequence
ed to that of native glucagon and in which the N-terminal amino acid residue is
deaminated, having the function of activating a glucagon receptor, but is not limited thereto, and
the native glucagon derivatives can be prepared by a combination of various methods for
ing the derivatives.
Additionally, such modification for the preparation of native glucagon derivatives may
include all of the modifications using L-type or D-type amino acids, and/or non-native type
amino acids; and/or a modification of native sequence, for example, modification of a functional
group, an intramolecular covalent g (e.g., a ring formation between side chains),
methylation, acylation, ubiquitination, phosphorylation, aminohexanation, biotinylation, etc.
Additionally, the modification may also include substitutions into non-native nds.
Additionally, the modification may also include all those where one or more amino acids
are added to the amino and/or carboxy terminal of native glucagon.
During the substitution or addition of amino acids, not only the 20 amino acids
commonly found in human proteins, but also atypical or non-naturally occurring amino acids can
be used. Commercial sources of atypical amino acids may include Sigma-Aldrich, ChemPep
Inc., and Genzyme Pharmaceuticals. The es ing these amino acids and typical
e sequences may be synthesized and purchased from cial suppliers, e.g., an
Peptide Company, Bachem (USA), or Anygen (Korea).
Amino acid derivatives may also be obtained in a similar manner, for example,
4-imidazoacetic acid, etc., may be used.
Since glucagon has a pH of about 7, it is insoluble in a solution having a physiological
pH (pH 4 to 8) and tends to precipitate at a neutral pH. In an aqueous solution with a pH of 3
or below, glucagon is dissolved at the initial stage but precipitates within one hour by forming a
gel. Since the gelated glucagon mainly consists of β-sheet s, the administration of the
recipitated glucagon via an injection needle or intravenous injection will block blood
s, and thus is not suitable for use as an injection agent. In order to delay the precipitation
process, acidic (pH 2 to 4) formulations are commonly used, and by doing so, glucagon can be
maintained in a relatively non-aggregated state for a short period of time. However, glucagon
can form s very rapidly at a low pH, and thus these acidic formulations must be injected
upon preparation.
In this regard, the present inventors have developed glucagon derivatives with extended
action profiles by modifying the pI of native glucagon via substitution of amino acid residues
having ve charges and positive charges. The glucagon derivatives of the present
invention, by having an altered pI compared to that of native glucagon, are characterized in
having improved solubility and/or high stability at a neutral pH, compared to that of native
glucagon.
In a specific embodiment of the present invention, the glucagon derivative may be a
peptide which es the amino acid sequence of the following General Formula 1:
X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F-X23-
X24-W-L-X27-X28-X29-X30 (General Formula 1, SEQ ID NO: 45)
In the above Formula,
X1 is histidine, desamino-histidyl, N-dimethyl-histidyl, β-hydroxy imidazopropionyl,
4-imidazoacetyl, β-carboxy imidazopropionyl, tryptophan, or tyrosine, or is absent;
X2 is α-methyl-glutamic acid, aminoisobutyric acid (Aib), D-alanine, glycine,
Sar(N-methylglycine), serine, or D-serine;
X7 is threonine, , or cysteine;
X10 is tyrosine or cysteine;
X12 is lysine or ne;
X13 is tyrosine or cysteine;
X14 is leucine or cysteine;
X15 is aspartic acid, ic acid, or cysteine;
X16 is glutamic acid, ic acid, serine, α-methyl-glutamic acid, or cysteine, or is
absent;
X17 is aspartic acid, glutamine, ic acid, lysine, ne, serine, cysteine, or
valine, or is absent;
X18 is alanine, aspartic acid, glutamic acid, arginine, valine, or cysteine, or is absent;
X19 is alanine, arginine, serine, , or cysteine, or is absent;
X20 is lysine, histidine, glutamine, aspartic acid, ne, α-methyl-glutamic acid, or
cysteine, or is absent;
X21 is aspartic acid, glutamic acid, leucine, valine, or cysteine, or is absent;
X23 is isoleucine, valine, or arginine, or is absent;
X24 is valine, arginine, alanine, cysteine, glutamic acid, lysine, glutamine,
α-methyl-glutamic acid, or e, or is absent;
X27 is cine, valine, e, , methionine, glutamine, or arginine, or is
X28 is glutamine, lysine, asparagine, or arginine, or is absent;
X29 is lysine, alanine, glycine, or threonine, or is absent; and
X30 is cysteine or is absent;
with the proviso that when the amino acid sequence of General Formula 1 is identical to
SEQ ID NO: 1, it is excluded.
More specifically,
in l Formula 1,
X1 is histidine, tryptophan, or tyrosine, or is absent;
X2 is serine or aminoisobutyric acid (Aib);
X7 is threonine, valine, or cysteine;
X10 is tyrosine or cysteine;
X12 is lysine or cysteine;
X13 is tyrosine or cysteine;
X14 is leucine or cysteine;
X15 is aspartic acid or cysteine;
X16 is glutamic acid, serine, or ne;
X17 is aspartic acid, glutamic acid, lysine, ne, , cysteine, or valine;
X18 is aspartic acid, glutamic acid, arginine, or cysteine;
X19 is alanine or cysteine;
X20 is glutamine, aspartic acid, lysine, or cysteine;
X21 is aspartic acid, glutamic acid, leucine, valine, or cysteine;
X23 is isoleucine, valine, or arginine;
X24 is valine, arginine, alanine, glutamic acid, lysine, glutamine, or leucine;
X27 is isoleucine, valine, alanine, methionine, glutamine, or arginine;
X28 is glutamine, lysine, asparagine, or arginine;
X29 is threonine; and
X30 is cysteine or is absent
with the proviso that when the amino acid ce of General Formula 1 is identical to
SEQ ID NO: 1, it is excluded.
For example, the peptide may be one which includes an amino acid sequence selected
from the group consisting of SEQ ID NOS: 2 to 44, and specifically, one which (essentially)
consists of an amino acid sequence ed from the group consisting of SEQ ID NOS: 2 to 44,
but is not limited thereto.
Additionally, although described as “a e consisting of a ular SEQ ID NO” in
the present invention, such expression does not exclude a mutation in the peptide that can occur
by a meaningless sequence addition am or downstream of the amino acid sequence of the
corresponding SEQ ID NO, or a naturally-occurring mutation therein, or a silent mutation n,
as long as the peptide having such mutation has an activity the same as or corresponding to that
of the peptide which consists of an amino acid sequence of the corresponding SEQ ID NO.
Even when the sequence addition or a mutation is present, it obviously belongs to the scope of
the present invention.
Those described above may be also applied to other specific embodiments or aspects of
the present invention, but are not limited thereto.
ically, in l Formula 1 above,
X1 may be histidine, tryptophan, or tyrosine;
X2 may be serine or aminoisobutyric acid (Aib);
X7 may be cysteine, threonine, or valine;
X10 may be tyrosine or cysteine;
X12 may be lysine or cysteine;
X13 may be tyrosine or cysteine;
X14 may be leucine or cysteine;
X15 may be aspartic acid or cysteine;
X16 may be glutamic acid, serine, or cysteine;
X17 may be glutamic acid, lysine, arginine, cysteine, or valine;
X18 may be arginine or cysteine;
X19 may be alanine or cysteine;
X20 may be ine or lysine;
X21 may be aspartic acid, glutamic acid, valine, or cysteine;
X23 may be valine;
X24 may be valine or glutamine;
X27 may be methionine;
X28 may be asparagine or arginine;
X29 may be threonine; and
X30 may be cysteine or is .
For e, the e may be one which es an amino acid sequence selected
from the group consisting of SEQ ID NOS: 3, 11 to 17, 19 to 27, 29, 31, 33, and 35 to 44, and
specifically, one which (essentially) consists of an amino acid sequence selected from the group
consisting of SEQ ID NOS: 3, 11 to 17, 19 to 27, 29, 31, 33, and 35 to 44, but is not limited
thereto.
Specifically, in General Formula 1 above,
X1 may be tyrosine;
X2 may be aminoisobutyric acid (Aib);
X7 may be cysteine, threonine, or valine;
X10 may be tyrosine or cysteine;
X12 may be lysine;
X13 may be tyrosine or cysteine;
X14 may be leucine or cysteine;
X15 may be aspartic acid or cysteine;
X16 may be glutamic acid, serine, or ne;
X17 may be lysine, arginine, cysteine, or valine;
X18 may be arginine or cysteine;
X19 may be alanine or cysteine;
X20 may be glutamine or lysine;
X21 may be aspartic acid, glutamic acid, or cysteine;
X23 may be valine;
X24 may be glutamine;
X27 may be methionine;
X28 may be asparagine or arginine;
X29 may be threonine; and
X30 may be cysteine or is absent,
with the proviso that when the amino acid sequence of General Formula 1 is cal to
SEQ ID NO: 1, it is excluded.
For example, the peptide may be one which includes an amino acid sequence selected
from the group consisting of SEQ ID NOS: 12, 14, 17, 19 to 25, 27, 29, 33, 35 to 38, 40 to 42,
and 44, and specifically, one which (essentially) consists of an amino acid ce selected
from the group consisting of SEQ ID NOS: 12, 14, 17, 19 to 25, 27, 29, 33, 35 to 38, 40 to 42,
and 44, but is not limited thereto.
Specifically, in General Formula 1,
X1 may be histidine, tryptophan, or tyrosine, or is absent;
X2 may be serine or aminoisobutyric acid (Aib);
X7 may be ine, valine, or cysteine;
X10 may be tyrosine or cysteine;
X12 may be lysine or cysteine;
X13 may be tyrosine or cysteine;
X14 may be leucine or ne;
X15 may be aspartic acid or ne;
X16 may be glutamic acid, serine, or ne;
X17 may be aspartic acid, glutamic acid, lysine, arginine, serine, cysteine, or valine;
X18 may be aspartic acid, ic acid, arginine, or cysteine;
X19 may be alanine or cysteine;
X20 may be glutamine, aspartic acid, or lysine;
X21 may be aspartic acid or glutamic acid;
X23 may be valine;
X24 may be valine or glutamine;
X27 may be isoleucine or methionine;
X28 may be asparagine or arginine;
X29 may be threonine; and
X30 may be cysteine or may be absent,
with the proviso that when the amino acid sequence of l Formula 1 is identical to
SEQ ID NO: 1, it is excluded.
For example, the peptide may be one which es an amino acid sequence selected
from the group consisting of SEQ ID NOS: 2 to 13, 15, 17, 20 to 24, 26 to 30, and 32 to 44, and
specifically, one which (essentially) consists of an amino acid sequence selected from the group
consisting of SEQ ID NOS: 2 to 13, 15, 17, 20 to 24, 26 to 30, and 32 to 44, but is not limited
thereto.
Specifically, in the General Formula 1,
X1 may be tyrosine;
X2 may be aminoisobutyric acid (Aib);
X7 may be threonine;
X10 may be tyrosine;
X12 may be lysine;
X13 may be tyrosine;
X14 may be leucine;
X15 may be aspartic acid or ne;
X16 may be ic acid, serine, or cysteine;
X17 may be lysine or arginine;
X18 may be arginine;
X19 may be alanine;
X20 may be glutamine, cysteine, or ;
X21 may be aspartic acid, cysteine, valine, or glutamic acid;
X23 may be valine or arginine;
X24 may be glutamine or leucine;
X27 may be methionine;
X28 may be asparagine or arginine;
X29 may be threonine; and
X30 may be .
For example, the peptide may be one which includes an amino acid sequence selected
from the group consisting of SEQ ID NOS: 14, 16, 18, 19, 25, and 31, and specifically, one
which (essentially) consists of an amino acid sequence selected from the group consisting of
SEQ ID NOS: 14, 16, 18, 19, 25, and 31, but is not limited thereto.
More specifically, the peptide may be a peptide which includes the amino acid ce
of the following l Formula 2:
Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-W-L-MN-T-X30
(General Formula 2, SEQ ID NO: 46)
In General Formula 2,
X7 may be threonine, valine, or cysteine;
X10 may be tyrosine or cysteine;
X12 may be lysine or cysteine;
X15 may be aspartic acid or cysteine;
X16 may be glutamic acid or serine;
X17 may be lysine or arginine;
X20 may be glutamine or ;
X21 may be aspartic acid or glutamic acid;
X24 may be valine or glutamine; and
X30 may be ne or may be absent.
For example, the peptide may be one which es an amino acid sequence selected
from the group consisting of SEQ ID NOS: 12, 13, 15, and 36 to 44, and specifically, one which
(essentially) consists of an amino acid sequence selected from the group ting of SEQ ID
NOS: 12, 13, 15, and 36 to 44, but is not limited thereto. More specifically, the peptide may be
one which es an amino acid ce of SEQ ID NO: 12, SEQ ID NO: 20, or SEQ ID NO:
37, or (essentially) consists of the corresponding amino acid sequence, but is not limited thereto.
Specifically, in General Formula 2,
X7 may be threonine, , or cysteine;
X10 may be tyrosine or cysteine;
X12 may be lysine;
X15 may be aspartic acid;
X16 may be glutamic acid or serine;
X17 may be lysine or ne;
X20 may be glutamine or lysine;
X21 may be aspartic acid or glutamic acid;
X24 may be glutamine; and
X30 may be cysteine or may be absent, but is not particularly limited thereto.
For example, the peptide may be one which includes an amino acid sequence selected
from the group ting of SEQ ID NOS: 12, 36 to 38, 40 to 42, and 44, and specifically, one
which (essentially) consists of an amino acid sequence selected from the group ting of
SEQ ID NOS: 12, 36 to 38, 40 to 42, and 44, but is not limited thereto.
However, among the isolated peptides, the es corresponding to SEQ ID NOS: 2 to
11, 14, 16 to 35, 49, and 50, and specifically, the peptides corresponding to SEQ ID NOS: 19, 33,
49, and 50 may be excluded from the claimed scope, but is not particularly limited thereto, and
all of the peptides described in claims must belong to the scope of the present invention unless
specified otherwise.
The glucagon derivative described above may include an intramolecular bridge (e.g.,
covalent crosslinking or non-covalent crosslinking), and specifically, may be in a form including
a ring. For example, the glucagon derivative may be in a form where a ring is formed between
the 16th and 20th amino acids of the glucagon derivative, but it is not particularly limited thereto.
Non-limiting examples of the ring may e a lactam crosslinking (or a lactam ring).
Additionally, the glucagon derivative es all of those which are modified to include
an amino acid capable of forming a ring at the desired site so as to include a ring.
The ring may be formed between side chains of amino acids within the glucagon
derivative (e.g., in the form of a ring formation between a side chain of lysine and a side chain of
a glutamic acid), but is not particularly limited thereto.
For e, the peptide including the amino acid sequence of General Formula 1 or 2
may be one in which each amino acid in each amino acid pair among the amino acid pairs of
X10 and X14, X12 and X16, X16 and X20, X17 and X21, X20 and X24, and X24 and X28 in
General Formula 1 or 2 may be tuted with glutamic acid or lysine, respectively, but is not
d thereto. In the Xn (n is an integer), n refers to the position of the amino acid from the
N-terminus of an amino acid sequence provided.
Additionally, the peptide including the amino acid sequence of General Formula 1 or 2
may be one in which each amino acid in each amino acid pair of X12 and X16 or the amino acid
pair of X16 and X20 or the amino acid pair of X17 and X21 is tively substituted with
glutamic acid or lysine, which is capable of forming a ring.
Additionally, in General Formula 1 or 2, the peptide may be one in which a ring (e.g., a
lactam ring) is formed between each amino acid in each amino acid pair among the amino acid
pairs of X10 and X14, X12 and X16, X16 and X20, X17 and X21, X20 and X24, and X24 and
X28, but is not limited thereto.
Additionally, in General Formula 1 or 2, X16 may be glutamic acid, X20 may be lysine,
and the side chains of X16 and X20 may form a lactam ring, but they are not limited thereto.
Additionally, the peptide according to the present invention may be in the form where
the inus and/or inus is not modified, however, those variants, where the amino
terminus and/or carboxy us, etc., of the peptide is chemically modified or protected by
organic groups, or amino acids added to the end of the e for its protection from proteases
in vivo while increasing its stability, may also be included in the scope of the peptides of the
present invention. In a case where the C-terminus is not modified, the end of the peptide
according to the present invention may have a carboxyl group, but is not particularly limited
In particular, in the case of a ally-synthesized peptide, its N- and C-termini are
electrically charged and thus the N- and C-termini of the peptide may be acetylated and/or
amidated, but the peptide is not particularly limited thereto.
Unless specified otherwise in the present invention, the ption in the detailed
description or claims with respect to “the peptide” according to the present invention or a
“conjugate”, in which such a peptide is covalently linked to a biocompatible material, may be
applied to the forms, which include not only include the corresponding peptide or conjugate but
also the salts of the corresponding peptide or conjugate (e.g., pharmaceutically acceptable salts
thereof), or solvates thereof. Accordingly, even in a case where a de” or “conjugate” is
described in the present invention, the description may also be equally applied to a particular salt
thereof, a particular solvate thereof, and a ular solvate of the particular salt thereof. These
salts may be, for example, in a form where any pharmaceutically acceptable salts are used. The
kind of the salt is not particularly limited. However, the salt is preferably one that is safe and
effective to a subject, e.g., a mammal, but is not particularly limited thereto.
The term “pharmaceutically acceptable” refers to a al which can be ively
used for the intended use within the scope of pharmaco-medical decision without inducing
excessive toxicity, irritation, allergic responses, etc.
As used , the term “pharmaceutically acceptable salt” refers to a salt derived from
ceutically acceptable inorganic salts, organic salts, or bases. Examples of the le
salts may include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid,
fumaric acid, maleic acid, phosphoric acid, ic acid, lactic acid, salicylic acid, succinic acid,
toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid,
benzoic acid, malonic acid, naphthalenesulfonic acid, benzenesulfonic acid, etc. Examples
of the salts derived from suitable bases may include alkali metals such as sodium, potassium,
etc.; alkali earth metals such as magnesium; ammonium, etc.
Additionally, as used herein, the term te” refers to a complex formed between the
peptide, conjugate, or a salt thereof according to the present invention and a solvent molecule.
onally, the e of the present invention may be synthesized by a method
well-known in the art, according to its length, e.g., by an automatic peptide synthesizer, and may
be produced by genetic engineering technology.
Specifically, the peptide of the present invention may be prepared by a standard
synthesis method, a recombinant expression system, or any other method known in the art.
Accordingly, the glucagon derivative of the present invention may be synthesized by various
methods including, for example, the methods bed below:
(a) a method of synthesizing a peptide by a solid-phase or liquid-phase method stepwise
or by fragment assembly, followed by isolation and purification of the final peptide t; or
(b) a method of expressing a c acid construct encoding a peptide in a host cell and
recovering the expression product from the host cell culture; or
(c) a method of performing an in vitro ree expression of a nucleic acid construct
encoding a peptide and recovering the expression product therefrom; or
a method of obtaining peptide fragments by any combination of the methods (a), (b), and
(c), obtaining the peptide by linking the e fragments, and then recovering the peptide.
In a more specific example, a desired glucagon tive may be produced by genetic
manipulation, which includes preparing a fusion gene encoding a fusion protein, including a
fusion partner and a glucagon tive, orming the resultant into a host cell, sing in
the form of a fusion protein, and cleaving the glucagon derivative from the fusion protein using a
protease or a compound which is capable of protein cleavage followed by separation. For this
purpose, for example, an amino acid residue-encoding DNA sequence that can be cleaved by a
protease such as Factor Xa or enterokinase, CNBr, or a compound such as ylamine, may
be inserted between the fusion partner and a polynucleotide encoding a on tive.
In a more ic embodiment, a glucagon derivative, for example, a peptide including
the amino acid sequence of General Formula 1 or 2, may be in the form of a long-acting
conjugate in which a patible material moiety capable of increasing in vivo half-life of the
peptide is linked to the peptide, but is not limited thereto. The biocompatible material moiety
may be interchangeably used with a carrier.
Specifically, the conjugate includes a peptide moiety and a biocompatible material
moiety which is covalently linked to the peptide moiety, and the peptide moiety may be a
ce which is the same as the amino acid sequence of General Formula 1 or 2, or a sequence
including the same.
As used herein, the term “long-acting conjugate”, being in the form where a
biocompatible al moiety or carrier is linked to a physiologically active material (e.g., a
glucagon derivative, insulinotropic peptide, etc.), refers to a conjugate which exhibits an
enhanced efficacy of duration (e.g., an increase of in vivo half-life) compared to that of a
logically active material to which a biocompatible material moiety or carrier is not linked.
In the long-acting conjugate, the biocompatible material moiety or carrier may be one that is
covalently linked to the physiologically active material, but is not particularly limited thereto.
In a specific embodiment of the present invention, the duration of efficacy of the above
conjugate of a glucagon derivative may increase compared to native glucagon or a glucagon
derivative thereof, to which a carrier is not linked.
As used herein, the term “biocompatible material ” refers to a material which can
be linked to a physiologically active material (e.g., a glucagon derivative, insulinotropic peptide,
etc.) and thereby enhance the cy of duration compared to a logically active material
to which a biocompatible material moiety or carrier is not linked. The biocompatible material
moiety may be one that is covalently linked to the physiologically active al, but is not
particularly limited thereto.
Examples of the biocompatible material moiety may include a r, fatty acid,
cholesterol, albumin and a fragment thereof, an albumin-binding material, a polymer of repeating
units of a particular amino acid sequence, an antibody, an antibody fragment, an FcRn-binding
al, in vivo connective tissue or a derivative thereof, a nucleotide, fibronectin, transferrin, a
saccharide, heparin, and elastin, but are not d thereto.
Examples of the polymer may be those selected from the group consisting of a
polyethylene glycol, a opylene glycol, an ethylene glycol-propylene glycol copolymer,
polyoxyethylated polyol, polyvinyl alcohol, a polysaccharide, dextran, polyvinyl ethyl ether, a
biodegradable polymer, a lipid polymer, chitin, hyaluronic acid, an oligonucleotide, and a
ation thereof, but is not particularly limited o.
The polyethylene glycol is a general term including all of the forms of homopolymers of
ethylene glycol, PEG copolymers, and thyl-substituted PEG polymers (mPEG), but is
not particularly limited thereto.
Additionally, the biocompatible material moiety may include poly-amino acids such as
poly-lysine, poly-aspartic acid, and poly-glutamic acid, but is not limited thereto.
Additionally, the fatty acid may be one having a binding affinity to albumin in vivo, but
is not particularly limited thereto.
In a more specific embodiment, the FcRn-binding material may be an globulin
Fc region, and more specifically, an IgG Fc region, but is not ularly limited thereto.
At least one amino acid side chain within the peptide of the present invention may be
attached to the biocompatible material moiety in order to increase in vivo solubility and/or
half-life, and/or increase bioavailability thereof. These modifications can reduce the clearance
of therapeutic proteins and es.
The biocompatible material moiety may be soluble (amphipathic or hilic) and/or
non-toxic and/or ceutically acceptable.
It is a known fact to a skilled person in the art that the thus-modified on derivative
can exhibit a superior therapeutic effect compared to native glucagon. Accordingly, the
variants of the glucagon derivative as described above also belong to the scope of the present
invention.
The biocompatible material moiety may be directly attached to the glucagon derivative
or linked thereto through a linker. When the biocompatible material moiety is linked to the
on derivative directly or via a linker, the linkage may be a covalent bond.
ically, the linker may be a peptide linker or non-peptide linker.
When linker is a e linker it can include one or more amino acids, for example, 1 to
1000 amino acids, but is not particularly limited o. In the present invention, s
known peptide linkers may be used (e.g., including [GS]x , [GGGS]x linker, and
[GGGGS]x linker, etc., wherein x is a natural number of at least 1), but the peptide linkers are
not limited thereto.
As used herein, “non-peptide linker” includes a biocompatible polymer in which at least
two repeating units are linked. The repeating units are linked with each other by any covalent
bond instead of a peptide bond. The non-peptide linker may be one constitution that establishes
a moiety of a long-acting conjugate of the present invention.
As used herein, the term “non-peptide linker” may be used interchangeably with
“non-peptide polymer”.
In a ic ment, the biocompatible material moiety and the peptide may be
covalently linked through a non-peptide linker which includes a reactive group that can be linked
to the biocompatible material moiety (specifically, an immunoglobulin Fc ) and the
peptide at both ends thereof, respectively.
ically, the non-peptide linker may be one selected from the group consisting of
fatty acid, a saccharide, a polymer, a low molecular weight compound, a nucleotide, and a
combination thereof.
Although not ularly limited, the lar weight of the non-peptide polymer to be
used in the present invention may be in the range of r than 0 kDa to about 100 kDa or less,
specifically, about 1 kDa to about 100 kDa, and more specifically, about 1 kDa to about 20 kDa,
but is not limited thereto.
Although not particularly limited, the non-peptide linker may be one selected from the
group consisting of a polyethylene glycol, a polypropylene glycol, an ethylene glycol-propylene
glycol copolymer, polyoxyethylated polyol, nyl alcohol, a polysaccharide, dextran,
polyvinyl ethyl ether, a biodegradable r such as polylactic acid (PLA) and
polylactic-glycolic acid (PLGA), lipid polymer, chitin, hyaluronic acid, an oligonucleotide, and a
combination thereof.
In a more specific embodiment, the non-peptide r may be polyethylene glycol,
but is not limited thereto. Additionally, the derivatives which are already known in the art and
the derivatives which can be easily prepared at the level of the technology in the art belong to the
scope of the present invention.
The non-peptide linker to be used in the present invention may be any polymer which
has a resistance to in vivo proteases, without limitation. The molecular weight of the
non-peptide polymer may be in the range of greater than 0 kDa to about 100 kDa or less,
ically about 1 kDa to about 100 kDa, and more specifically, about 1 kDa to about 20 kDa,
but is not limited thereto. Additionally, the non-peptide linker of the present ion, which
is linked to the polypeptide including the immunoglobulin Fc region, may include not only a
single kind of a polymer but also a combination of different kinds of polymers.
As used , the term “about” refers to a range including all of ± 0.5, ± 0.4, ± 0.3, ±
0.2, ± 0.1, etc., and it includes all of the values equivalent to those which come immediately after
the term “above” or those in a similar range.
ically, the linker may be one that is tively linked to the peptide moiety and
the biocompatible material moiety through covalent bonds, which were respectively formed
when one end of the linker reacted with an amine group or thiol group of the biocompatible
material moiety while the other end of the linker reacted with an amine group or thiol group of
the peptide moiety (i.e., the peptide moiety including the amino acid sequence of General
Formula 1 or 2).
In a specific embodiment, one end of the non-peptide linker may be linked to an amine
group or thiol group of an immunoglobulin Fc region while the other end of the non-peptide
linker may be linked to an amine group or thiol group of a glucagon derivative. Specifically,
the non-peptide polymer may include a reactive group at both ends thereof, respectively, which
can be linked to a biocompatible material moiety, specifically an immunoglobulin Fc region, and
a glucagon derivative; for example, a reactive group which can respectively form a covalent
bond to be linked to the patible material and the glucagon derivative by reacting with an
amine group of N-terminus or lysine of the glucagon derivative, or a thiol group of cysteine of
the glucagon derivative, an amine group of N-terminus or lysine of the biocompatible material or
a thiol group of cysteine of the patible material (e.g., the immunoglobulin Fc region), but
is not limited thereto.
Additionally, the reactive end group of the non-peptide polymer that can be linked to the
biocompatible material moiety, specifically the immunoglobulin Fc region and the glucagon
derivative may be selected from the group consisting of an aldehyde group, a ide group,
and a succinimide derivative, but is not limited thereto.
In the above, es of the aldehyde group may include a propionaldehyde group or a
butyraldehyde group, but are not limited thereto.
In the above, as a succinimide derivative, succinimidyl valerate, succinimidyl
methylbutanoate, succinimidyl propionate, succinimidyl butanoate, succinimidyl
propionate, N-hydroxysuccinimide, hydroxy succinimidyl, succinimidyl ymethyl, or
succinimidyl ate may be used, but is not limited thereto.
Additionally, the final product produced through reductive amination via an aldehyde
bond is more stable than that linked by an amide bond. The aldehyde reactive group selectively
reacts with a N-terminus at a low pH condition while it can form a nt bond with a lysine
residue at high pH, e.g., pH 9.0.
The reactive groups at both ends of the ptide linker may be the same as or different
from each other, for example, a maleimide reactive group may be provided at one end and an
aldehyde group, a propionaldehyde group, or a butyraldehyde group may be provided at the
other end. However, if an immunoglobulin Fc region and a glucagon derivative can be
ated at each end of the non-peptide linker, it is not particularly limited.
For example, the non-peptide polymer may possess a maleimide group at one end and an
aldehyde group, a propionaldehyde group, or a butyraldehyde group at the other end.
When a polyethylene glycol having a ve hydroxy group at both ends thereof is used
as the non-peptide polymer, the hydroxy group may be activated to various reactive groups by
known al reactions, or a polyethylene glycol having a commercially available modified
reactive group may be used so as to prepare the long-acting protein conjugate of the present
invention.
In a specific embodiment, the non-peptide polymer may be one which can be linked to a
cysteine residue of a glucagon derivative, and more specifically, to the -SH group of cysteine,
but is not d thereto. In particular, the non-peptide polymer may be polyethylene glycol,
but is not particularly limited thereto, and other kinds of non-peptide polymers described
previously may also be included therein.
In a specific ment, the ate may be one in which a peptide including the
amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 20, or SEQ ID NO: 37 is linked to the
immunoglobulin Fc region by a non-peptide polymer, and in particular, the non-peptide polymer
may be one which is linked to the cysteine residue located on the 30th of the amino acid sequence
of SEQ ID NO: 12, the cysteine residue located on the 17th of the amino acid sequence of SEQ
ID NO: 20, or the ne residue located on the 30th of the amino acid sequence of SEQ ID
NO: 37, but is not limited thereto. In particular, the non-peptide polymer may be polyethylene
glycol, but is not particularly limited thereto, and other kinds of non-peptide polymers described
previously may also be included therein.
When maleimide-PEG-aldehyde is used, the maleimide group may be linked to the -SH
group of the glucagon derivative by a thioether bond and the aldehyde group may be linked to
the -NH2 of the immunoglobulin Fc through reductive amination, but is not d thereto and
the above is merely an ment.
Additionally, in the above conjugate, the reactive group of the non-peptide polymer may
be one that is linked to NH2 located at the N-terminus of the immunoglobulin Fc region, but this
is merely an exemplary embodiment.
In the present invention, “immunoglobulin Fc region” refers to a region including the
heavy chain constant region 2 (CH2) and/or the heavy chain constant region 3 (CH3), excluding
the heavy chain and light chain variable regions of an immunoglobulin. The immunoglobulin
Fc region may be one constitution that establishes a moiety of a protein conjugate of the present
invention.
The globulin Fc region may include a hinge region in the heavy chain constant
region, but is not d thereto. Additionally, the immunoglobulin Fc region of the present
ion may be an extended Fc region including a part or the entirety of the heavy chain
nt region 1 (CH1) and/or the light chain constant region 1 (CL1), excluding the heavy
chain and the light chain variable regions of the immunoglobulin, as long as the immunoglobulin
Fc region has an effect substantially the same as or improved compared to the native type.
Additionally, the globulin Fc region of the present invention may be a region in which a
fairly long part of the amino acid sequence corresponding to CH2 and/or CH3 is removed.
For example, the immunoglobulin Fc region of the present invention may be 1) a CH1
domain, a CH2 domain, a CH3 domain, and a CH4 domain; 2) a CH1 domain and a CH2
domain; 3) a CH1 domain and a CH3 domain; 4) a CH2 domain and a CH3 ; 5) a
combination between one or two or more domains among a CH1 domain, a CH2 domain, a CH3
domain, and a CH4 domain and an immunoglobulin hinge region (or a part of the hinge region);
and 6) a dimer between each domain of the heavy chain constant region and the light chain
nt region, but is not limited thereto.
Additionally, in a specific embodiment, the immunoglobulin Fc region may be in a
dimeric form, and one molecule of a glucagon derivative may be covalently linked to a Fc region
in a dimeric form, and in particular, the immunoglobulin Fc and the glucagon derivative may be
interlinked by a non-peptide polymer. Furthermore, two molecules of the glucagon derivative
may be possibly conjugated in a symmetrical manner to a single Fc region in a dimeric form.
In particular, the immunoglobulin Fc and the glucagon derivative or the insulinotropic peptide
may be inked by a non-peptide linker, but are not limited to the embodiment bed
above.
Additionally, the immunoglobulin Fc region of the present invention not only includes a
native amino acid sequence but also a ce derivative thereof. An amino acid sequence
derivative refers to an amino acid sequence which has a difference in at least one amino acid
residue due to on, insertion, nservative or conservative tution, or a
combination thereof.
For example, the amino acid residues at positions 214 to 238, 297 to 299, 318 to 322, or
327 to 331, which are known to be in the binding of an immunoglobulin Fc, may be used as
suitable sites for modification.
Additionally, other various derivatives are possible, including one that has a deletion of a
region capable of forming a disulfide bond, or a deletion of some amino acid residues at the
N-terminus of native Fc or an addition of a methionine residue at the N-terminus of native Fc.
Further, to remove effector functions, a deletion may occur in a complement-binding site, such
as a nding site and an antibody ent cell mediated cytotoxicity (ADCC) site.
Techniques of preparing such sequence derivatives of the globulin Fc region are
disclosed in International Patent Publication Nos. WO 97/34631, WO 96/32478, etc.
Amino acid ges in proteins and peptides, which do not generally alter the activity
of the proteins or peptides, are known in the art (H. Neurath, R. L. Hill, The Proteins, Academic
Press, New York, 1979). The most commonly occurring exchanges are r, Val/Ile,
Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Thy/Phe, Ala/Pro, Lys/Arg,
Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly, in both directions. In addition, the Fc region
may, if necessary, be modified by phosphorylation, sulfation, acrylation, glycosylation,
methylation, farnesylation, acetylation, amidation, etc.
The above-described Fc derivatives show ical activity identical to that of the Fc
region of the present invention and have improved structural stability against heat, pH, etc.
Further, the immunoglobulin Fc region may be obtained from native forms isolated in
vivo from humans or animals such as cows, goats, pigs, mice, rabbits, hamsters, rats, guinea pigs,
etc., or may be recombinants or derivatives thereof, obtained from transformed animal cells or
microorganisms. Herein, the Fc region may be obtained from a native immunoglobulin by
ing a whole immunoglobulin from a living human or animal body and ng the isolated
immunoglobulin with protease. When the whole immunoglobulin is treated with papain, it is
cleaved into Fab and Fc regions, whereas when the whole immunoglobulin is d with pepsin,
it is d into pF’c and F(ab)2 fragments. Fc or pF’c can be isolated using size exclusion
chromatography, etc. In a more specific embodiment, a human-derived Fc region is a
recombinant immunoglobulin Fc region ed from a microorganism.
In addition, the immunoglobulin Fc region may have natural glycans, increased or
decreased glycans ed to the natural type, or be in a deglycosylated form. The increase,
decrease, or removal of the s of the immunoglobulin Fc may be achieved by conventional
methods such as a al method, an enzymatic , and a genetic engineering method
using a microorganism. The immunoglobulin Fc region obtained by removal of glycans from
the Fc region shows a significant decrease in binding affinity to the C1q part and a decrease or
loss in antibody-dependent cytotoxicity or complement-dependent xicity, and thus it does
not induce unnecessary immune responses in vivo. In this regard, an immunoglobulin Fc region
in a deglycosylated or aglycosylated globulin Fc region may be a more suitable form to
meet the original object of the present invention as a drug carrier.
As used herein, the term “deglycosylation” refers to enzymatically removing sugar
moieties from an Fc region, and the term “aglycosylation” refers to an unglycosylated Fc region
produced in prokaryotes, more specifically, E. coli.
ile, the immunoglobulin Fc region may be derived from humans or other
animals including cows, goats, pigs, mice, rabbits, hamsters, rats, and guinea pigs. In a more
specific embodiment, it is d from humans.
In addition, the immunoglobulin (Ig) Fc region may be derived from IgG, IgA, IgD, IgE,
IgM, or a combination or hybrid thereof. In a more specific embodiment, it is derived from IgG
or IgM, which are among the most abundant ns in human blood, and in an even more
specific ment, it is derived from IgG, which is known to enhance the half-lives of
ligand-binding proteins. In a yet even more specific embodiment, the globulin Fc
region is an IgG4 Fc region, and in the most specific embodiment, the IgG4 Fc region is an
aglycosylated Fc region derived from human IgG4, but is not limited thereto.
In particular, as used herein, the term “combination” means that polypeptides encoding
single-chain immunoglobulin Fc regions of the same origin are linked to a single-chain
polypeptide of a different origin to form a dimer or multimer. That is, a dimer or multimer may
be formed from two or more fragments selected from the group consisting of IgG Fc, IgA Fc,
IgM Fc, IgD Fc, and IgE Fc fragments.
The composition of the present invention can be used for preventing or treating
congenital nsulinism, hypoglycemia, or lic syndrome.
As used herein, the term “prevention” refers to all kinds of actions associated with the
inhibition or delay of the ence of the target disease (e.g., congenital hyperinsulinism,
hypoglycemia, or metabolic syndrome) by the administration of the glucagon derivative, a
conjugate containing the same, or the composition, and the term “treatment” refers to all kinds of
actions associated with the ement or advantageous changes in ms of the target
disease (e.g., congenital hyperinsulinism, hypoglycemia, or metabolic syndrome) by the
administration of the glucagon derivative, a conjugate containing the same, or the ition.
As used herein, the term “administration” refers to an introduction of a ular
material to a patient by an appropriate manner. The composition may be administered by a
general route that enables the delivery of the composition to a target tissue in vivo, for example,
intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, asal,
intrapulmonary, and intrarectal administration, but is not particularly limited thereto.
As used herein, the term “hypoglycemia” refers to a health state, in which blood
glucose levels are lower than those of normal people, and in general, refers to a state
when the blood glucose levels are 50 mg/dL or less, but is not particularly limited thereto.
Hypoglycemia is frequently caused when a person who takes an oral hypoglycemic agent
or insulin has eaten less than usual or has performed activities or exercised more than
usual. Additionally, hypoglycemia may occur due to drinking of alcohols, use of
glucose level-lowering drugs, severe physical diseases, hormone deficiency such as
adrenocortical hormones and glucagon, tumor in insulin-producing pancreas, insulin
autoimmune disease, gastrectomy patients, inborn error of carbohydrate metabolism
disorder, etc.
In the present invention, the hypoglycemia includes both acute and c
hypoglycemia.
Symptoms of ycemia include weakness, trembling, pale skin, cold sweat,
dizziness, excitement, anxiety, pounding heart, empty stomach, he, e, etc. In the
case of persistent hypoglycemia, it may lead to convulsion or seizure, and may cause shock and
thus fainting.
More specifically, the hypoglycemia may be caused by persistent hyperinsulinism due to
a genetic defect. Examples of known causes of hyperinsulinism due to a genetic defect may
e a mutation on SUR gene or Kir6.2 gene localized on chromosome 11p15.1, or an
increase of glucokinase (GK) activity due to a mutation on GK gene localized on chromosome
7p15-p13, an increase of ATP in islet cells due to a mutation on ate dehydrogenase
(GDH) gene, etc.
Meanwhile, congenital hyperinsulinism is one of the leading causes of severe and
persistent hypoglycemia in newborns and children. It may be caused by an abnormal function
of pancreatic cells due to a temporary increase of insulin secretion or c mutation in
low-birth-weight infants or infants from diabetic mothers, etc. It is known that on may
be used for the treatment of the congenital hyperinsulinism.
onally, the glucagon derivative or a conjugate containing the same may be used
for ting or ng hypoglycemia.
Additionally, the glucagon derivative or a conjugate containing the same of the present
invention may be used as a pharmaceutical medicament not only for ting body weight
increase, ing body weight decrease, reducing overweight, and treating obesity including
morbid obesity (e.g., by controlling te, ingestion, food , calorie intake, and/or energy
consumption), but also for treating obesity-related inflammation, obesity-related gallbladder
disease, and obesity-induced sleep apnea, but is not d thereto, and may be used for treating
the associated diseases or health ions thereof. The glucagon derivative of the present
invention or a ate containing the same may also be used for treating metabolic syndrome
other than obesity, i.e., obesity-related diseases such as impaired glucose tolerance,
hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, nonalcoholic hepatitis
(nonalcoholic steatohepatitis, NASH), atherosclerosis caused by dyslipidemia, sclerosis,
arteriosclerosis, coronary heart disease, , etc. However, the effects of the peptide
according to the present invention may be mediated entirely or lly by the body
weight-related s described above or may be independent of the same.
As used herein, the term “metabolic syndrome” refers to a symptom where various
diseases that occur due to chronic metabolic disorder occur alone or in combination. In
particular, examples of diseases that belong to metabolic syndrome may include impaired
glucose tolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension,
nonalcoholic steatohepatitis (NASH), arteriosclerosis due to dyslipidemia, atherosclerosis,
arteriosclerosis, coronary heart disease, stroke, etc., but are not limited thereto.
As used herein, the term “obesity” refers to a l condition with excess body fat
accumulation and people are generally defined to be obese when their body mass index (BMI; a
value of body mass (kg) over body height squared (m)) is 25 or higher. Obesity is most
commonly caused by energy imbalance due to excessive food intake compared to energy
consumption over a long period of time. Obesity, being a metabolic disease that affects the
entire body, increases the possibility of developing diabetes and hyperlipidemia, ses the
risk of the incidence of sexual dysfunction, arthritis, and cardiovascular disease, and is associated
with cancer development in some cases.
The on derivative according to the present invention has an altered pI and thus
can exhibit improved solubility and higher stability at a neutral pH condition compared to native
glucagon. Additionally, the glucagon derivative ing to the present invention can exhibit
an activity on a glucagon receptor and thus can be effectively used for preventing or treating
target diseases including hypoglycemia, metabolic syndrome, and congenital nsulinism.
The pharmaceutical composition of the present invention may contain a
pharmaceutically acceptable carrier, excipient, or diluent. As used herein, the term
“pharmaceutically acceptable” refers to the properties of having a sufficient amount to exhibit a
therapeutic effect and not causing adverse effects, and may be easily determined by a d
person in the art based on the factors well known in the medical field, such as the kind of disease,
age, body weight, health status, sex, drug sensitivity of a patient, administration route,
administration method, administration frequency, duration of treatment, a drug to be mixed or
administered aneously in combination, etc.
The pharmaceutical composition of the present invention containing the peptide or a
conjugate ning the same of the present invention may further contain a pharmaceutically
acceptable carrier. The pharmaceutically acceptable carrier may include, for oral
administration, a binder, a t, a disintegrant, an ent, a solubilizing agent, a dispersant,
a stabilizing agent, a suspending agent, a coloring agent, a flavoring agent, etc.; for ions, a
buffering agent, a preserving agent, an analgesic, a solubilizing agent, an isotonic agent, a
stabilizing agent, etc., which may be combined to be used; and for l administrations, a base,
an excipient, a lubricant, a preserving agent, etc., although it is not limited thereto.
The ation type of the composition ing to the present ion may be
prepared variously by combining with a pharmaceutically acceptable carrier as described above.
For example, for oral administration, the composition may be formulated into tablets, troches,
capsules, elixirs, suspensions, syrups, wafers, etc. For injections, the composition may be
formulated into single-dose ampoules or ose containers. The composition may be also
formulated into solutions, suspensions, tablets, capsules, and sustained-release formulations.
Meanwhile, examples of suitable rs, excipients, and diluents may include lactose,
dextrose, sucrose, sorbitol, mannitol, l, erythritol, maltitol, starch, acacia rubber, alginate,
gelatin, m phosphate, m silicate, cellulose, methyl cellulose, microcrystalline
cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc,
magnesium stearate, mineral oil, etc. Additionally, the composition may further contain a filler,
an anti-coagulant, a lubricant, a humectant, a flavoring agent, a preservative, etc.
Additionally, the pharmaceutical composition of the present invention may be prepared
in any formulation type selected from the group consisting of tablets, pills, powders, granules,
capsules, suspensions, liquid medicine for internal use, ons, syrups, sterile injection
solutions, non-aqueous solvents, lyophilized formulations, and suppositories.
Additionally, the composition may be formulated into a single dosage form suitable for
the patient’s body, and specifically, it is formulated into a preparation useful for e drugs
ing to the typical method used in the pharmaceutical field to be administered by an oral or
parenteral route, such as through skin, intravenously, intramuscularly, intra-arterially,
intramedullarily, intrathecally, intraventricularly, pulmonarily, transdermally, subcutaneously,
intraperitoneally, intranasally, intragastrically, topically, sublingually, vaginally, or rectally, but
is not limited thereto.
Additionally, the peptide or conjugate may be used by ng with various
pharmaceutically acceptable carriers such as physiological saline or organic solvents. In order
to increase the stability or absorptivity, carbohydrates such as glucose, sucrose, or dextrans;
idants such as ascorbic acid or glutathione; ing agents; low molecular weight
proteins; or other stabilizers may be used.
The administration dose and ncy of the pharmaceutical composition of the present
invention are determined by the type of active ingredient(s), along with various factors, such as
the disease to be treated, administration route, patient’s age, sex, and body weight, and severity
of the disease.
Although not particularly limited thereto, the pharmaceutical composition of the present
invention may contain the above ingredient (active ingredient) in an amount of 0.01% (W/V) to
99% (W/V).
The total effective dose of the ition of the t invention may be stered
to a patient in a single dose, or may be administered for a long period of time in multiple doses
ing to a fractionated treatment protocol. In the pharmaceutical ition of the
present invention, the t of active ingredient(s) may vary depending on the disease severity.
Specifically, the preferable total daily dose of the peptide or conjugate of the present invention
may be approximately 0.0001 μg to 500 mg per 1 kg of body weight of a patient. However, the
effective dose of the peptide or conjugate is determined considering various factors ing
patient’s age, body weight, health conditions, sex, disease severity, diet, and excretion rate, in
on to administration route and ent frequency of the pharmaceutical composition. In
this , those skilled in the art may easily determine the effective dose suitable for the
particular use of the pharmaceutical composition of the present invention. The pharmaceutical
composition according to the present invention is not particularly limited to the formulation and
administration route and mode, as long as it shows the effects of the present invention.
The pharmaceutical composition of the t invention can exhibit excellent in vivo
duration of efficacy and titer, and thus the number and ncy of administration can be
significantly reduced compared to other ceutical preparations, but is not particularly
limited thereto.
In particular, since the pharmaceutical composition of the present invention contains, as
an active ingredient, a glucagon derivative having an altered pI different from that of native
glucagon, it shows improved solubility and/or high stability according to the pH of a given
solution, and thus the pharmaceutical composition of the t invention can be effectively
used in the preparation of a stable glucagon formulation for treating target diseases including
congenital hyperinsulinism, hypoglycemia, or metabolic me.
With regard to a pharmaceutical composition for preventing or ng metabolic
syndrome, or a therapy for preventing or treating metabolic syndrome, the pharmaceutical
composition may further n a compound or al that has a therapeutic activity with
regard to metabolic syndrome, and the therapy may further include the use of the above
compound or material.
Examples of the compound or material having a therapeutic activity for metabolic
syndrome to be ed in the ed administration or the ition of the present
invention may include an insulinotropic peptide, a glucagon like peptide-1 (GLP-1) receptor
agonist, a leptin receptor agonist, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, a Y5 receptor
antagonist, a melanin-concentrating hormone (MCH) receptor antagonist, a Y2/4 or
agonist, a melanocortin 3/4 (MC 3/4) receptor agonist, a gastric/pancreatic lipase inhibitor, an
agonist of 5-hydroxytryptamine receptor 2C (5HT2C), a β3A receptor agonist, an amylin
receptor agonist, a ghrelin antagonist, a ghrelin receptor antagonist, a peroxisome
proliferator-activated receptor alpha (PPARα) agonist, a peroxisome proliferator-activated
receptor delta (PPARδ) agonist, a Farnesoid X receptor (FXR) agonist, an -CoA
carboxylase inhibitor, a peptide YY, cholecystokinin (CCK), xenin, glicentin, obestatin, in,
nesfatin, n, and a glucose-dependent insulinotropic peptide (GIP), but is not d thereto.
onally, all medicaments which are effective for obesity treatment and the medicaments
capable of inhibiting hepatic inflammation and fibrosis may be included.
Specifically, the insulinotropic peptide may be selected from the group consisting of
GLP-1, exendin-3, exendin-4, an agonist thereof, a derivative thereof, a fragment thereof, a
variant thereof, and a combination f.
More specifically, the insulinotropic peptide may be an insulinotropic peptide derivative
in which the N-terminal histidine e of the insulinotropic peptide is tuted with one
selected from the group consisting of desamino-histidyl, thyl-histidyl, β-hydroxy
opropionyl, 4-imidazoacetyl, and β-carboxy imidazopropionyl, but is not limited thereto.
In ular, the insulinotropic peptide may be GLP-1, exendin-3, or exendin-4.
Even more specifically, the insulinotropic peptide may be selected from the group
consisting of native exendin-4; an exendin-4 derivative in which the N-terminal amine group of
exendin-4 is deleted; an exendin-4 derivative in which the N-terminal amine group of exendin-4
is substituted with a hydroxyl group; an exendin-4 derivative in which the N-terminal amine
group of exendin-4 is modified with a dimethyl group; an exendin-4 derivative in which the
α-carbon of the 1stamino acid of exendin-4, histidine, is deleted; an exendin-4 derivative in
which the 12th amino acid of n-4, , is substituted with serine, and an exendin-4
derivative in which the 12th amino acid of exendin-4, lysine, is substituted with arginine, but is
not limited thereto.
Meanwhile, as an example of the insulinotropic peptide or a long-acting conjugate
thereof, the entire disclosure of U.S. Patent Application Publication No. 2010-0105877 is
enclosed in the present invention as a reference, but is not limited thereto.
Additionally, the insulinotropic peptide may be in the form of a conjugate which
includes a peptide moiety, that includes the amino acid sequence of the above-mentioned
notropic peptide, and a biocompatible al moiety linked to the e moiety, but is
not limited thereto. Specifically, the peptide moiety that includes the amino acid sequence of
the insulinotropic peptide is characterized in that it is in the form of a conjugate covalently
linked to the biocompatible material moiety through a linker, but is not particularly d
thereto. The conjugate of the insulinotropic peptide may be a long-acting conjugate, and the
definition with regard to the long-acting type is the same as explained above.
For all features with regard to the ate, in particular, the biocompatible material
moiety (immunoglobulin Fc) and linker (e.g., non-peptide polymer), all of those described
previously will be applied. For example, the linker may be one that is respectively linked to the
peptide moiety and the biocompatible material moiety through nt bonds, which were
respectively formed when one end of the linker reacted with an amine group or thiol group of the
patible material moiety while the other end of the linker reacted with an amine group or
thiol group of the peptide .
In a specific embodiment, one end of the non-peptide linker may react with an amine
group or thiol group of an immunoglobulin Fc region while the other end of the linker react with
an amine group or thiol group of the insulinotropic peptide and thereby form a covalent bond,
respectively.
In a more specific embodiment, the composition for ting or treating the
above-mentioned metabolic syndrome or therapy may be a composition or therapy containing or
using the peptide including the amino acid sequence of General a 2 below or the
conjugate a biocompatible material moiety covalently linked to the peptide, but is not
particularly limited thereto.
Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-W-L-MN-T-X30
(General Formula 2, SEQ ID NO: 46)
In l Formula 2,
X7 is threonine, valine, or cysteine;
X10 is tyrosine or cysteine;
X12 is lysine or cysteine;
X15 is aspartic acid or cysteine;
X16 is glutamic acid or serine;
X17 is lysine or arginine;
X20 is glutamine or lysine;
X21 is aspartic acid or glutamic acid;
X24 is valine or glutamine; and
X30 is cysteine, or is absent.
The peptide according to the previous specific embodiment, when the amino acid
sequence of General Formula 2 is identical to any one of SEQ ID NOS: 19, 33, 49, and 50, all or
part of the peptides may be excluded.
More specifically, the composition may include both (i) a conjugate, which includes the
peptide moiety including the amino acid sequence of SEQ ID NO: 37, and a biocompatible
material moiety covalently linked to the peptide moiety; and (ii) a conjugate, which includes an
imidazo-acetyl exendin-4 moiety where the α-carbon of the 1st amino acid of exendin-4 (i.e.,
histidine) is deleted and a biocompatible material moiety covalently linked to the imidazo-acetyl
n-4 moiety. Even more specifically, the peptide moiety including the amino acid
sequence of SEQ ID NO: 37 and the imidazo-acetyl n-4 moiety may be linked to their
respective biocompatible material moietys through a linker, but are not particularly limited
thereto.
The administration does of the compound or material having a therapeutic ty with
regard to metabolic syndrome, specifically the conjugate where the notropic peptide is
linked to a biocompatible material , may be in the range of about 0.0001 μg to about 500
mg per 1 kg of body weight of a patient, but is not particularly limited thereto.
Additionally, the pharmaceutical composition of the t invention may contain the
above materials for combined administration, that is, the compound or al having a
therapeutic activity with regard to lic syndrome and a glucagon derivative or a conjugate
containing the same (or each ingredient of the above materials for combined administration), in
an amount of 0.01% (W/V) to 99% (W/V).
Meanwhile, in an aspect, the compound or material having a therapeutic activity with
regard to metabolic syndrome and a glucagon derivative or a conjugate containing the same,
specifically a conjugate where a biocompatible material moiety is linked to the insulinotropic
e (e.g., an insulinotropic peptide-PEG-IgFc conjugate) and a conjugate where a
patible material moiety is linked to a glucagon derivative may be used in a molar ratio of
1 : 0.01 to 1 : 50, but is not particularly limited thereto.
In r aspect, the present invention provides a kit including a glucagon derivative or
a conjugate containing the same, and specifically, a kit for preventing or ng congenital
hyperinsulinism, hypoglycemia, or metabolic syndrome including a glucagon derivative or a
conjugate containing the same.
The glucagon tive, or a conjugate containing the same, congenital hyperinsulinism,
hypoglycemia, metabolic syndrome, prevention, or treatment are the same as ned above.
The kinds of ingredients that may be further contained in the kit of the present invention may
include all of those which may be contained in the composition explained above.
In ular, when the kit is a kit for preventing or treating metabolic syndrome, both (i)
the glucagon derivative, specifically the peptide including the amino acid sequence of General
Formula 1 or 2, or a conjugate containing the same, and (ii) an insulinotropic peptide, in
particular GLP-1, exendin-3, exendin-4, or a derivative thereof, or a conjugate containing the
same, but is not particularly limited thereto.
In another aspect, the present invention provides a glucagon derivative.
The glucagon derivative is the same as explained above.
More specifically, the derivative is characterized in that it is an isolated peptide
including the amino acid sequence of l Formula 1 represented by SEQ ID NO: 45
described above. For the explanation and combination with regard to the ed peptide
including the amino acid sequence of l Formula 1, all of those described above will be
applied.
The derivative is characterized in that it is an isolated peptide including the amino acid
sequence of the ing General Formula 2.
Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-W-L-MN-T-X30
(General Formula 2, SEQ ID NO: 46)
In General Formula 2,
X7 is threonine, valine, or cysteine;
X10 is tyrosine or ne;
X12 is lysine or cysteine;
X15 is aspartic acid or cysteine;
X16 is glutamic acid or serine;
X17 is lysine or ne;
X20 is glutamine or lysine;
X21 is aspartic acid or glutamic acid;
X24 is valine or glutamine; and
X30 is cysteine, or is absent.
When the amino acid sequence of General Formula 2 is cal to any one of SEQ ID
NOS: 19, 33, 49, and 50, it may be excluded.
More ically, in the peptide including the amino acid sequence of General Formula
2, X16 may be glutamic acid, X20 may be lysine, and the side chains of X16 and X20 may form
a lactam ring, but is not limited thereto.
Additionally, the C-terminus of the peptide including the amino acid sequence of
General Formula 2 may be ed or unmodified, but is not d thereto.
Additionally, the peptide may be a glucagon derivative capable of activating a glucagon
receptor, but is not limited thereto.
More ically, the peptide may include an amino acid sequence selected from the
group consisting of SEQ ID NOS: 12, 13, 15, and 36 to 44, but is not limited thereto.
In still another aspect, the present invention provides an isolated polynucleotide
ng the glucagon derivative, a vector including the polynucleotide, and an isolated cell
including the polynucleotide or the vector.
The glucagon derivative is the same as explained above.
Specifically, the derivative may be an isolated peptide including the amino acid sequence of
General Formula 1 represented by SEQ ID NO: 45 described above. For the explanation and
combination with regard to the ed peptide including the amino acid sequence of General
Formula 1, all of those described above will be applied. Additionally, specifically, the
derivative may be an isolated peptide including the amino acid sequence of l Formula 2
represented by SEQ ID NO: 46 described above. For the explanation and combination with
regard to the isolated peptide including the amino acid sequence of General Formula 2, all of
those described above will be applied.
As used herein, the term “homology” indicates ce similarity with a wild-type
amino acid sequence or wild-type nucleotide sequence, and the homology comparison may be
done with the naked eye or using a commercially available comparison program. Using a
commercially available computer program, the homology between two or more ces may
be sed as a percentage (%), and the homology (%) between nt ces may be
calculated.
As used , the term “recombinant vector” refers to a DNA construct including the
sequence of a cleotide encoding a target e, e.g., a glucagon derivative, which is
operably linked to an appropriate regulatory sequence to enable the expression of the target
peptide, e.g., a glucagon derivative, in a host cell.
The regulatory sequence includes a promoter capable of ting transcription, any
operator sequence for the regulation of the transcription, a sequence encoding an appropriate
mRNA ribosome-binding domain, and a sequence regulating the termination of transcription and
ation. The recombinant vector, after being transformed into a suitable host cell, may be
replicated or function irrespective of the host genome, or may be integrated into the host genome
itself.
The recombinant vector used in the present invention may not be particularly limited as
long as the vector is replicable in the host cell, and it may be constructed using any vector known
in the art. Examples of the vector conventionally used may include natural or recombinant
plasmids, cosmids, viruses, and iophages. The vectors to be used in the present invention
may be any expression vector known in the art.
The inant vector is used for the transformation of a host cell for producing
glucagon derivatives of the present invention. Additionally, these transformed cells, as a part of
the present invention, may be used for the amplification of nucleic acid fragments and vectors, or
may be cultured cells or cell lines used in the recombinant production of glucagon derivatives of
the present invention.
As used herein, the term “transformation” refers to a s of introducing a
recombinant vector including a polynucleotide encoding a target protein into a host cell, thereby
enabling the expression of the n d by the polynucleotide in the host cell. For the
transformed polynucleotide, it does not matter whether it is inserted into the chromosome of a
host cell and d thereon or located outside of the chromosome, as long as it can be
expressed in the host cell, and both cases are included.
Additionally, the polynucleotide includes DNA and RNA which encode the target
n. The polynucleotide may be ed in any form insofar as it can be introduced into a
host cell and expressed n. For example, the polynucleotide may be introduced into a host
cell in the form of an expression cassette, which is a gene construct including all the essential
elements required for self-expression. The expression cassette may conventionally include a
er operably linked to the polynucleotide, a transcription ation signal, a
ribosome-binding domain, and a translation termination signal. The expression cassette may be
in the form of an expression vector capable of self-replication. Additionally, the polynucleotide
may be introduced into a host cell as it is and operably linked to a sequence essential for its
expression in the host cell, but is not limited o.
Additionally, as used herein, the term “operably linked” refers to a functional connection
n a promoter sequence, which initiates and mediates the ription of the
polynucleotide encoding the target peptide of the present invention, and the above gene
sequence.
An appropriate host to be used in the present invention may not be particularly limited as
long as it can express the polynucleotide of the present invention. Examples of the appropriate
host may include bacteria belonging to the genus Escherichia such as E. coli; bacteria belonging
to the genus Bacillus such as Bacillus subtilis; bacteria belonging to the genus Pseudomonas
such as Pseudomonas ; yeasts such as Pichia pastoris, Saccharomyces siae, and
Schizosaccharomyces pombe; insect cells such as Spodoptera frugiperda (Sf9), and animal cells
such as CHO, COS, and BSC.
In still another aspect, the present invention provides an ed conjugate in which a
glucagon derivative is linked to a biocompatible material moiety which is capable of increasing
in vivo half-life of the glucagon derivative. The ate may be a long-acting ate.
Specifically, the present invention provides an isolated conjugate which includes a
peptide moiety and a biocompatible material moiety, and the peptide moiety is the same
sequence as that of General Formula 1 or 2, or a sequence including the same.
With regard to the glucagon derivative, the amino acid sequence of General Formula 1
or 2, the biocompatible material, and the constitution of the ate, all of those described
above are applied.
Specifically, the derivative may be an isolated peptide including the amino acid
sequence of General Formula 1 represented by SEQ ID NO: 45 described above. For the
feature and ation with regard to the isolated peptide including the amino acid ce of
l Formula 1, all of those described above are applied.
Additionally, specifically, the derivative may be an isolated peptide including the amino
acid sequence of General Formula 2 represented by SEQ ID NO: 46 described above. For the
feature and combination with regard to the isolated peptide including the amino acid sequence of
General Formula 2, all of those described above are applied.
Specifically, the biocompatible material moiety may be ed from the group
consisting of a polymer, fatty acid, cholesterol, albumin and a fragment thereof, an
albumin-binding al, a polymer of repeating units of a particular amino acid sequence, an
antibody, an antibody fragment, an FcRn-binding material, in vivo connective tissue or a
derivative thereof, a nucleotide, fibronectin, transferrin, a saccharide, heparin, and elastin, but is
not limited o. In particular, the r may be selected from the group consisting of a
polyethylene glycol, a opylene glycol, an ne glycol-propylene glycol copolymer,
polyoxyethylated polyol, polyvinyl alcohol, a polysaccharide, dextran, polyvinyl ethyl ether, a
biodegradable polymer, a lipid polymer, chitin, hyaluronic acid, an oligonucleotide, and a
combination thereof, but is not particularly limited thereto.
More specifically, the FcRn-binding material may be a polypeptide including an
immunoglobulin Fc region, but is not particularly limited thereto. The same explanation with
respect to the immunoglobulin Fc region is also applied to this aspect.
The isolated conjugate may be one in which the glucagon derivative moiety, specifically
the peptide moiety including the amino acid sequence of the glucagon derivative e, and a
biocompatible al moiety are linked with each other through a linker. The same
explanation with respect to the linker is also applied to this aspect.
Additionally, the glucagon derivative moiety, specifically the peptide moiety ing
the amino acid sequence of the glucagon derivative peptide, may be linked to a biocompatible
material moiety by a linker selected from the group consisting of a polyethylene glycol, a
polypropylene glycol, an ne glycol-propylene glycol copolymer, polyoxyethylated polyol,
polyvinyl alcohol, a polysaccharide, dextran, polyvinyl ethyl ether, a biodegradable polymer
such as polylactic acid (PLA) and ctic-glycolic acid (PLGA), lipid polymer, chitin,
hyaluronic acid, fatty acid, a polymer, a low lar weight compound, a nucleotide, and a
ation thereof, but is not limited thereto.
Additionally, the biocompatible al moiety may be an FcRn-binding material, and
the isolated peptide may be linked to a biocompatible al moiety by a peptide linker or a
non-peptide linker ed from the group consisting of a polyethylene glycol, a polypropylene
glycol, an ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl
alcohol, a polysaccharide, n, polyvinyl ethyl ether, a biodegradable polymer such as
polylactic acid (PLA) and polylactic-glycolic acid (PLGA), lipid polymer, chitin, hyaluronic acid,
and a combination thereof, but is not limited thereto.
In particular, the FcRn-binding material may be a polypeptide including the
immunoglobulin Fc region and the linker may be specifically hylene glycol, but is not
limited thereto.
Additionally, the linker may be one that is linked to a cysteine residue of the glucagon
derivative, but is not particularly limited thereto.
onally, the linker may be one that is respectively linked to the glucagon derivative
and the biocompatible material moiety through covalent bonds, which were respectively formed
when one end of the linker reacted with an amine group or thiol group of the biocompatible
material moiety while the other end of the linker reacted with an amine group or thiol group of
the peptide moiety, but is not ularly limited thereto.
In still another aspect, the present invention provides a method for preventing or treating
congenital hyperinsulinism, hypoglycemia or metabolic syndrome, including administering the
on derivative, a conjugate containing the same, or a composition containing the same to a
subject.
The glucagon derivative, the conjugate containing the same, composition containing the
same, congenital hyperinsulinism, ycemia, metabolic syndrome, prevention, and treatment
are the same as explained above.
In the t invention, the term “subject” refers to those suspected of having congenital
hyperinsulinism, hypoglycemia or lic syndrome, which means mammals including
humans, mice, and ock having congenital hyperinsulinism, hypoglycemia, or lic
syndrome or having the risk of congenital hyperinsulinism, hypoglycemia, or metabolic
syndrome. However, any subject to be treated with the glucagon derivative of the present
invention or the composition containing the same is included without limitation. Further, the
subject suspected of having congenital hyperinsulinism, hypoglycemia, or obesity can be
effectively treated by administering with the pharmaceutical composition containing the
glucagon tive of the present ion. The congenital hyperinsulinism, hypoglycemia,
and obesity are the same as explained above.
The method of the present invention may include administering the pharmaceutical
composition containing the peptide at a ceutically effective amount. The total daily
dose should be determined within appropriate medical judgment by a physician, and
administered once or several times in divided doses. Regarding the objects of the present
invention, the specific therapeutically effective dose for any particular patient may be preferably
applied differently, depending on various s well known in the l art, including the
kind and degree of the se to be achieved, specific compositions including whether other
agents are occasionally used therewith or not, the patient’s age, body weight, general health
conditions, sex and diet, the time and route of administration, secretion rate of the composition,
duration of treatment, other drugs used in combination or concurrently with the composition of
the present invention, and like factors well-known in the l arts.
ile, the method for preventing or treating metabolic syndrome may be a therapy
using combined administration which further contains at least one compound or al having
the therapeutic activity with regard to metabolic syndrome, although the method is not
ularly limited thereto.
As used herein, the term “combined administration” must be understood to refer to a
aneous, individual, or sequential administration. When the administration is a sequential
or individual administration, the interval for the administration of the secondary ient must
be one which does not lose the advantageous effect of the combined administration.
In still another , the present invention provides use of the glucagon derivative or
the isolated conjugate or the composition in the preparation of a medicament (or a
pharmaceutical composition) for preventing or treating congenital hyperinsulinism,
hypoglycemia, or metabolic syndrome.
The glucagon derivative, the isolated conjugate, the composition, congenital
hyperinsulinism, ycemia, and lic syndrome are the same as explained above.
Hereinafter, the present invention will be bed in more detail with reference to the
following examples and mental examples. However, the following examples and
experimental examples are provided for illustrative purposes only, and the scope of the present
invention should not be limited thereto in any manner.
Example 1: Production of cell line showing cAMP response to glucagon
PCR was performed using a region corresponding to Open Reading Frame (ORF) in the
cDNA (OriGene Technologies, Inc., USA) of human glucagon receptor gene as a template along
with the following forward and reverse primers (SEQ ID NOS: 47 and 48, tively), which
include each of the EcoRI and XhoI restriction sites.
In particular, PCR was performed for a total of 30 cycles under the following conditions:
95°C denaturation for 60 sec, annealing at 55°C for 60 sec, and polymerization at 68°C for 30
sec. The amplified PCR products were subjected to a 1.0% agarose gel electrophoresis and a
450 bp band was obtained by elution.
Forward primer (SEQ ID NO: 47):
’-CAGCGACACCGACCGTCCCCCCGTACTTAAGGCC-3’
Reverse primer (SEQ ID NO: 48):
’-CTAACCGACTCTCGGGGAAGACTGAGCTCGCC-3’
The PCR product was cloned into a known animal cell expression vector, x0GC/dhfr, to
prepare a recombinant vector x0GC/GCGR.
CHO DG44 cell line cultured in DMEM/F12 ining 10% FBS) medium was
transfected with the recombinant vector x0GC/GCGR using Lipofectamine®, and ed in a
selection medium containing G418 (1 mg/mL) and methotraxate (10 nM). Single clone cell
lines were selected rom by a limit on technique, and a cell line showing excellent
cAMP response to glucagon in a concentration-dependent manner was finally selected therefrom.
Example 2: Synthesis of glucagon derivative
In order to e glucagon tives with improved physical properties, the amino
acid sequence of native glucagon of SEQ ID NO: 1 was substituted with amino acid residues
having positive and negative charges, and thereby glucagon derivatives were synthesized as
shown in Table 1 below. The relative in vitro activities described below were measured by the
method described in Example 4.
[Table 1] Amino acid sequences of native glucagon and glucagon tives
In vitro Activity
SEQ ID
Peptide Sequence Ring Formation pI (Relative Activity
to SEQ ID
NO: 1, %)
SEQ ID HSQGTFTSDYSKYLDSRRAQDF
- 6.8 100
NO: 1 VQWLMNT
SEQ ID HSQGTFTSDYSKYLDCDRAQDF
- 4.56 0.6
NO: 2 VQWLMNT
SEQ ID HSQGTFTSDYSKYLDCERAQDF
- 4.66 6.1
NO: 3 VQWLMNT
SEQ ID HSQGTFTSDYSKYLDSCDAQDF
- 4.13 < 0.1
NO: 4 VQWLMNT
SEQ ID HSQGTFTSDYSKYLDSCEAQDF
- 4.22 0.3
NO: 5 VQWLMNT
SEQ ID HSQGTFTSDYSKYLDSCEADDF
- 4.03 < 0.1
NO: 6 VQWLMNT
SEQ ID YSQGTFTSDYSKYLDSCEADDF
- 3.71 < 0.1
NO: 7 VQWLMNT
SEQ ID YXQGTFTSDYSKYLDSCDAQDF
- 3.77 < 0.1
NO: 8 VQWLINT
SEQ ID YXQGTFTSDYSKYLDSCDAQDF
- 3.77 < 0.1
NO: 9 VVWLINT
SEQ ID YXQGTFTSDYSKYLDSCDADDF
- 3.66 < 0.1
NO: 10 VVWLINT
SEQ ID YXQGTFTSDYSKYLDEKCAKEF
- 4.78 4.6
NO: 11 VQWLMNT
SEQ ID TSDYSKYLDEKRAKEF
ring formed 6.20 56.3
NO: 12 VQWLMNTC
SEQ ID TSDYSCYLDSRRAQDF
- 4.43 5.2
NO: 13 VQWLMNT
SEQ ID YXQGTFTSDYSKYLDCKRAKEF
- 8.12 18.1
NO: 14 VQWLMNT
SEQ ID YXQGTFTSDYSKYLCEKRAQDF
- 6.11 1.1
NO: 15 VVWLMNT
SEQ ID YXQGTFTSDYSKYLDCRRAQVF
- 9.11 4.2
NO: 16 T
SEQ ID YXQGTFTSDYSKYLDCVRAQDF
- 6.03 23.2
NO: 17 VQWLMRT
SEQ ID YXQGTFTSDYSKYLDSRRACDF
- 8.15 < 0.1
NO: 18 RLWLMNT
SEQ ID YXQGTFTSDYSKYLCEKRAKEF
ring formed 8.12 12.1
NO: 19 VQWLMNT
SEQ ID YXQGTFTSDYSKYLDECRAKEF
ring formed 4.78 299.7
NO: 20 VQWLMNT
SEQ ID YXQGTFTSDYSKYLDEKCAKEF
ring formed 4.78 57.8
NO: 21 T
SEQ ID YXQGTFTSDYSKYLDEKRCKEF
ring formed 6.20 147.8
NO: 22 VQWLMNT
SEQ ID YXQGTFTSDYSKYCDEKRAKEF
ring formed 6.20 76.8
NO: 23 VQWLMNT
SEQ ID YXQGTFTSDYSKCLDEKRAKEF
ring formed 6.21 58.0
NO: 24 VQWLMNT
SEQ ID YXQGTFTSDYSKYLDEKRAKCF
ring formed 8.12 46.9
NO: 25 VQWLMNT
SEQ ID WXQGTFTSDYSKYLDECRAKDF
ring formed 4.68 1.0
NO: 26 VQWLMNT
SEQ ID YXQGTFVSDYSKYLDECRAKDF
ring formed 4.68 93.6
NO: 27 VQWLMNT
SEQ ID WXQGTFVSDYSKYLDECRAKD
ring formed 4.68 < 0.1
NO: 28 FVQWLMNT
SEQ ID YXQGTFTSDYSKCLDERRAKDF ring formed 6.15 61.3
NO: 29 T
SEQ ID WXQGTFTSDYSKCLDERRAKDF
ring formed 4.44 0.3
NO: 30 VQWLMNT
SEQ ID YXQGTFTSDYSKYLDCKRAKEF
ring formed 8.12 6.3
NO: 31 VQWLMNT
SEQ ID -SQGTFTSDYSKYLDECRAKEFV
ring formed 4.78 0.7
NO: 32 QWLMNT
SEQ ID TSDYSKYLDSRRAQDF
- 6.04 108.2
NO: 33 VQWLMNT
SEQ ID WXQGTFTSDYSKYCDERRAKEF
ring formed 6.21 0.2
NO: 34 VQWLMNT
SEQ ID YXQGTFTSDYSKYCDERRAKEF
ring formed 6.2 17.7
NO: 35 VQWLMNT
SEQ ID YXQGTFTSDCSKYLDERRAKEF
ring formed 6.21 9.9
NO: 36 VQWLMNT
SEQ ID YXQGTFTSDYSKYLDERRAKEF
ring formed 6.21 225.5
NO: 37 VQWLMNTC
SEQ ID YXQGTFCSDYSKYLDERRAKEF
ring formed 6.15 167.3
NO: 38 VQWLMNT
SEQ ID YXQGTFVSDCSKYLDERRAKDF
ring formed 6.15 3.7
NO: 39 VQWLMNT
SEQ ID YXQGTFVSDYSKYLDERRAKDF
ring formed 6.15 40.8
NO: 40 VQWLMNTC
SEQ ID YXQGTFCSDYSKYLDERRAKDF
ring formed 6.03 45.2
NO: 41 VQWLMNT
SEQ ID YXQGTFCSDYSKYLDSRRAQDF
- 6.03 37.9
NO: 42 VQWLMNT
SEQ ID YXQGTFTSDCSKYLDSRRAQDF
- 6.03 1.6
NO: 43 VQWLMNT
SEQ ID YXQGTFTSDYSKYLDSRRAQDF
- 6.21 75.4
NO: 44 VQWLMNTC
In the amino acids sequences described in Table 1, the amino acid represented by X
represents a non-native amino acid, aminoisobutyric acid (Aib), the underlined amino acid
residues represent formation of a lactam ring n the side chains of the corresponding amino
acids, and “-” in the amino acid sequence indicates that no amino acid e is present on the
corresponding position. Additionally, in the rows with regard to ring formation, “-” indicates
that there is no ring formation in the corresponding sequences.
Example 3: Measurement of pI of glucagon derivatives
In order to measure the ed physical properties of glucagon derivatives
synthesized in Example 2, pI values were calculated based on the amino acid sequences using the
pI/Mw tool (http://expasy.org/tools/pi_tool.html; Gasteiger et al., 2003) in the ExPASy server.
As shown in Table 1 above, while the native glucagon of SEQ ID NO: 1 had a pI of 6.8,
the some glucagon derivatives according to the present ion showed pI values in the range
of from about 4 to about 6. Since the glucagon derivatives according to the present invention
have pI values lower or more than that of native on, they can exhibit improved lity
and higher stability at a neutral pH condition compared to native glucagon.
ingly, when the glucagon derivatives according to the present invention are used
as a therapeutic agent for treating a target disease such as ital hyperinsulinism,
hypoglycemia, etc., they can improve patient compliance, and are also suitable for administration
in ation with other besity agents or anti-diabetes agents, and thus the glucagon
derivatives of the present invention can be effectively used as a therapeutic agent for treating
hypoglycemia and metabolic syndromes including obesity, diabetes, nonalcoholic steatohepatitis
(NASH), dyslipidemia, and coronary heart disease.
Example 4: Measurement of cAMP activity of glucagon derivatives
The activities of the glucagon derivatives synthesized in Example 2 were measured in
cell lines having the human on receptors produced in Example 1. Specifically, the
transfected cell line was subcultured 3 to 4 times a week, aliquoted into a 384-well plate in an
amount of 6×103 cell lines/well, and cultured for 24 hours. Native glucagon and glucagon
derivatives were suspended in Hank’s balanced salt solution (HBSS) buffer containing 0.5 mM
of 3-isobutylmethylxanthine (IBMX), 0.1% bovine serum albumin (BSA), and 5 mM
4-(2-hydroxyethyl)piperazineethanesulfonic acid (HEPES) with the culture cells, at
trations of 200 nM and 1600 nM, tively, continuously subjected into a 4-fold
dilution 10 times, applied to a cAMP assay kit (LANCE cAMP 384 kit, PerkinElmer), and added
to the cultured cells, and their fluorescence value was measured. Upon measurement, the
highest fluorescence value was set at 100% and then EC50 values of the glucagon derivative were
calculated based on the same and compared with that of native glucagon, respectively. The
results are shown in Table 1 below.
e 5: Preparation of a conjugate including a glucagon derivative and an
immunoglobulin Fc (SEQ ID NO: 12 or 20-immunoglobulin Fc region conjugate)
For the pegylation of a 10kDa PEG having a maleimide group and an aldehyde group,
respectively, at both ends (named as “maleimide-PEG-aldehyde”, 10 kDa, NOF, Japan) into the
cysteine residue of a glucagon derivative (SEQ ID NO: 12 or 20), the on derivatives and
maleimide-PEG-aldehyde were reacted at a molar ratio of 1 : 1 to 5, at a protein concentration of
3 mg/mL to 10 mg/mL at low temperature for 1 to 3 hours. In particular, the reaction was
ted in an nment in which 20% to 60% isopropanol was added. Upon completion
of the reaction, the reactants were applied to SP sepharose HP (GE healthcare, USA) to purify
the glucagon derivatives mono-pegylated on cysteine.
Then, the purified mono-pegylated glucagon derivatives and an immunoglobulin Fc
were reacted at a molar ratio of 1 : 2 to 10, at a protein concentration of 10 mg/mL to 50 mg/mL
at 4C to 8C for 12 hours to 18 hours. The reaction was conducted in an environment in which
sodium cyanoborohydride (NaCNBH3) and 10% to 20% isopropanol were added to 100mM
calcium ate buffer (pH 6.0). Upon completion of the reaction, the nts were applied
to the Butyl sepharose FF purification column (GE healthcare, USA) and Source ISO
purification column (GE healthcare, USA) to purify the conjugate including the glucagon
derivatives and the immunoglobulin Fc.
After preparation, the purity analyzed by reverse phase chromatography, size exclusion
chromatography, and ion exchange chromatography was shown to be 95% or higher.
In particular, the conjugate in which the glucagon derivative of SEQ ID NO: 12 and an
immunoglobulin Fc were linked by PEG was named as “the ate including the glucagon
derivative of SEQ ID NO: 12 and an immunoglobulin Fc”, “a long-acting conjugate of SEQ ID
NO: 12”, or “a long-acting derivative of SEQ ID NO: 12”, and they can be used interchangeably
in the present invention.
In particular, the conjugate in which the glucagon derivative of SEQ ID NO: 20 and an
immunoglobulin Fc were linked by PEG was named as “a conjugate including the glucagon
derivative of SEQ ID NO: 20 and an immunoglobulin Fc”, “a long-acting conjugate of SEQ ID
NO: 20”, or “a long-acting tive of SEQ ID NO: 20”, and they can be used interchangeably
in the present invention.
Example 6: Preparation of a conjugate including an exendin-4 derivative and an
immunoglobulin Fc
A 3.4 kDa PEG having a propionaldehyde group at both ends, i.e., 3.4k PropionALD (2)
PEG, was reacted with the Lys of CA exendin-4 using imidazo-acetyl exendin-4 where the alpha
carbon of N-terminal histidine was deleted (CA exendin-4, AP, USA), and the isomer peak at the
rearmost part ) between the two Lys peaks, which is quite reactive and clearly
guished from the N-terminal isomer, was ted. Subsequently, a coupling was
conducted using the ted peptide .
The coupling was conducted by reacting the above-mentioned pegylated imidazo-acetyl
exendin-4 peptide and an immunoglobulin Fc at a molar ratio of 1 : 8, at the total protein
concentration of 60 mg/mL at 4C for 20 hours. The reactant was 100 mM K-P (pH 6.0) and
mM SCB, a ng agent, was added. The coupling reactants were purified by passing
through with two purification s. First, a large amount of immunoglobulin Fc not
involved in the coupling reaction was removed using the SOURCE Q (XK-16mL, Amersham
Biosciences). Upon application of a salt gradient using 1 M NaCl at 20 mM Tris (pH 7.5)
results in the immediate elution of the globulin Fc, which has a relatively weak binding
ty, followed immediately by the elution of exendinimmunoglobulin Fc. The
globulin Fc is removed to some extent by the primary purification, however, complete
separation was not achieved by ion exchange column because of the small difference in binding
ty between the immunoglobulin Fc and the exendinimmunoglobulin Fc. Accordingly,
secondary purification was med using the hydrophobicity of the two different materials.
The sample, which passed through the primary purification, was bound to the SOURCE ISO
(HR16 mL, Amersham Biosciences) using 20 mM Tris (pH 7.5) and 1.5 M ammonium sulfate,
and was then eluted while the concentration of ammonium sulfate was gradually lowered. As a
result, the immunoglobulin Fc, which has a weak binding affinity for the HIC column, was
eluted first, followed by the elution of the exendinimmunoglobulin Fc sample, which has a
strong binding affinity, to the rear part. The separation was more easily performed compared
with the ion exchange column due to the larger ence in hydrophobicity.
: SOURCE Q (XK 16 mL, Amersham ences)
Flow rate: 2.0 mL/min
nt: A0 ->25% 70 min B (A: 20 mM Tris, pH 7.5, B: A+ 1 M NaCl)
Column: SOURCE ISO (HR 16 mL, Amersham Biosciences)
Flow rate: 7.0 mL/min
Gradient: B 100 -> 0% 60 min B [A: 20 mM Tris (pH 7.5), B: A + 1.5 M ammonium
sulfate ((NH4)2SO4)]
The thus-prepared conjugate, in which the exendin-4 derivative and the immunoglobulin
Fc region were linked by PEG, was named as “a long-acting exendin-4 derivative”. Also, such
term can be interchangeable used with “a long-acting exendin tive” in the present
invention.
Example 7: Preparation of a conjugate including a glucagon derivative and an
immunoglobulin Fc (SEQ ID NO: 37 - Immunoglobulin Fc region conjugate)
For the pegylation of a 10kDa PEG having a maleimide group and an aldehyde group,
respectively, at both ends (named as “maleimide-PEG-aldehyde”, 10 kDa, NOF, Japan) into the
cysteine residue of a on tive (SEQ ID NO: 37), the on derivatives and
maleimide-PEG-aldehyde were reacted at a molar ratio of 1 : 1 to 5, at a protein tration of
3 mg/mL to 10 mg/mL at low temperature for 1 to 3 hours. In particular, the reaction was
conducted in an environment in which 20% to 60% isopropanol was added. Upon completion
of the reaction, the reactants were applied to SP sepharose HP (GE healthcare, USA) to purify
the glucagon derivatives mono-pegylated on cysteine.
Then, the purified mono-pegylated glucagon derivatives and an immunoglobulin Fc
were reacted at a molar ratio of 1 : 2 to 10, at a protein concentration of 10 mg/mL to 50 mg/mL
at 4C to 8C for 12 hours to 18 hours. The reaction was conducted in an environment in which
10mM to 50mM sodium cyanoborohydride (NaCNBH3), which is reducing agent, and 10% to
% isopropanol were added to 100mM calcium phosphate buffer (pH 6.0). Upon completion
of the reaction, the reactants were d to the Butyl sepharose FF purification column (GE
healthcare, USA) and Source ISO purification column (GE healthcare, USA) to purify the
conjugate including the glucagon tives and the immunoglobulin Fc.
After preparation, the purity analyzed by reverse phase chromatography, size exclusion
chromatography, and ion exchange chromatography was shown to be 95% or higher.
In particular, the conjugate in which the glucagon derivative of SEQ ID NO: 37 and an
immunoglobulin Fc were linked by PEG was named as “the conjugate ing the glucagon
derivative of SEQ ID NO: 37 and an immunoglobulin Fc”, “a long-acting conjugate of SEQ ID
NO: 37”, or “a long-acting derivative of SEQ ID NO: 37”, and they can be interchangeably used
in the present invention.
Experimental Example 1: Effect of body weight reduction in rats with high fat
diet-induced obesity
In this experiment, high-fat nduced obesity rats, which are widely used as obesity
animal models, were used. Specifically, high fat diet-induced s are most commonly used
animal models for preclinical evaluation of the effect of obesity-treating agents in reducing body
weight and the models were induced as follows. When normal rats or mice were fed with a
feed having a 60% fat content for 4 weeks (rats) or 6 months (mice), the body weight of the rats
showed an increase of body weight by about 600 g and the mice showed an increase of body
weight by about 55 g compared to their body weight before the feeding, and the blood lipid
levels also increased thus showing a state of y as in humans. The body weight of the rats
used in this Experimental Example before stration was about 600 g. The rats were
housed individually during the experiment and were given ad m access to water. Lighting
was not provided between 6 PM and 6 AM.
The test groups fed with high-fat diet include: Group 1, with an excipient not containing
long-acting glucagon (administration: 2 mL/kg; injection once every 3 days) - vehicle; Group 2,
the long-acting exendin derivative of Example 6 at 3.3 nmol/kg tion once every 3 days);
Group 3, the long-acting derivative of SEQ ID NO: 12 at 1.6 nmol/kg (injection once every 3
days); Group 4, the long-acting tive of SEQ ID NO: 12 at 3.3 nmol/kg (injection once
every 3 days); Group 5, the long-acting tive of SEQ ID NO: 12 at 6.6 nmol/kg (injection
once every 3 days); Group 6, the long-acting exendin derivative of Example 6 at 3.3 nmol/kg +
the long-acting derivative of SEQ ID NO: 12 at 1.6 nmol/kg (injection once every 3 days,
respectively); Group 7, the cting exendin derivative of Example 6 at 3.3 nmol/kg + the
long-acting derivative of SEQ ID NO: 12 at 3.3 nmol/kg tion once every 3 days,
respectively); Group 8, the long-acting exendin derivative of Example 6 at 3.3 nmol/kg + the
long-acting derivative of SEQ ID NO: 12 at 6.6 g (injection once every 3 days,
respectively); Group 9, a paired-feeding with Group 4; and Group 10, a paired-feeding with
Group 7.
The experiment was terminated on the 15th day, and the changes in body weight of the
rats in each group were measured at 3-day intervals during the ss of the experiment.
Upon termination of the experiment, the amount of mesenteric fat and liver weight were
measured by autopsy. Statistical analysis was performed to compare between the excipient
group (vehicle) and test groups by one-way ANOVA.
As a result of the measurement of changes in body weight, as can be confirmed in
the groups administered with either the long-acting exendin derivative alone or the long-acting
derivative of SEQ ID NO: 12 alone showed a decrease in body weight by -8% and -7% to -22%,
ed to that before administration, whereas in groups with a combined administration of the
long-acting exendin derivative and the long-acting derivative of SEQ ID NO: 12, the effect of
reducing body weight was improved further from -22% to -35%.
Additionally, when the effect of a body weight decrease in the group stered with
the long-acting derivative of SEQ ID NO: 12 alone and the group administered with the
combination of the long-acting exendin derivative and the long-acting derivative of SEQ ID NO:
12 was compared with that of the paired feeding group, respectively, a difference of about -11%
and about -17% was shown, respectively, thus ming that the body weight reducing effect
was shown when stered with the on derivative alone or the combined
administration, by actions other than dietary .
That is, it was confirmed that the long-acting glucagon derivative of the present
invention could play an additional role in body weight reduction in addition to the effect of
anorexia.
Additionally, as a result of the measurement of the amount of mesenteric fat and liver
weight, as can be confirmed in FIGS. 2 and 3, the combined administration of the long-acting
exendin derivative and the long-acting derivative of SEQ ID NO: 12 showed a significant
decrease in body fat and also a decrease in the weight of the liver compared to that of the group
administered with an excipient. In ular, the increase/decrease of the weight of the liver is
lly caused by the increase/decrease of the fat present in the liver, and the above effect of
decrease in the weight of the liver shows the effect of reducing the liver fat. Accordingly, the
decrease of the fat in the liver can be measured as a method for measuring the therapeutic effect
of metabolic syndrome such as obesity, diabetes, nonalcoholic steatohepatitis, etc.
mental Example 2: Effect of body weight reduction in mice with high fat
diet-induced obesity
In this experiment, high-fat diet-induced obesity mice, which are widely used as obesity
animal models, were used. The body weight of the mice before administration was about 55 g.
The mice were housed 7 mice per each group during the experiment and were given ad libitum
access to water. ng was not provided between 6 PM and 6 AM.
The test groups fed with at diet include: Group 1, with an excipient not containing
long-acting glucagon (administration: 5 mL/kg; injection once every 2 days) - vehicle; Group 2,
the long-acting exendin derivative of Example 6 at 4.3 nmol/kg (injection once every 2 days);
Group 3, the long-acting derivative of SEQ ID NO: 20 at 4.4 g (injection once every 2
days); Group 4, the long-acting derivative of SEQ ID NO: 20 at 8.8 nmol/kg tion once
every 2 days); Group 5, the long-acting exendin derivative of Example 6 at 4.3 nmol/kg + the
long-acting tive of SEQ ID NO: 20 at 4.4 nmol/kg (injection once every 2 days); Group 6,
the long-acting exendin derivative of Example 6 at 2.1 nmol/kg + the cting derivative of
SEQ ID NO: 20 at 6.6 nmol/kg (injection once every 2 days); and Group 7, the long-acting
exendin derivative of Example 6 at 0.8 nmol/kg + the long-acting derivative of SEQ ID NO: 20
at 8.0 nmol/kg (injection once every 2 days).
The ment was terminated on the 22nd day, and the changes in body weight of the
mice in each group were measured at 2-day intervals during the progress of the experiment.
Upon termination of the ment, the weight of the mouse livers was measured after autopsy.
As a result of the measurement of changes in body weight, as can be confirmed in
each of the groups administered with the long-acting derivative of SEQ ID NO: 20 (8.8 nmol/kg,
injection once every 2 days) alone showed a decrease in body weight by -25% and -29%,
respectively, compared to that before administration. Additionally, the effect of reducing body
weight was shown to increase further when administered in combination with the long-acting
exendin tive. It was also med that the combined administration of the long-acting
exendin derivative and the long-acting derivative of SEQ ID NO: 20 at a ratio of 1:1, 1:3, and
1:10 further increased the effect of reducing body weight by -50% or higher. Additionally, the
effect of reducing body weight according to the ratio between the long-acting exendin tive
and the long-acting tive of SEQ ID NO: 20 was not significant, however, the effect of
anorexia became higher along with the increase in the percentage of the long-acting exendin
derivative, thus confirming that the glucagon long-acting derivative of the present ion
could play an additional role in body weight reduction in addition to the effect of anorexia.
Additionally, as a result of the measurement of the total cholesterol levels in the blood,
as can be confirmed in each of the groups administered with the long-acting exendin
derivative (4.4 g, injection once every 2 days) and the cting derivative of SEQ ID
NO: 20 (8.8 nmol/kg, injection once every 2 days) showed a decrease in cholesterol levels by
-35% and -71%, respectively. From the above, it was confirmed that the glucagon long-acting
derivative of the present invention could play an additional role in reducing blood cholesterol in
addition to the effect of anorexia. Statistical analysis was performed to compare between the
excipient group (vehicle) and test groups by one-way ANOVA.
Experimental Example 3: Effect of combined administration of long-acting exendin
derivative and long-acting conjugate of SEQ ID NO: 37 in mice with high fat diet-induced
obesity
In this ment, high-fat diet-induced obesity mice, which are widely used as obesity
animal , were used. The body weight of the mice before administration was about 55 g.
The mice were housed 7 mice per each group during the experiment and were given ad m
access to water. Lighting was not provided between 6 PM and 6 AM.
The test groups fed with high-fat diet include: Group 1, with an excipient not containing
long-acting glucagon (administration: 5 mL/kg; injection once every 2 days) - vehicle; Group 2,
of liraglutide (Novo k) at 50 nmol/kg (injection twice daily); Group 3, the long-acting
exendin derivative of e 6 at 4.3 nmol/kg (injection once every 2 days); and Group 4, the
cting exendin derivative of Example 6 at 4.3 nmol/kg (injection once every 2 days) + the
cting derivative of SEQ ID NO: 37 at 2.2 nmol/kg (injection once every 2 days).
The experiment was terminated on the 28th day, and the eritoneal e tolerance
test (IPGTT) was measured. The changes in body weight of the mice in each group were
measured at 2-day intervals during the progress of the experiment. Upon termination of the
experiment, the blood cholesterol levels and weight of the mouse livers were ed after
autopsy.
As a result of the measurement of the changes in body weight, as can be confirmed in
each of the groups administered with liraglutide (Novo Nordisk) at 50 nmol/kg (injection
twice daily) or the long-acting n derivative of Example 6 at 4.3 nmol/kg (injection once
every 2 days) alone showed a decrease of body weight by -22% and -32% compared to that of
vehicle, respectively, and the group with combined stration of the long-acting exendin
derivative at 4.3 nmol/kg (injection once every 2 days) + the long-acting derivative of SEQ ID
NO: 37 at 2.2 nmol/kg (injection once every 2 days) showed a further decrease of body weight
by from -32% to -62% compared to that of vehicle.
The effect of reducing fat weight was also increased further in the group with combined
administration of the long-acting exendin derivative at 4.3 nmol/kg (injection once every 2 days)
+ the long-acting derivative of SEQ ID NO: 37 at 2.2 nmol/kg (injection once every 2 days) by
from -62% to -88% compared to the group with the administration of the long-acting exendin
derivative at 4.3 nmol/kg (injection once every 2 days) alone.
onally, as a result of the measurement of the changes in the total cholesterol levels
in the blood, as can be confirmed in each of the groups administered with liraglutide
(Novo Nordisk) at 50 nmol/kg tion twice daily) or the long-acting exendin derivative at 4.3
nmol/kg tion once every 2 days) alone showed a decrease of cholesterol levels by -40% and
-49% compared to that of vehicle, respectively, and the group with combined stration of
the cting exendin derivative at 4.3 nmol/kg (injection once every 2 days) + the long-acting
derivative of SEQ ID NO: 37 at 2.2 nmol/kg (injection once every 2 days) showed a further
decrease of cholesterol levels by from -49% to -70% compared to that of vehicle.
As a result of the measurement of the intraperitoneal glucose tolerance test (IPGTT), as
shown in Fig. 6, the group with the administration of the long-acting exendin tive at 4.3
nmol/kg (injection once every 2 days) alone and the group with combined administration of the
long-acting exendin derivative at 4.3 nmol/kg (injection once every 2 days) + the long-acting
derivative of SEQ ID NO: 37 at 2.2 nmol/kg tion once every 2 days) showed similar effects
of -61% and -67%, respectively.
From the above results, it was confirmed that the combined administration of the
long-acting exendin derivative at 4.3 nmol/kg (injection once every 2 days) + the long-acting
derivative of SEQ ID NO: 37 at 2.2 nmol/kg tion once every 2 days) showed a similar
effect with regard to the regulation of blood glucose levels while showing more excellent effect
with regard to the effects of reducing body weight and blood cholesterol levels compared to that
of their respective stration.
Experimental Example 4: Effect of ameliorating acute ycemia of long-acting
ate of SEQ ID NO: 37
SD rats were fasted for 4 hours and subcutaneously injected with insulin (0.65 U/kg) to
induce hypoglycemia. Forty-five minutes after the injection, the rats were confirmed with
regard to their hypoglycemia, subcutaneously injected with an excipient (2 mL/kg; single
injection, vehicle), intravenously injected with a long-acting conjugate of SEQ ID NO: 37 (at
concentrations of 5.16 nmol/kg, 10.31 nmol/kg, and 20.63 nmol/kg, respectively), and
subcutaneously injected with native glucagon (60 nmol/kg), and the changes in blood glucose
levels were measured.
As a result, it was confirmed that the long-acting conjugate of SEQ ID NO: 37 at all of
the stration doses ameliorated the hypoglycemia in the SD rats induced by insulin as
shown in From the results, it was confirmed that the long-acting conjugate of SEQ ID
NO: 37 has a therapeutic effect on hypoglycemia-related diseases.
Experimental Example 5: Effect of ameliorating chronic hypoglycemia of
long-acting conjugate of SEQ ID NO: 37
An evaluation of the effect of the cting conjugate of SEQ ID NO: 37 as a
therapeutic agent for congenital hyperinsulinism was conducted in s inserted with an
insulin pump. The congenital hyperinsulinism disease model was induced by inserting the
insulin pump into the rodents (rats or mice) through surgery. Since insulin is continuously
secreted from the inserted pump of the rodents, tent ycemia is induced and the
model is thus placed in a state similar to congenital hyperinsulinism in humans.
Specifically, SD rats were subjected to surgery of subcutaneous insertion of an osmotic
pump filled with insulin. The blood glucose levels of the SD rats were ed for a week
and those rats which showed persistent ycemia were selected and subcutaneously ed
with an excipient le) and the long-acting conjugate of SEQ ID NO: 37 (at a concentration
of 3 nmol/kg or 6 nmol/kg) at 3 day intervals (Q3D) and the s in blood glucose levels
were measured for 2 weeks, and the blood glucose area under the curve (AUCBG) was calculated.
The area under the curve (AUC) refers to a general method for fying the change in
blood glucose levels during long-term administration of a drug. As a result, it was confirmed
that the SD rats administered with the long-acting conjugate of SEQ ID NO: 37 at all of the
administration doses continuously showed a significant increase in the blood glucose levels
compared to those administered with the excipient not containing long-acting glucagon (2
mL/kg; once every 3 days, vehicle), which were rats with chronic hypoglycemia, as shown in
(**p < 0.01, *** p <0.001 vs. chronic hypoglycemia rats, excipient, by one-way
ANOVA). From the results, it was confirmed that the cting conjugate of SEQ ID NO: 37
has a therapeutic effect on chronic hypoglycemia that occurs in patients with congenital
hyperinsulinism.
Those of ordinary skill in the art will recognize that the present invention may be
embodied in other specific forms without departing from its spirit or essential characteristics.
The bed embodiments are to be considered in all respects only as illustrative and not
restrictive. The scope of the present invention is therefore indicated by the appended claims
rather than by the ing description. All changes which come within the meaning and
range of lency of the claims are to be embraced within the scope of the present invention.
Claims (57)
1. [Claim 1] A ceutical composition for preventing or treating congenital hyperinsulinism comprising a e comprising the amino acid sequence of the following General Formula 1: X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F -X23-X24-W-L-X27-X28-X29-X30 al a 1, SEQ ID NO: 45) wherein, in General Formula 1, X1 is histidine (H), desamino-histidyl, N-dimethyl-histidyl, β-hydroxy opropionyl, 4-imidazoacetyl, β-carboxy imidazopropionyl, tryptophan (W), or tyrosine (Y), or is absent; X2 is α-methyl-glutamic acid, aminoisobutyric acid (Aib), D-alanine, glycine (G), Sar (N-methylglycine), serine (S), or D-serine; X7 is threonine (T), valine (V), or cysteine (C); X10 is tyrosine (Y) or cysteine (C); X12 is lysine (K) or cysteine (C); X13 is tyrosine (Y) or cysteine (C); X14 is leucine (L) or cysteine (C); X15 is aspartic acid (D), glutamic acid (E), or cysteine (C); X16 is glutamic acid (E), aspartic acid (D), serine (S), α-methyl-glutamic acid, or cysteine (C), or is absent; X17 is aspartic acid (D), glutamine (Q), glutamic acid (E), lysine (K), arginine (R), serine (S), cysteine (C), or valine (V), or is absent; X18 is alanine (A), aspartic acid (D), ic acid (E), arginine (R), valine (V), or cysteine (C), or is ; X19 is e (A), arginine (R), serine (S), valine (V), or cysteine (C), or is X20 is lysine (K), histidine (H), glutamine (Q), aspartic acid (D), arginine (R), α-methyl-glutamic acid, or cysteine (C), or is absent; X21 is aspartic acid (D), glutamic acid (E), leucine (L), valine (V), or cysteine (C), or is absent; X23 is isoleucine (I), valine (V), or arginine (R), or is absent; X24 is valine (V), arginine (R), alanine (A), cysteine (C), glutamic acid (E), lysine (K), glutamine (Q), α-methyl-glutamic acid, or leucine (L), or is absent; X27 is isoleucine (I), valine (V), alanine (A), lysine (K), methionine (M), glutamine (Q), or arginine (R), or is absent; X28 is glutamine (Q), lysine (K), asparagine (N), or arginine (R), or is absent; X29 is lysine (K), alanine (A), e (G), or ine (T), or is absent; and X30 is cysteine (C), or is absent; with the proviso that when the amino acid ce of l Formula 1 is cal to SEQ ID NO: 1, it is ed.
2. [Claim 2] The pharmaceutical composition of claim 1, wherein, in General Formula 1, X1 is ine (H), tryptophan (W), or tyrosine (Y), or is absent; X2 is serine (S) or aminoisobutyric acid (Aib); X7 is threonine (T), valine (V), or cysteine (C); X10 is tyrosine (Y) or cysteine (C); X12 is lysine (K) or cysteine (C); X13 is tyrosine (Y) or cysteine (C); X14 is leucine (L) or cysteine (C); X15 is aspartic acid (D) or cysteine (C); X16 is glutamic acid (E), serine (S), or cysteine (C); X17 is aspartic acid (D), glutamic acid (E), lysine (K), arginine (R), serine (S), cysteine (C), or valine (V); X18 is aspartic acid (D), glutamic acid (E), ne (R), or cysteine (C); X19 is alanine (A) or cysteine (C); X20 is glutamine (Q), aspartic acid (D), lysine (K), or cysteine (C); X21 is aspartic acid (D), glutamic acid (E), leucine (L), valine (V), or cysteine X23 is isoleucine (I), valine (V), or arginine (R); X24 is valine (V), arginine (R), alanine (A), glutamic acid (E), lysine (K), glutamine (Q), or leucine (L); X27 is isoleucine (I), valine (V), alanine (A), methionine (M), glutamine (Q), or arginine (R); X28 is glutamine (Q), lysine (K), asparagine (N), or arginine (R); X29 is threonine (T); and X30 is cysteine (C) or is absent.
3. [Claim 3] The pharmaceutical composition of claim 1, wherein, in General Formula 1, X1 is histidine (H), tryptophan (W), or ne (Y); X2 is serine (S) or aminoisobutyric acid (Aib); X7 is cysteine (C), threonine (T), or valine (V); X10 is tyrosine (Y) or cysteine (C); X12 is lysine (K) or cysteine (C); X13 is tyrosine (Y) or cysteine (C); X14 is leucine (L) or cysteine (C); X15 is aspartic acid (D) or cysteine (C); X16 is glutamic acid (E), serine (S), or cysteine (C); X17 is glutamic acid (E), lysine (K), arginine (R), cysteine (C), or valine (V); X18 is arginine (R) or cysteine (C); X19 is alanine (A) or ne (C); X20 is glutamine (Q) or lysine (K); X21 is aspartic acid (D), glutamic acid (E), valine (V), or cysteine (C); X23 is valine (V); X24 is valine (V) or glutamine (Q); X27 is methionine (M); X28 is asparagine (N) or arginine (R); X29 is threonine (T); and X30 is ne (C) or is absent.
4. [Claim 4] The pharmaceutical composition of claim 1, wherein, in General Formula 1, X1 is tyrosine (Y); X2 is aminoisobutyric acid (Aib); X7 is cysteine (C), threonine (T), or valine (V); X10 is tyrosine (Y) or cysteine (C); X12 is lysine (K); X13 is tyrosine (Y) or ne (C); X14 is leucine (L) or cysteine (C); X15 is aspartic acid (D) or cysteine (C); X16 is glutamic acid (E), serine (S), or cysteine (C); X17 is lysine (K), arginine (R), cysteine (C), or valine (V); X18 is arginine (R) or cysteine (C); X19 is e (A) or cysteine (C); X20 is glutamine (Q) or lysine (K); X21 is aspartic acid (D), glutamic acid (E), or cysteine (C); X23 is valine (V); X24 is glutamine (Q); X27 is methionine (M); X28 is asparagine (N) or arginine (R); X29 is threonine (T); and X30 is cysteine (C) or is absent.
5. [Claim 5] The pharmaceutical composition of claim 1, wherein, in General Formula 1, X1 is histidine (H), phan (W), or tyrosine (Y), or is ; X2 is serine (S) or aminoisobutyric acid (Aib); X7 is threonine (T), valine (V), or cysteine (C); X10 is tyrosine (Y) or cysteine (C); X12 is lysine (K) or ne (C); X13 is tyrosine (Y) or cysteine (C); X14 is leucine (L) or cysteine (C); X15 is aspartic acid (D) or cysteine (C); X16 is ic acid (E), serine (S), or cysteine (C); X17 is aspartic acid (D), glutamic acid (E), lysine (K), arginine (R), serine (S), cysteine (C), or valine (V); X18 is aspartic acid (D), ic acid (E), arginine (R), or cysteine (C); X19 is e (A) or cysteine (C); X20 is glutamine (Q), aspartic acid (D), or lysine (K); X21 is aspartic acid (D) or glutamic acid (E); X23 is valine (V); X24 is valine (V) or glutamine (Q); X27 is isoleucine (I) or methionine (M); X28 is asparagine (N) or arginine (R); X29 is threonine (T); and X30 is cysteine (C) or is absent.
6. [Claim 6] The pharmaceutical composition of claim 1, wherein, in General Formula 1, X1 is tyrosine (Y); X2 is aminoisobutyric acid (Aib); X7 is threonine (T); X10 is tyrosine (Y); X12 is lysine (K); X13 is tyrosine (Y); X14 is e (L); X15 is aspartic acid (D) or cysteine (C); X16 is glutamic acid (E), serine (S), or cysteine (C); X17 is lysine (K) or arginine (R); X18 is arginine (R); X19 is alanine (A); X20 is glutamine (Q), cysteine (C), or lysine (K); X21 is aspartic acid (D), cysteine (C), valine (V), or glutamic acid (E); X23 is valine (V) or arginine (R); X24 is glutamine (Q) or leucine (L); X27 is methionine (M); X28 is asparagine (N) or arginine (R); X29 is threonine (T); and X30 is absent.
7. [Claim 7] The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of the following General a 2: Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-WL-M-N-T-X30 (General Formula 2, SEQ ID NO: 46) wherein, in General Formula 2, X7 is threonine (T), valine (V), or cysteine (C); X10 is tyrosine (Y) or ne (C); X12 is lysine (K) or cysteine (C); X15 is aspartic acid (D) or cysteine (C); X16 is ic acid (E) or serine (S); X17 is lysine (K) or arginine (R); X20 is glutamine (Q) or lysine (K); X21 is aspartic acid (D) or glutamic acid (E); X24 is valine (V) or glutamine (Q); and X30 is cysteine (C) or is absent.
8. [Claim 8] The pharmaceutical composition of claim 1, wherein the peptide has an isoelectric point (pI) value different from that of native glucagon (6.8).
9. [Claim 9] The pharmaceutical composition of claim 1, n each amino acid in at least one amino acid pair among the amino acid pairs of X10 and X14, X12 and X16, X16 and X20, X17 and X21, X20 and X24, and X24 and X28 in General Formula 1 is substituted with glutamic acid or , which is capable of forming a ring, respectively.
10. [Claim 10] The pharmaceutical composition of claim 9, wherein each amino acid in the amino acid pair of X12 and X16 or each amino acid in the amino acid pair of X16 and X20 or each amino acid in the amino acid pair of X17 and X21 is respectively substituted with glutamic acid or lysine, which is capable of forming a ring.
11. [Claim 11] The pharmaceutical composition of claim 1, wherein, in l Formula 1, a ring is formed between each amino acid in at least one amino acid pair among the amino acid pairs of X10 and X14, X12 and X16, X16 and X20, X17 and X21, X20 and X24, and X24 and X28.
12. [Claim 12] The pharmaceutical composition of claim 1, wherein the C-terminus of the peptide is amidated.
13. [Claim 13] The pharmaceutical composition of claim 1, wherein the C-terminus of the peptide is unmodified.
14. [Claim 14] The pharmaceutical composition of claim 1, wherein the peptide is a native glucagon derivative e of activating a glucagon receptor.
15. [Claim 15] The pharmaceutical composition of claim 1, wherein the peptide comprises an amino acid sequence selected from the group ting of SEQ ID NOS: 2 to 44.
16. [Claim 16] The pharmaceutical composition of claim 7, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 12, 13, 15, and 36 to 44.
17. [Claim 17] The pharmaceutical ition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 37.
18. [Claim 18] The ceutical composition according to any one of claims 1 to 17, wherein the peptide is in the form of a long-acting conjugate, in which a biocompatible material moiety is linked to a peptide moiety comprising the amino acid sequence of General Formula 1.
19. [Claim 19] The pharmaceutical composition of claim 18, wherein the biocompatible al moiety is selected from the group consisting of a polymer, fatty acid, cholesterol, albumin and a fragment thereof, an albumin-binding material, a polymer of ing units of a particular amino acid sequence, an antibody, an antibody fragment, an inding material, in vivo connective tissue or a tive thereof, a nucleotide, fibronectin, transferrin, a saccharide, heparin, and elastin.
20. [Claim 20] The pharmaceutical composition of claim 19, wherein the r is selected from the group consisting of a polyethylene glycol, a polypropylene glycol, an ethylene glycol-propylene glycol copolymer, polyoxyethylated , polyvinyl l, a polysaccharide, dextran, polyvinyl ethyl ether, a biodegradable polymer, a lipid polymer, chitin, hyaluronic acid, an oligonucleotide, and a combination thereof.
21. [Claim 21] The pharmaceutical composition of claim 19, wherein the FcRn-binding material is a polypeptide comprising an immunoglobulin Fc region.
22. [Claim 22] The pharmaceutical ition of claim 18, wherein the peptide moiety and the biocompatible material moiety are linked with each other through a linker.
23. [Claim 23] The pharmaceutical composition of claim 22, wherein the linker is selected from the group ting of a peptide, fatty acid, a saccharide, a polymer, a low molecular weight nd, a nucleotide, and a combination thereof.
24. [Claim 24] The pharmaceutical composition of claim 23, wherein the polymer is selected from the group consisting of a polyethylene glycol, a polypropylene glycol, an ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, a polysaccharide, dextran, polyvinyl ethyl ether, a biodegradable polymer, a lipid polymer, , hyaluronic acid, an oligonucleotide, and a combination thereof.
25. [Claim 25] The pharmaceutical composition of claim 22, n the linker is a polyethylene glycol.
26. [Claim 26] The pharmaceutical composition of claim 21, n the immunoglobulin Fc region is aglycosylated.
27. [Claim 27] The pharmaceutical composition of claim 21, wherein the immunoglobulin Fc region is selected from the group consisting of: (a) a CH1 domain, a CH2 , a CH3 domain, and a CH4 ; (b) a CH1 domain and a CH2 domain; (c) a CH1 domain and a CH3 domain; (d) a CH2 domain and a CH3 domain; (e) a combination between one or at least two domains among a CH1 domain, a CH2 , a CH3 domain, and a CH4 domain, and an immunoglobulin hinge region or a part of the hinge region; and (f) a dimer between each domain of the heavy chain constant region and the light chain constant region.
28. [Claim 28] The pharmaceutical composition of claim 21, wherein the ptide comprising an immunoglobulin Fc region is in the form of a dimer.
29. [Claim 29] The pharmaceutical composition of claim 21, wherein the globulin Fc region is a native Fc derivative in which the region capable of forming a disulfide bond is deleted, a native Fc derivative in which a part of the amino acid(s) in the N-terminus is removed, a native Fc derivative in which a methionine residue is added to the N-terminus, a native Fc derivative in which a complement-binding site is deleted, or a native Fc derivative in which an antibody dependent cell mediated cytotoxicity (ADCC) site is deleted.
30. [Claim 30] The pharmaceutical composition of claim 21, wherein the immunoglobulin Fc region is derived from an immunoglobulin selected from the group consisting of IgG, IgA, IgD, IgE, and IgM.
31. [Claim 31] The pharmaceutical ition of claim 30, wherein the immunoglobulin Fc region is an IgG4 Fc region.
32. [Claim 32] The pharmaceutical composition of claim 21, wherein the immunoglobulin Fc region is an aglycosylated Fc region derived from human IgG4.
33. [Claim 33] The pharmaceutical composition of claim 22, n the linker is linked to a cysteine residue of a peptide comprising the amino acid sequence of General
34. [Claim 34] The pharmaceutical composition of claim 22, wherein the linker is respectively linked to the e moiety and the biocompatible material moiety through covalent bonds, which are respectively formed by reacting one end of the linker with an amine group or thiol group of the biocompatible material moiety and reacting the other end of the linker with an amine group or thiol group of the peptide moiety including the amino acid sequence of General Formula 1.
35. [Claim 35] An isolated e comprising the amino acid sequence of the following General a 2: Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-W- L-M-N-T-X30 (General a 2, SEQ ID NO: 46) wherein, in General Formula 2, X7 is threonine (T), valine (V), or cysteine (C); X10 is tyrosine (Y) or cysteine (C); X12 is lysine (K) or cysteine (C); X15 is aspartic acid (D) or cysteine (C); X16 is glutamic acid (E) or serine (S); X17 is lysine (K) or arginine (R); X20 is glutamine (Q) or lysine (K); X21 is aspartic acid (D) or glutamic acid (E); X24 is valine (V) or glutamine (Q); and X30 is cysteine (C) or is absent, with the proviso that the peptides corresponding to SEQ ID NOS: 19, 33, 49, and 50 are excluded from the isolated peptides comprising the amino acid sequence of General Formula 2.
36. [Claim 36] The peptide of claim 35, wherein, in General Formula 2, X16 is glutamic acid, X20 is lysine, and the side chains of X16 and X20 form a lactam ring.
37. [Claim 37] The peptide of claim 35, wherein the inus of the peptide comprising the amino acid ce of General a 2 is amidated.
38. [Claim 38] The peptide of claim 35, wherein the C-terminus of the peptide comprising the amino acid sequence of General Formula 2 is unmodified.
39. [Claim 39] The peptide of claim 35, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 12, 13, 15, and 36 to
40. [Claim 40] An isolated conjugate comprising a e moiety and a biocompatible material moiety which is linked to the peptide moiety, wherein the peptide moiety is the same sequence as that of amino acid sequence of the ing General Formula 2 or a ce including the same: Y-Aib-QGTF-X7-SD-X10-S-X12-Y-L-X15-X16-X17-R-A-X20-X21-F-V-X24-WL-M-N-T-X30 (General Formula 2, SEQ ID NO: 46) wherein, in General Formula 2, X7 is threonine (T), valine (V), or cysteine (C); X10 is tyrosine (Y) or cysteine (C); X12 is lysine (K) or cysteine (C); X15 is aspartic acid (D) or cysteine (C); X16 is glutamic acid (E) or serine (S); X17 is lysine (K) or arginine (R); X20 is glutamine (Q) or lysine (K); X21 is aspartic acid (D) or glutamic acid (E); X24 is valine (V) or glutamine (Q); and X30 is ne (C) or is absent.
41. [Claim 41] The isolated conjugate of claim 40, wherein the biocompatible al moiety is selected from the group consisting of a r, fatty acid, cholesterol, albumin and a fragment thereof, an albumin-binding material, a polymer of ing units of a particular amino acid sequence, an antibody, an antibody fragment, an FcRn-binding material, in vivo connective tissue or a derivative thereof, a nucleotide, fibronectin, transferrin, a saccharide, heparin, and elastin.
42. [Claim 42] The isolated conjugate of claim 41, wherein the polymer is selected from the group consisting of a polyethylene glycol, a polypropylene glycol, an ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, nyl alcohol, a polysaccharide, dextran, polyvinyl ethyl ether, a biodegradable polymer, a lipid polymer, chitin, hyaluronic acid, an oligonucleotide, and a combination thereof.
43. [Claim 43] The isolated conjugate of claim 41, n the FcRn-binding material is a polypeptide comprising an immunoglobulin Fc region.
44. [Claim 44] The isolated conjugate of claim 40, wherein the e moiety and the biocompatible material moiety are covalently linked with each other through a linker.
45. [Claim 45] The isolated ate of claim 44, wherein the linker is selected from the group ting of a e, fatty acid, a saccharide, a r, a low molecular weight compound, a nucleotide, and a combination thereof.
46. [Claim 46] The isolated conjugate of claim 45, wherein the polymer is selected from the group consisting of a polyethylene , a polypropylene glycol, an ethylene glycol-propylene glycol copolymer, polyoxyethylated , polyvinyl alcohol, a polysaccharide, dextran, nyl ethyl ether, a biodegradable polymer, a lipid polymer, chitin, hyaluronic acid, an oligonucleotide, and a combination f.
47. [Claim 47] A pharmaceutical composition comprising: (i) the isolated peptide according to any one of claims 35 to 39 or the isolated conjugate according to any one of claims 40 to 46; and (ii) a pharmaceutically acceptable excipient.
48. [Claim 48] The pharmaceutical composition according to claim 47, further comprising at least one compound or material having a therapeutic activity for metabolic me.
49. [Claim 49] Use of the isolated peptide according to any one of claims 35 to 39 or the isolated conjugate according to any one of claims 40 to 46 in the manufacture of a pharmaceutical formulation for preventing or treating ital hyperinsulinism.
50. [Claim 50] Use of the isolated peptide according to any one of claims 35 to 39 or the isolated conjugate according to any one of claims 40 to 46 in the manufacture of a pharmaceutical formulation for preventing or treating hypoglycemia.
51. [Claim 51] Use of the isolated peptide according to any one of claims 35 to 39 or the isolated ate ing to any one of claims 40 to 46 in the manufacture of a pharmaceutical formulation for preventing or treating metabolic syndrome.
52. [Claim 52] The use according to claim 51, wherein the ment is to be administered with at least one nd or material having a therapeutic activity for metabolic syndrome.
53. [Claim 53] The use according to claim 52, wherein the isolated peptide or the isolated ate and at least one compound or material having a therapeutic activity for metabolic syndrome are to be administered simultaneously, individually, or sequentially.
54. [Claim 54] The pharmaceutical composition according to claim 48 or the use of claim 52, wherein the compound or material having a therapeutic activity for metabolic syndrome is selected from the group consisting of an insulinotropic peptide, a glucagon like peptide-1 (GLP-1) receptor agonist, a leptin receptor agonist, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, a Y5 receptor antagonist, a melanin-concentrating hormone (MCH) receptor antagonist, a Y2/4 or agonist, a cortin 3/4 (MC 3/4) receptor agonist, a gastric/pancreatic lipase inhibitor, an agonist of 5-hydroxytryptamine receptor 2C (5HT2C, G-protein d), a β3A receptor agonist, an amylin receptor t, a ghrelin antagonist, a ghrelin receptor antagonist, a peroxisome proliferator-activated receptor alpha ) agonist, a some proliferator-activated receptor delta (PPARδ) agonist, a Farnesoid X receptor (FXR) agonist, an acetyl-CoA carboxylase inhibitor, a peptide YY, cholecystokinin (CCK), xenin, glicentin, obestatin, secretin, nesfatin, insulin, and a glucose-dependent notropic peptide (GIP).
55. [Claim 55] The use according to claim 51, wherein the metabolic syndrome is selected from the group consisting of impaired e tolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, nonalcoholic steatohepatitis (NASH), atherosclerosis caused by dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease, and stroke.
56. [Claim 56] The pharmaceutical composition according to claim 48, comprising: (i) a conjugate, which comprises the peptide moiety comprising the amino acid sequence of SEQ ID NO: 37, and a biocompatible material moiety ntly linked to the peptide moiety; and (ii) a ate, which comprises an imidazo-acetyl n-4 moiety where the α-carbon of the 1st amino acid of exendin-4 (which is histidine) is deleted and a biocompatible material moiety covalently linked to the o-acetyl exendin-4 moiety.
57. [Claim 57] The pharmaceutical composition according to claim 53, n the peptide moiety comprising the amino acid sequence of SEQ ID NO: 37 and the o-acetyl exendin-4 moiety are respectively linked to their respective biocompatible material moietys through a linker. [ (S> 0 c£ 40 - ns ***f u -20 - ^ -40 T T 0 3 6 9 12 15 Time (days) “©" Excipient -a- Long-acting exendin-4 derivative (3.3 nmol/kg) ~£r Long-acting derivative of SEQ ID NO: 12 (1.6 nmol/kg) -V“ Long-acting tive of SEQ ID NO: 12 (3.3 nmol/kg) -o- Long-acting derivative of SEQ ID NO: 12 (6.6 nmol/kg) -At cting exendin-4 derivative (3.3 nmol/kg) + Long-acting derivative of SEQ ID NO: 12 (1.6 nmol/kg) Long-acting exendin-4 tive (3.3 nmol/kg) + Long-acting derivative of SEQ ID NO: 12 (3.3 nmol/kg) Long-acting exendin-4 derivative (3.3 nmol/kg) + Long-acting derivative of SEQ ID NO: 12 (6.6 nmol/kg) M Paired feeding (with Group administered with Long-acting derivative of SEQ ID NO: 12 (3.3 nmol/kg)) # Paired feeding (with Group administered with cting exendin-4 derivative (3.3 nmol/kg) and Long-acting derivative of SEQ ID NO: 12 (3.3 nmol/kg)) [ ^ 12- Ll_ fait • I H f • • • • ■ k • * cu 1■ I • f* » • » Vb1!1! c *,**t**,| 0) • ■ • ■ q 6. Mv/ f* y;:*: Xy!j 1 • B • • I ^*•*^1 ;lyly Iy!y! Excipient □ Long-acting exendin-4 derivative (3.3 nmol/kg) EZ3 Long-acting derivative of SEQ ID NO: 12 (1.6 nmol/kg) ffl Long-acting tive of SEQ ID NO: 12 (3.3 nmol/kg) El Long-acting derivative of SEQ ID NO: 12 (6.6 g) □ Long-acting exendin-4 derivative (3.3 nmol/kg) + Long-acting derivative of SEQ ID NO: 12 (1.6 nmol/kg) m Long-acting exendin-4 derivative (3.3 g) + Long-acting derivative of SEQ ID NO: 12 (3.3 nmol/kg) EZ3 Long-acting exendin-4 derivative (3.3 g) + Long-acting derivative of SEQ ID NO: 12 (6.6 nmol/kg) C3 Paired g (with Group administered with Long-acting derivative of SEQ ID NO: 12 (3.3 nmol/kg)) E21 Paired feeding (with Group administered with Long-acting exendin-4 derivative (3.3 nmol/kg) and Long-acting derivative of SEQ ID NO: 12 (3.3 nmol/kg)) [ 5? 12 - It# *** ;■:■:■ CD iv.; mi {■: ;■ I > 6 * !!>■; l:: I 0 i i A Excipient □ Long-acting n-4 derivative (3.3 nmol/kg) E3 Long-acting derivative of SEQ ID NO: 12 (1.6 nmol/kg) ■ Long-acting derivative of SEQ ID NO: 12 (3.3 nmol/kg) BS Long-acting derivative of SEQ ID NO: 12 (6.6 nmol/kg) O Long-acting exendin-4 tive (3.3 nmol/kg) + Long-acting derivative of SEQ ID NO: 12 (1.6 nmol/kg) Long-acting exendin-4 derivative (3.3 nmol/kg) + Long-acting derivative of SEQ ID NO: 12 (3.3 nmol/kg) iSl Long-acting exendin-4 derivative (3.3 nmol/kg) + Long-acting derivative of SEQ ID NO: 12 (6.6 nmol/kg) ESI Paired feeding (with Group administered with Long-acting derivative of SEQ ID NO: 12 (3.3 nmol/kg)) EZZI Paired feeding (with Group administered with cting exendin-4 derivative (3.3 nmol/kg) and Long-acting derivative of SEQ ID NO: 12 (3.3 nmol/kg)) [ o 0 222!2aa£ | S, 5 -30» "os 1 m -60 0 2 4 6 8 10 12 14 16 18 20 22 Time (days) o Excipient B Long-acting exendin-4 derivative (4.3 g) Long-acting derivative of SEQ ID NO: 20 (4.4 nmol/kg) Long-acting derivative of SEQ ID NO: 20 (8.8 nmol/kg) Long-acting n-4 derivative (4.3 nmol/kg) + Long-acting derivative of SEQ ID NO: 20 (4.4 nmol/kg) Long-acting exendin-4 derivative (2.1 nmol/kg) + Long-acting tive of SEQ ID NO: 20 (6.6 nmol/kg) Long-acting exendin-4 derivative (0.8 nmol/kg) + Long-acting derivative of SEQ ID NO: 20 (8.0 nmol/kg) [ 400 i ^ 300 - I o 200 - (U ill o 100 - •k-frk *** *** *!fe* u KS4 ■. *** o « **£ S mmAmmmmm mm i m m ™»» Excipient IO Long-acting exendin-4 derivative (4.3 nmol/kg) SIS Long-acting derivative of SEQ ID NO: 20 (4.4 nmol/kg) B Long-acting derivative of SEQ ID NO: 20 (8.8 nmol/kg) Long-acting exendin-4 derivative (4.3 g) + Long-acting derivative of SEQ ID NO: 20 (4.4 nmol/kg) BH Long-acting exendin-4 derivative (2.1 nmol/kg) + Long-acting tive of SEQ ID NO: 20 (6.6 g) 121 Long-acting exendin-4 derivative (0.8 nmol/kg) + Long-acting derivative of SEQ ID NO: 20 (8.0 nmol/kg) [ Obesity Lipid Metabolism Blood Glucose Body Weight Change Mesenteric Fat Blood Cholesterol AUC /pGTT 1 z sp -40* OJ A S -100*1 0 Liraglutide 2 Long-acting exendin tive 50 nmol/kg BID 4.3 nmol/kg Q2D (3 mg/day in humans) (6 mg/week in humans) | Long-acting exendin derivative + Long-acting derivative of SEQ ID NO: 37 4.3 nmol/kg Q2D 2.2 nmol/kg Q2D (6 k in humans) (3 mg/week in humans) [ ^ 20© i I* US 'S 150- 0, 125- § 100- ■Oo 75- CQ 50- 0.0 0.5 1 1.5 2.0 2.5 3 Time (hour) -a- Long-acting conjugate of SEQ ID NO: 37 (5.16 nmol/kg) Long-acting conjugate of SEQ ID NO: 37 (10.31 nmol/kg) Long-acting conjugate of SEQ ID NO: 37 (20.63 nmol/kg) - Native glucagon (60 nmol/kg) [ £ 1500 X #*# >> ** "O ' g 1000 ■ ■■«■> Normal Rats, Excipient Rats with Chronic Hypoglycemia, Excipient Rats with Chronic Hypoglycemia, Long-acting conjugate of SEQ ID NO: 37 (3 nmol/kg) Rats with Chronic Hypoglycemia, Long-acting conjugate of SEQ ID NO: 37 (6 nmol/kg) 7809743_1.txt <110> HANMI PHARM. CO., LTD. <120> glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof <130> 15 <150> KR 10‐2016‐0081995 <151> 2016‐06‐29 <150> KR 10‐2016‐0182982 <151> 2016‐12‐29 <150> KR 7‐0069217 <151> 2017‐06‐02 <160> 50 <170> KoPatentIn 3.0 <210> 1 <211> 29 <212> PRT <213> homo sapiens <400> 1 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 2 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <400> 2 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Cys 1 5 10 15 Asp Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 3 <211> 29 Page 1 7809743_1.txt <212> PRT <213> Artificial Sequence <220> <223> glucagon tive <400> 3 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Cys 1 5 10 15 Glu Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 4 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <400> 4 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Cys Asp Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 5 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <400> 5 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Cys Glu Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 6 <211> 29 <212> PRT Page 2 7809743_1.txt <213> Artificial Sequence <220> <223> glucagon derivative <400> 6 His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Cys Glu Ala Asp Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 7 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <400> 7 Tyr Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Cys Glu Ala Asp Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 8 <211> 29 <212> PRT <213> Artificial ce <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 8 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Cys Asp Ala Gln Asp Phe Val Gln Trp Leu Ile Asn Thr 20 25 Page 3 7809743_1.txt <210> 9 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 9 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Cys Asp Ala Gln Asp Phe Val Val Trp Leu Ile Asn Thr 20 25 <210> 10 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> on derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 10 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Cys Asp Ala Asp Asp Phe Val Val Trp Leu Ile Asn Thr 20 25 <210> 11 <211> 29 <212> PRT <213> Artificial Sequence Page 4 7809743_1.txt <220> <223> glucagon derivative <220> <221> EATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 11 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Lys Cys Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 12 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 12 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Lys Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr Cys 20 25 30 <210> 13 <211> 29 <212> PRT <213> Artificial Sequence Page 5 7809743_1.txt <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 13 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Cys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 14 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon tive <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 14 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Cys 1 5 10 15 Lys Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 15 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> Page 6 7809743_1.txt <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 15 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Cys Glu 1 5 10 15 Lys Arg Ala Gln Asp Phe Val Val Trp Leu Met Asn Thr 20 25 <210> 16 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> EATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 16 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Cys 1 5 10 15 Arg Arg Ala Gln Val Phe Val Gln Trp Leu Met Arg Thr 20 25 <210> 17 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 17 Page 7 7809743_1.txt Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Cys 1 5 10 15 Val Arg Ala Gln Asp Phe Val Gln Trp Leu Met Arg Thr 20 25 <210> 18 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon tive <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 18 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Cys Asp Phe Arg Leu Trp Leu Met Asn Thr 20 25 <210> 19 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 19 Page 8 7809743_1.txt Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Cys Glu 1 5 10 15 Lys Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 20 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at ons 16 and 20 form a ring <400> 20 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Cys Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 21 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> Page 9 7809743_1.txt <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at ons 16 and 20 form a ring <400> 21 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Lys Cys Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 22 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 22 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Lys Arg Cys Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 23 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> Page 10 7809743_1.txt <221> MISC_FEATURE <222> (2) <223> Xaa is sobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 23 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Cys Asp Glu 1 5 10 15 Lys Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 24 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 24 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Cys Leu Asp Glu 1 5 10 15 Lys Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 25 <211> 29 <212> PRT <213> Artificial Sequence Page 11 7809743_1.txt <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 25 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Lys Arg Ala Lys Cys Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 26 <211> 29 <212> PRT <213> cial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 26 Trp Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Cys Arg Ala Lys Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 Page 12 7809743_1.txt <210> 27 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> EATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 27 Tyr Xaa Gln Gly Thr Phe Val Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Cys Arg Ala Lys Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 28 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring Page 13 7809743_1.txt <400> 28 Trp Xaa Gln Gly Thr Phe Val Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Cys Arg Ala Lys Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 29 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 29 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Cys Leu Asp Glu 1 5 10 15 Arg Arg Ala Lys Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 30 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> on derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) Page 14 7809743_1.txt <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 30 Trp Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Cys Leu Asp Glu 1 5 10 15 Arg Arg Ala Lys Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 31 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (21) <223> amino acids at positions 17 and 21 form a ring <400> 31 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Cys 1 5 10 15 Lys Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 32 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative Page 15 7809743_1.txt <220> <221> EATURE <222> (15)..(19) <223> amino acids at positions 15 and 19 form a ring <400> 32 Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu Cys 1 5 10 15 Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 33 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 33 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 34 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) Page 16 3_1.txt <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 34 Trp Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Cys Asp Glu 1 5 10 15 Arg Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 35 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 35 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Cys Asp Glu 1 5 10 15 Arg Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 36 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative Page 17 7809743_1.txt <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 36 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Cys Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 37 <211> 30 <212> PRT <213> cial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 37 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr Cys 20 25 30 <210> 38 <211> 29 <212> PRT Page 18 7809743_1.txt <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is sobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 38 Tyr Xaa Gln Gly Thr Phe Cys Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 39 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 39 Tyr Xaa Gln Gly Thr Phe Val Ser Asp Cys Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Arg Ala Lys Asp Phe Val Gln Trp Leu Met Asn Thr Page 19 7809743_1.txt 20 25 <210> 40 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring <400> 40 Tyr Xaa Gln Gly Thr Phe Val Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Arg Ala Lys Asp Phe Val Gln Trp Leu Met Asn Thr Cys 20 25 30 <210> 41 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon tive <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (16)..(20) <223> amino acids at positions 16 and 20 form a ring Page 20 7809743_1.txt <400> 41 Tyr Xaa Gln Gly Thr Phe Cys Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Arg Arg Ala Lys Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 42 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 42 Tyr Xaa Gln Gly Thr Phe Cys Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 43 <211> 29 <212> PRT <213> cial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 43 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Cys Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Page 21 7809743_1.txt 20 25 <210> 44 <211> 30 <212> PRT <213> cial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <400> 44 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 1 5 10 15 Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Cys 20 25 30 <210> 45 <211> 30 <212> PRT <213> cial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (1) <223> Xaa is histidine, desamino‐histidyl, N‐dimethyl‐histidyl, beta‐hydroxy imidazopropionyl, 4‐imidazoacetyl, beta‐carboxy imidazopropionyl, tryptophan, or ne, or is absent <220> <221> MISC_FEATURE <222> (2) <223> Xaa is alpha‐methyl‐glutamic acid, aminoisobutyric acid (Aib), D‐alanine, glycine, Sar (N‐methylglycine), serine, or D‐serine <220> <221> MISC_FEATURE Page 22 7809743_1.txt <222> (7) <223> Xaa is threonine, valine, or cysteine <220> <221> EATURE <222> (10) <223> Xaa is tyrosine or cysteine <220> <221> MISC_FEATURE <222> (12) <223> Xaa is lysine or cysteine <220> <221> MISC_FEATURE <222> (13) <223> Xaa is tyrosine or cysteine <220> <221> MISC_FEATURE <222> (14) <223> Xaa is leucine or cysteine <220> <221> MISC_FEATURE <222> (15) <223> Xaa is aspartic acid, glutamic acid, or cysteine <220> <221> MISC_FEATURE <222> (16) <223> Xaa is glutamic acid, aspartic acid, serine, alpha‐methyl‐glutamic acid, or cysteine, or is absent; <220> <221> MISC_FEATURE <222> (17) <223> Xaa is aspartic acid, glutamine, ic acid, , arginine, serine, cysteine, or valine, or is absent <220> <221> MISC_FEATURE <222> (18) <223> Xaa is alanine, ic acid, glutamic acid, arginine, valine, Page 23 7809743_1.txt or cysteine, or is absent <220> <221> MISC_FEATURE <222> (19) <223> Xaa is alanine, arginine, serine, , or cysteine, or is absent <220> <221> MISC_FEATURE <222> (20) <223> Xaa is lysine, histidine, glutamine, aspartic acid, lysine, arginine, alpha‐methyl‐glutamic acid, or cysteine, or is absent <220> <221> MISC_FEATURE <222> (21) <223> Xaa is aspartic acid, glutamic acid, leucine, valine, or cysteine, or is absent <220> <221> MISC_FEATURE <222> (23) <223> Xaa is isoleucine, , or ne, or is absent <220> <221> MISC_FEATURE <222> (24) <223> Xaa is , arginine, e, cysteine, glutamic acid, lysine, glutamine, alpha‐methyl‐glutamic acid, or leucine, or is absent; <220> <221> MISC_FEATURE <222> (27) <223> Xaa is isoleucine, valine, alanine, lysine, methionine, glutamine, or arginine, or is absent <220> <221> MISC_FEATURE <222> (28) <223> Xaa is glutamine, lysine, asparagine, or arginine, or is absent <220> Page 24 7809743_1.txt <221> MISC_FEATURE <222> (29) <223> Xaa is lysine, alanine, glycine, or ine, or is absent <220> <221> MISC_FEATURE <222> (30) <223> Xaa is cysteine, or is absent <400> 45 Xaa Xaa Gln Gly Thr Phe Xaa Ser Asp Xaa Ser Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Trp Leu Xaa Xaa Xaa Xaa 20 25 30 <210> 46 <211> 30 <212> PRT <213> Artificial ce <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid (Aib) <220> <221> MISC_FEATURE <222> (7) <223> Xaa is threonine, valine, or cysteine <220> <221> MISC_FEATURE <222> (10) <223> Xaa is tyrosine or cysteine <220> <221> MISC_FEATURE <222> (12) <223> Xaa is lysine or cysteine Page 25 7809743_1.txt <220> <221> MISC_FEATURE <222> (15) <223> Xaa is aspartic acid or cysteine <220> <221> MISC_FEATURE <222> (16) <223> Xaa is glutamic acid or serine <220> <221> MISC_FEATURE <222> (17) <223> Xaa is lysine or arginine <220> <221> MISC_FEATURE <222> (20) <223> Xaa is glutamine or lysine <220> <221> MISC_FEATURE <222> (21) <223> Xaa is aspartic acid or ic acid <220> <221> MISC_FEATURE <222> (24) <223> Xaa is valine or glutamine <220> <221> MISC_FEATURE <222> (30) <223> Xaa is cysteine or is absent <400> 46 Tyr Xaa Gln Gly Thr Phe Xaa Ser Asp Xaa Ser Xaa Tyr Leu Xaa Xaa 1 5 10 15 Xaa Arg Ala Xaa Xaa Phe Val Xaa Trp Leu Met Asn Thr Xaa 20 25 30 <210> 47 <211> 34 Page 26 7809743_1.txt <212> DNA <213> Artificial Sequence <220> <223> d primer <400> 47 cagcgacacc gaccgtcccc ccgtacttaa ggcc 34 <210> 48 <211> 32 <212> DNA <213> Artificial ce <220> <223> reverse primer <400> 48 ctaaccgact ctcggggaag actgagctcg cc 32 <210> 49 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> glucagon derivative <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid <400> 49 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Cys Tyr Leu Asp Glu 1 5 10 15 Lys Arg Ala Lys Glu Phe Val Gln Trp Leu Met Asn Thr 20 25 <210> 50 <211> 29 <212> PRT <213> Artificial Sequence Page 27 7809743_1.txt <220> <223> glucagon tive <220> <221> MISC_FEATURE <222> (2) <223> Xaa is aminoisobutyric acid <400> 50 Tyr Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Cys Glu 1 5 10 15 Lys Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 20 25 Page 28
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0081995 | 2016-06-29 | ||
KR10-2016-0182982 | 2016-12-29 | ||
KR10-2017-0069217 | 2017-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ789486A true NZ789486A (en) | 2022-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11142559B2 (en) | Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof | |
US11667688B2 (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
US20190321485A1 (en) | Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof | |
EP3862019A1 (en) | Therapeutic uses of glucagon and combined product comprising same | |
NZ789486A (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
EA042163B1 (en) | GLUCAGON DERIVATIVE, GLUCAGON-BASED CONJUGATE, COMPOSITION CONTAINING THEM AND THEIR THERAPEUTIC APPLICATION | |
EA040165B1 (en) | GLUCAGON DERIVATIVE AND COMPOSITION CONTAINING A LONG-ACTING CONJUGATE OF THIS DERIVATIVE | |
NZ618811B2 (en) | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |